Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the issuer’s common stock, par value $0.0001 per share, as of November ~~22, 2021,~~8, 2022, was ~~148,886,141~~149,983,265.

The business of Adamis Pharmaceuticals Corporation ("we," "us," "our," "Adamis," or the "company") is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled "Risk Factors." These risks include, but are not limited to, the following:

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

CONDENSED CONSOLIDATED ~~BALANCE SHEETS~~STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (UNAUDITED)

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

~~The accompanying notes are an integral part of these Condensed Consolidated Financial Statements~~

The accompanying notes are in an integral part of these Condensed Consolidated Financial Statements

~~The accompanying notes are an integral part of these Condensed Consolidated Financial Statements~~

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 108 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures normally included in annual financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments and the elimination of intercompany accounts) considered necessary for a fair statement of all periods presented. The results of operations of Adamis Pharmaceuticals Corporation ("(“the ~~Company"~~Company”) for any interim periods are not necessarily indicative of the results of operations for any other interim periods or for a full fiscal year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 (the ~~"2020~~“2021 Form ~~10-K"~~10-K”).

~~On January~~For the three and nine months ended September 30, ~~2020,~~2022 and September 30, 2021, and year ended December 31, 2021, the ~~World Health Organization~~assets, liabilities, operations, and cash flows of the Company’s subsidiary, US Compounding, Inc. (“~~WHO”~~USC”) declared that the novel coronavirus (COVID-19) outbreak was a global health emergency, which prompted national governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. The governmental actions and the widespread disruptions arising, have been separated from the ~~pandemic have adversely affected certain aspects of our business. The extent and duration~~comparative period amounts to conform to the current period presentation as discontinued operations as the result of the ~~pandemic is unknown,~~Company’s decision to wind down and ~~the future effects on our business are uncertain and difficult to predict, including in light~~cease operations of recent new variants of the virus. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 280, Segment Reporting (“ASC 280”), establishes standards for the way that public business enterprises report information about operating segments in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company’s business segments are based on the organization structure used by the chief operating decision maker for making operating and investment decisions and for assessing performance. Commencing April 1, 2020, our management, including the chief executive officer, who is our chief operating decision maker (“CODM”), began managing our operations as operating in two business segments: Drug Development and Commercialization which includes without limitation out-licensing the Company’s FDA approved products; and Compounded Pharmaceuticals which includes the Company’s registered outsourcing facility, based on changes to the way that management monitors performance, aligns strategies, and allocates resources results. We determined that each of these operating segments represented a reportable segment. These consolidated financial statements and related footnotes, including prior year financial information, are presented as if there were two reporting segments for all periods presented, to the extent described in Note 12. We are a specialty biopharmaceutical company focused on developing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease; and a registered drug compounding outsourcing facility, which compounds sterile prescription medications and certain nonsterile preparations and compounds for human and veterinary use by patients, physician clinics, hospitals, surgery centers, vet clinics and other clients throughout most of the United States. See note 13 for a discussion of subsequent events affecting USC and ~~our Compounded Pharmaceuticals business.~~ liquidate its remaining assets. See Note 2.

The ~~Company's~~Company’s cash and cash equivalents ~~and restricted cash~~ were $~~40,618,554~~2,419,960 and $~~6,855,355~~23,220,770 at ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively.

The ~~Company prepared the~~ condensed consolidated financial statements ~~assuming~~were prepared under the assumption that the Company will continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. In preparing these condensed consolidated financial statements, consideration was given to the Company’s future business as described below, which may preclude the Company from realizing the value of certain assets.

The Company has significant operating cash flow deficiencies. Additionally, the Company ~~may~~will need additional funding in the near term and thereafter in the future to ~~help support commercialization of its products~~sustain operations, satisfy existing and ~~conduct the clinical and regulatory activities relating to the Company’s product candidates, satisfy existing~~future obligations and liabilities, and otherwise support the Company’s ~~intended~~operations and business activities and working capital needs. The preceding conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements for the ~~six~~nine months ended ~~June~~September 30, ~~2021,~~2022, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Our unaudited condensed consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. Management’s plans include attempting to secure additional required funding through equity or debt financings if available, seeking to enter into one or more strategic agreements regarding, or sales or out-licensing of, intellectual property or other assets, products, product candidates or technologies, seeking ~~partnerships~~to enter into agreements with ~~other pharmaceutical companies or~~ third parties to co-develop and fund research and development efforts, ~~or similar transactions, and through~~ revenues from existing ~~agreements.~~agreements, a merger, sale or reverse merger of the Company, or other strategic transaction. There is no assurance that the Company will be successful in obtaining the necessary funding to sustain its operations or meet its business objectives. The process of obtaining funding, or the terms of a strategic transaction, could result in significant dilution to our existing stockholders. In addition, ~~the COVID-19 pandemic has had an adverse impact on the Company. A~~a severe or prolonged economic downturn, or political disruption or pandemic, such as the COVID-19 pandemic, could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all.

Under ASC 260, the Company is required to apply the two-class method to compute earnings per share (or, EPS). Under the two-class method both basic and diluted EPS are calculated for each class of common stock and participating security considering both dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method results in an allocation of all undistributed earnings as if all those earnings were distributed. Considering the Company has generated losses in each reporting period since its inception through September 30, 2022, the Company also considered the guidance related to the allocation of the undistributed losses under the two-class method. The contractual rights and obligations of the preferred stock shares were evaluated to determine if they have an obligation to share in the losses of the Company. As there is no obligation for the preferred stock shareholders to fund the losses of the Company nor is the contractual principal or mandatory redemption amount of the preferred stock shares reduced as a result of losses incurred by the Company, under the two-class method, the undistributed losses will be allocated entirely to the common stock securities.

The Company computes basic loss per share by dividing the loss attributable to holders of common stock for the period by the weighted average number of shares of common stock outstanding during the period. The diluted loss per share calculation is based on the if-converted method for convertible preferred shares and gives effect to dilutive if-converted shares and the treasury stock method and gives effect to dilutive options, warrants and other ~~potential~~potentially dilutive common stock. The ~~effect~~preferred stock, however, is not considered potentially dilutive due to the contingency on the conversion feature not being tied to stock price or price of the convertible instrument. The common stock equivalents ~~was~~were anti-dilutive and ~~was~~were excluded from the calculation of weighted average shares outstanding. ~~Potential~~Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the ~~six~~nine months ended ~~June~~September 30, 2022 and September 30, 2021, ~~and June 30, 2020,~~ consist of outstanding warrants covering ~~15,095,238~~14,952,824 shares and ~~24,634,670~~14,202,824 shares, respectively, outstanding options covering 4,436,362 shares and 5,844,239 shares, respectively ~~issuable upon exercise of outstanding equity classified warrants;~~ ~~6,113,866~~ ~~shares~~ and~~7,238,761~~ ~~shares, respectively, issuable upon exercise of outstanding options;~~ ~~2,034,260~~ ~~shares and~~ ~~2,534,107~~ ~~shares, respectively, issuable following vesting of~~ outstanding restricted stock ~~units;~~units covering 650,000 shares and 01,747,124 shares, respectively.

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and ~~1,000,000, respectively, issuable upon conversion~~financial results when the component/s of ~~convertible preferred stock.~~

an entity meets the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes, shall be reported as components of net loss separate from the net loss of continuing operations. The Company disposed of a component of its business in August 2021 and met the definition of a discontinued operation with respect to that business. Accordingly, the operating results of the business disposed are reported as loss from discontinued operations in the accompany unaudited condensed statements of operations for the nine months and year ended September 30, 2022 and December 31, 2021.

In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future.

In August 2021, the Company announced an agreement with Fagron Compounding Services, LLC (“Fagron”) to sell to Fagron certain assets of the Company’s subsidiary, US Compounding, Inc. (“USC”), related to the Company’s human compounding pharmaceutical business including certain customer information and information on products sold to such customers by USC, including related formulations, know-how, and expertise regarding the compounding of pharmaceutical preparations, clinical support knowledge and other data and certain other information relating to the customers and products. The agreement included fixed consideration of approximately $107,000 and variable consideration estimated at approximately $6,385,000. The variable consideration was tied to Fagron’s sales to former USC customers for the twelve-month-period commencing on the agreement date. The Company used the expected value method to estimate Fagron’s sales over the twelve-month period following the agreement date. For the twelve-month agreement period the Company relied on historical data and its judgement to make estimates, and as such, the total variable consideration changed as more information became available, which resulted in adjustments to the receivable during the twelve-month period. During the three and nine months ended September 30, 2022, the Company recognized an increase (decrease) in variable consideration of $278,000 and $(919,000), respectively, which was included in net loss from continuing operations, as the change occurred subsequent to the disposal of the USC business. In connection with the transaction, the Company accrued as of December 31, 2021 and paid in January 2022 a $700,000 liability for a transaction fee payable to a financial advisor which was recorded in selling, general and administrative expenses of continuing operations.

In July 2021, the Company approved a restructuring process to wind down and cease the remaining operations at USC, with the remaining USC assets to be sold, liquidated or otherwise disposed of. The Company disposed of a component of its business in August 2021 and met the definition of a discontinued operation as of September 30, 2021. Accordingly, the operating results of the business disposed are reported as loss from discontinued operations in the accompany unaudited condensed statements of operations for the three months and nine months ended September 30, 2022 and 2021. As of December 31, 2021, the Company had shut down the operations of USC, terminated all of USC’s employees and was engaged in the process of selling or attempting to sell or otherwise dispose of USC’s remaining assets.

Discontinued operations comprise those activities that were disposed of during the period, abandoned or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that was previously distinguished as Compounded Pharmaceuticals segment for operational and financial reporting purposes in prior reported financial statements.

The Company considers assets to be held for sale when management approves and commits to a plan to actively market the assets for sale at a reasonable price in relation to its fair value, the assets are available for immediate sale in their present condition, an active program to locate a buyer and other actions required to complete the sale have been initiated, the sale of the assets is expected to be completed within one year and it is unlikely that significant changes will be made to the plan. Upon designation as held for sale, the Company ceases to record depreciation and amortization expenses and measures the assets at the lower of their carrying value or estimated fair value less costs to sell. Assets held for sale are included as current assets of discontinued operations in the Company’s consolidated balance sheets and the gain or loss from sale of assets held for sale is included in the Company’s general and administrative expenses.

The major assets and liabilities associated with discontinued operations included in our consolidated balance sheets are as follows (unaudited):

Carrying amounts of major classes of assets included as part of discontinued operations (unaudited):

The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations were as follows (unaudited):

Compounded Pharmaceuticals Facility Revenue Recognition. With respect to sales of prescription compounded medications by the Company’s USC subsidiary, revenue arrangements consisted of a single performance obligation which was satisfied at the point in time when goods were delivered to the customer. The transaction price was determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer which was the price reflected in the individual customer’s order. Additionally, the transaction price for medication sales was adjusted for estimated product returns that the Company expected to occur under its return policy. The estimate was based upon historical return rates, which has been immaterial. The standard payment terms were 2%/10 and Net 30. The Company does not have a history of offering a broad range of price concessions or payment term changes, however, when the transaction price included variable consideration, the Company estimated the amount of variable consideration that should have been included in the transaction price utilizing the expected value method. Any estimates, including the effect of the constraint on variable consideration, were evaluated at each reporting period for any changes. Variable consideration was not a significant component of the transaction price for sales of medications by USC.

USC has two operating leases, one for an office space and one for office equipment. As of September 30, 2022, the leases have remaining terms between more than one year and less than four years, respectively. The operating leases do not include an option to extend beyond the life of the current term. There are no short-term leases, and the lease agreements do not require material variable lease payments, residual value guarantees or restrictive covenants. The Company leases a building which requires monthly base rent of $10,824 through December 31, 2023.

As part of the restructuring process to wind down and cease the operations at USC, the Company is working to cancel or transfer the leases of the discontinued operations. During the year ended December 31, 2021, the Right-of-Use assets related to the leases of approximately $448,000 were fully impaired because there is no benefit expected from the subject leases. As of September 30, 2022, and December 31, 2021 the liabilities of the discontinued operations included approximately $285,000 and $412,000 in lease liabilities, respectively.

As of September 30, 2022, and December 31, 2021, the outstanding liabilities related to the contract termination costs recorded in contingent loss liability of discontinued operations was approximately $410,000, reflecting estimated costs of termination of a contract between USC and a vendor.

On November 10, 2016, a Loan Amendment and Assumption Agreement was entered with into the lender. Pursuant to the agreement, as subsequently amended, the Company agreed to pay the lender monthly payments of principal and interest which were approximately $19,000 per month, with a final payment due and payable in August 2021.

In July 2021, the Company, in connection with the sale of certain USC assets to Fagron, paid to the lender the outstanding principal balance, accrued unpaid interest and other obligations under the Company’s loan agreement, promissory note and related loan documents relating to the outstanding building loan relating to the building and property on which USC’s offices are located. The land and building were included in the assets of discontinued operations.

The loan bore an interest of 6.00% per year and interest expense for the three months ended September 30, 2022 and September 30, 2021, was approximately $0 and $0, respectively. Interest expense for the nine months ended September 30, 2022 and 2021 was approximately $0 and $71,000 respectively. The amount of interest allocated to the discontinued operations was based on the legal obligations of USC.

Revenue is recognized pursuant to ASC Topic 606, “Revenue from Contracts with Customers” (ASC 606). Accordingly, revenue is recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

Adamis is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s subsidiary US Compounding, Inc. or USC, ~~provides~~(a discontinued operation - see Note 2) provided compounded sterile prescription medications and certain nonsterile preparations and compounds, for human and veterinary use by patients, physician clinics, hospitals, surgery centers, vet clinics and other clients throughout most of the United States. USC’s product offerings broadly ~~include,~~included, among others, corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables. In July 2021, the Company sold certain assets relating to USC’s human compounding pharmaceutical business and approved a restructuring process to wind down the remaining USC business and sell, liquidate or otherwise dispose of the remaining USC assets. Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer selling compounded pharmaceutical or veterinary products.

Adamis and USC (prior to the sale of certain of its assets) have contracts with customers when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

~~Compounded Pharmaceuticals Facility Revenue Recognition~~Exclusive Distribution and Commercialization Agreement for SYMJEPI^® and ZIMHI^™ with US WorldMeds

With respect to sales of prescription compounded medications by the Company’s USC subsidiary, revenue arrangements consist of a single performance obligation which is satisfied at the point in time when goods are delivered to the customer. The transaction price is determined based on the consideration to which On May 11, 2020 (the “Effective Date”) the Company will be entitled in exchange for transferring goods and services to the customer which is the price reflected in the individual customer’s order. Additionally, the transaction price for medication sales is adjusted for estimated product returns that the Company expects to occur under its return policy. The estimate is based upon historical return rates, which has been immaterial. ~~The standard payment terms are 2%/10 and Net 30~~. The Company does not have a history of offering a broad range of price concessions or payment term changes, however, when the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Variable consideration is not a significant component of the transaction price for sales of medications by USC.

~~See Note 5 to our consolidated financial statements in the 2020 Form 10-K for information relating to our~~entered into an exclusive distribution and commercialization agreement ~~dated~~(the “USWM Agreement”) with USWM for the United States commercial rights for the SYMJEPI products, as well as for the Company’s ZIMHI (naloxone HCI Injection, USP) 5mg/0.5mL product intended for the emergency treatment of ~~July 1, 2018~~opioid overdose. The Company’s revenues relating to its FDA approved products SYMJEPI and ZIMHI are dependent on the USWM Agreement.

Under the terms of the USWM Agreement, the Company appointed USWM as the exclusive (including as to the Company) distributor of SYMJEPI in the United States and related territories (“Territory”) effective upon the termination of a Distribution and Commercialization Agreement previously entered into with Sandoz Inc. ~~(the “Sandoz Agreement”)~~, ~~which was terminated~~and of the ZIMHI product if approved by the U.S. Food and Drug Administration (“FDA”) for marketing, and granted USWM an exclusive license under the Company’s patent and other intellectual property rights and know-how to market, sell, and otherwise commercialize and distribute the products in the Territory, subject to the provisions of the USWM Agreement, in partial consideration of an initial payment by USWM and potential regulatory and commercial based milestone payments totaling up to $26 million, if the milestones are achieved. There can be no assurances that any of these milestones will be met or that any milestone payments will be paid to the Company. The Company retains rights to the intellectual property subject to the USWM Agreement and to commercialize both products outside of the Territory. In addition, the Company may continue to use the licensed intellectual property (excluding certain of the licensed trademarks) to develop and commercialize other products (with certain exceptions), including products that utilize the Company’s Symject™ syringe product platform.

The initial term for the USWM Agreement began on the Effective Date and continues for a period of 10 years from the launch by USWM of the first product in the United States pursuant to the agreement, unless terminated earlier in accordance with its terms.

The Company has determined that the individual purchase orders, whose terms and conditions taken with the distribution and commercialization agreement, creates a ~~termination agreement entered into on May 11, 2020.~~ contract according to ASC 606. The term will automatically renew for five-year terms after the initial 10-year term, unless terminated by either party.

The Company has determined that there are ~~two~~multiple performance obligations in ~~its exclusive distribution and commercialization agreement (the "USWM Agreement") with USWM, LLC ("USWM" or "US WorldMeds"): (i)~~the contract which are the following: the manufacture and supply of SYMJEPI™ and ZIMHI™ products to ~~USWM;~~USWM, the license to distribute and ~~(ii) the exclusive distribution~~commercialize SYMJEPI™ and ~~commercialization~~ZIMHI™ products in the United ~~States.~~ States and the clinical development of ZIMHI™.

The Company utilized significant judgement to develop estimates of the stand-alone selling price for each distinct performance obligation based upon the relative stand-alone selling price. The transaction price allocated to the clinical development of ZIMHI was immaterial.

Revenues from the manufacture and supply of SYMJEPI™ and ZIMHI™ are recognized at a point in time upon delivery to ~~USWM.~~the carrier. The ~~right of exclusive distribution~~licenses to distribute and ~~commercialization~~commercialize SYMJEPI™ and ZIMHI™ products in the United States is ~~considered a symbolic~~distinct from the other performance obligations identified in the arrangement and has stand-alone functionality; the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and ~~will be recognized over time over~~ the ~~life~~licensee is able to benefit from the license.

Payments received under USWM Agreement may include non-refundable fees at the inception of the contract. The Company believes that due to ongoing efforts to comply with regulations that a performance obligation continues to exist over the life of the contract. Under the terms of the USWM Agreement, the Company is entitled to receive various amounts andarrangements, milestone payments ~~including: (1) certain non-refundable up-front fees~~ for ~~executing the agreement~~specific achievements and ~~regulatory milestone payments, both of which will be recognized over the expected customer life, estimated to be equal to the initial~~ 10~~-year term of the agreement; (2)~~ net-profit sharing payments based on certain percentages of net profit generated from the ~~sale~~sales of products over a given ~~quarter;~~quarter. At the inception of arrangements that include milestone payments, the Company uses judgement to evaluate whether the milestones are probable of being achieved and ~~(3) commercial~~estimates the amount to include in the transaction price utilizing the most likely amount method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within the Company or the licensee’s control, such as regulatory approvals are not included in the transaction price until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of development milestones and any related constraint and adjusts the estimate of the overall transaction price, if necessary. The Company recognizes aggregate sales-based milestones, and net-profit sharing as royalties from product sales at the later of when the related sales occur or when the performance obligation to which the sales-based milestone ~~payments. Items (2)~~or royalty has been allocated has been satisfied. The amounts receivable from USWM have a payment term of Net 30.

Revenues do not include any state or local taxes collected from customers on behalf of governmental authorities. The Company made the accounting policy election to continue to exclude these amounts from revenues.

On March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and ~~(3) are royalties generated~~0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level, due to the potential clogging of the needle preventing the dispensing of epinephrine. USWM will handle the entire recall process for the Company, with Company oversight. SYMJEPI is manufactured and tested for us by Catalent Belgium S.A. The costs of the recall and the allocation of costs of the recall, including the costs to us resulting from the ~~exclusive right~~recall, were estimated at approximately $2.0 million; moreover, the recall could cause the Company to ~~distribute and commercialize SYMJEPI and ZIMHI~~suffer reputational harm, depending on the resolution of matters relating to the recall could result in the ~~United States; these~~Company incurring financial costs and expenses which could be material, could adversely affect the supply of SYMJEPI products until manufacturing is resumed, and depending on the resolution of matters relating to the recall could have a material adverse effect on our business, financial condition, and results of operations.

For the period ended September 30, 2022 and December 31, 2021, a liability of approximately $408,000 and $2.0 million, respectively, associated with the recall is reflected in the balance sheet. The estimated costs of the recall were reflected in the consolidated statement of operations for the year ended December 31, 2021 as a reduction of net sales because we expect to offer the customers a cash refund or credit. Approximately, $388,000 of additional product recall costs were reflected in the consolidated results of operations as a reduction to net sales based on recall-related products returned during the quarter-ended September 30, 2022. Total product recall costs from inception of the recall through September 30, 2022, were approximately $2.4 million. The Company may be able to be reimbursed by certain third parties for some of the costs of the recall under the terms of its manufacturing agreements or insurance policies, but there are ~~considered sales-based royalties~~no assurances regarding the amount or timing of ~~intellectual property~~any such recovery.

Deferred revenue are contract liabilities that the Company records when cash payments are received or due in advance of the Company’s satisfaction of performance obligations. The Company’s performance obligation is met when control of the promised goods is transferred to the Company’s customers. For the three months ended September 30, 2022 and 2021, approximately $587,000 and $25,000 of the revenues recognized were reported as ~~they occur.~~deferred revenue as of December 31, 2021 and 2020, respectively, and for the nine months ended September 30, 2022 and 2021, approximately $587,000 and $75,000 of the revenues recognized were reported as deferred revenue as of December 31, 2021, and 2020, respectively. Included in the deferred revenue at September 30, 2022 and December 31, 2021 was approximately $213,000 and $850,000, respectively, relating to the non-refundable upfront payment received from USWM pursuant to the USWM Agreement. The increase of approximately $562,000 in recognition of deferred revenue for the three and nine months ended September 30,2022, was due to the Company's reassessment of performance obligations met under the USWM agreement.

The Company capitalizes incremental costs of obtaining a contract with a customer if the Company expects to recover those costs and that it would not have been incurred if the contract had not been obtained. The deferred costs, reported in the prepaid expenses and other current assets and other non-current assets on the Company’s consolidated balance sheets, will be amortized over the economic benefit period of the contract.

As part of the adoption of the ASC Topic 606, the Company elected to use the following practical expedients: (i) incremental costs of obtaining a contract in the form of sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded within Selling, General and Administrative expenses; (ii) taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products, are excluded from revenues; and (iii) shipping and handling activities are accounted for as fulfillment costs and recorded in cost of sales.

Our sterile environment operations are governed by specific regulatory and quality requirements. Any deviation from these standards could result in a stoppage of operations, recall of products, and a significant reduction in revenues. The Company outsources the manufacturing of the SYMJEPI product to third party manufacturers who bear the responsibility of maintaining a suitable environment as governed by specific regulatory and quality requirements.

~~The following table presents the Company's revenues disaggregated~~ ~~by outsourced manufacturing, sterile and non-sterile regulatory environments for the three months and six months ended June 30, 2021 and 2020.~~

The Company's revenues relating to its FDA approved product SYMJEPI are dependent on the USWM Agreement with USWM, which replaced Sandoz in May 2020 in connection with the above-mentioned termination of the Sandoz Agreement, and the Company’s revenues relating to pharmacy formulations rely, in large part, on sales generated from clinics and hospital customers. Adverse economic conditions pose a risk that the Company’s customers may reduce or cancel spending, which would impact the Company’s revenues. The COVID-19 outbreak has adversely affected revenues from sales of USC products, in part due to reductions or cancellations of elective surgeries and reduction in office visits to physicians' offices, healthcare facilities or clinics by patients, and the resulting decreased demand by USC’s customers for certain of USC’s products, and will likely continue to adversely affect revenues from sales of products to such customers for a period of time which cannot be predicted.

~~The following table presents the Company's revenue disaggregated by end market for the three months and six months ended June 30, 2021 and 2020.~~Note 4: Inventories

Deferred Revenue are contract liabilities that the Company records when cash payments are received or due in advance of the Company’s satisfaction of performance obligations. The Company’s performance obligation is met when control of the promised goods is transferred to the Company’s customers. For the three months ended June 30, 2021 and 2020, $ ~~45,692~~ ~~and $~~ ~~476,343~~ ~~of the revenues recognized were reported as deferred revenue as of March 31, 2021 and 2020, respectively, and for the six months ended June 30, 2021 and 2020, $50,070~~ ~~and $478,171~~ ~~of the revenues recognized were reported as deferred revenue as of December 31, 2020 and 2019, respectively.~~ ~~Included in the deferred revenue balance at June 30, 2021 and December 31, 2020 was $900,000~~ ~~and $~~ ~~950,000~~, respectively, relating to the non-refundable upfront payment received from USWM pursuant to the USWM Agreement. On May 11, 2020, the Company entered into a termination agreement with Sandoz which resulted in the acceleration of recognition of the upfront payment from Sandoz to revenue over the transition service agreement period.

The Company capitalizes costs related to contracts that would have not been incurred if the contract was not obtained and the Company expects to recover such costs. The deferred costs, reported in the prepaid expenses and other current assets and other non-current assets on the Company’s Condensed Consolidated Balance Sheets, will be amortized over the economic benefit period of the contract.

~~In 2018, the Company capitalized the $~~2.0 million fee paid to a financial advisor as an incremental cost of obtaining a contract to commercialize and distribute the Company’s first FDA approved product SYMJEPI with Sandoz. On May 11, 2020, the Company entered into a termination agreement with Sandoz. As a result of entering into the termination agreement, the Company determined that its financial results for the quarter ending June 30, 2020 included the recognition of a full $~~1,750,000~~ ~~impairment of the capitalized cost to obtain a contract that was reflected on its condensed consolidated balance sheet as of March 31, 2020.~~

Inventories at ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020~~2021 consisted of the ~~following~~following: :

There was no reserve for obsolescence as of ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020 was approximately $577,000~~2021. ~~and $446,000, respectively.~~

Fixed ~~assets~~Assets, net at ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020~~2021 are summarized in the table ~~below~~below::

Depreciation expense for the three months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 was approximately $~~439,000~~399,000 and $~~396,000~~375,000, respectively; and for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, depreciation expense was approximately $~~847,000~~1,111,000 and $~~780,000~~1,072,000, respectively.

~~Intangible assets at June 30, 2021 and December 31, 2020 are summarized in the tables below~~:

~~Amortization expense for the three months ended June 30, 2021 and 2020 was approximately $238,000~~ ~~and $481,000, respectively; and for the six months ended June 30, 2021 and 2020, amortization expense was approximately $477,000~~ ~~and $963,000, respectively.~~

~~Estimated amortization expense of definite-lived intangible assets at June 30, 2021 for each of the five succeeding years and thereafter is as follows:~~

We have two operating segments and two reporting units. During the three months ended March 31, 2020, COVID-19 spread across the globe and adversely impacted economic growth, including as a result of government mandated shut-downs, stay-at-home policies and social distancing efforts intended to mitigate the spread of the virus. In light of the current economic downturn, that we believe affected the trading prices of our common stock, we determined that it was more likely than not that the fair value of our reporting unit was less than its carrying value. This triggered the Company to perform an interim impairment assessment to test the carrying value of goodwill, all of which is related to the Compounded Pharmaceuticals reporting unit, as of March 31, 2020. We also performed our annual impairment testing related to our Compounded Pharmaceuticals reporting unit as of December 31, 2020. The results of the annual impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to a decline in projected net cash flows as a result of the continued impact of COVID-19 on revenue and related cash flows.

For both the interim and annual impairment assessments, the Company utilized a combination of the market-based approach and income approach to determine the fair value of our Compounded Pharmaceuticals business segment. Our quantitative assessments utilized a market-based approach and assessed guideline publicly traded companies operating in the drug manufacturing and compounding industry in the healthcare sector that are similar from an investment standpoint to the Company. The income approach required management to estimate the future cash flows related to our reporting unit and included an adjustment to the discount rate for a company specific risk premium to account for the increased risk to future cash flows in the current environment. As a result of these analyses, the carrying value of our reporting unit exceeded the fair value by approximately $~~3,143,000~~ ~~and $3,629,000~~ as of March 31, 2020 and December 31, 2020, respectively. The difference between the carrying values and fair values which were recorded as goodwill impairment expense in their respective periods. No impairment charge was recorded for the year ended December 31, 2019.

~~The carrying value of the Company's goodwill as of June 30, 2021 and December 31, 2020 was approximately $868,000~~.

~~The change in the carrying amount of goodwill consisted of the following activity~~:

The Company has ~~three~~one operating ~~leases, one~~lease for an office ~~space, another for an office space and manufacturing facility, and one for office equipment; and one finance lease for plant equipment.~~space. As of ~~June~~September 30, ~~2021,~~2022, the ~~leases have~~lease has a remaining ~~terms between more than~~term of approximately ~~two years~~14 ~~and less than~~ ~~five years~~.months. The operating ~~leases do~~lease does not include an option to extend beyond the life of the current term. There are no short-term leases, and the lease ~~agreements do~~agreement does not require material variable lease payments, residual value guarantees or restrictive covenants.

~~The tables below present the operating and financing lease assets and liabilities recognized on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020~~:

The amortizable lives of operating and financing leased assets are limited by the expected lease term.

The ~~Company's leases generally do~~Company’s lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating and financing lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for leases that commenced prior to that date.

The ~~Company's~~Company’s weighted average remaining lease term and weighted average discount rate for operating and financing leases as of ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020 ar~~2021 were:e:

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the unaudited condensed consolidated balance sheets as of ~~June~~September 30, ~~202~~2022:1:

Operating lease expense for the three months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 was approximately $~~136,000~~88,000 and $~~128,000~~88,000, respectively; and for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021, operating lease expense was approximately $~~271,000~~265,000 and $~~257,000~~265,000, respectively. Operating lease costs are included within selling, general and administrative expenses on the condensed consolidated statements of operations.

~~Amortization expense related to our financing leases for the three months ended June 30, 2021 and 2020 was approximately $1,000~~ ~~and $1,000, respectively; and for the six months ended June 30, 2021 and 2020, amortization expense related to our financing leases was approximately $2,000~~ ~~and $2,000, respectively. Interest expense related to the financing leases for the three months ended June 30, 2021 and 2020 was approximately $~~1 ~~and $~~45~~, respectively; and for the six months ended June 30, 2021 and 2020, interest lease expense related to financing leases was approximately $~~10 ~~and $100, respectively. Financing lease costs are included within selling, general and administrative expenses on the condensed consolidated statements of operations.~~

Cash paid for amounts included in the measurement of operating lease liabilities were approximately $~~137,000~~93,000 and $~~127,000~~90,000 for the three months ended ~~June~~September 30, ~~2021~~2022, and ~~2020,~~2021, respectively, and approximately $~~274,000and $254,000for the six months ended June 30, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of financing lease liabilities were approximately $400~~278,000 and $~~1,000~~269,000 for the ~~three~~nine months ended ~~June~~September 30, 2022 and 2021, ~~and 2020, respectively, and approximately $1,600and $2,000for the six months ended June 30, 2021 and 2020,~~ respectively.

In connection with the closing of the acquisition of USC by the Company in April 2016 and the agreements relating to the transaction, an entity of which certain then-current or former officers, or stockholders, of USC were members, agreed to sell to the Company, the building and property owned by the entity on which USC’s offices are located, in consideration of the Company being added as an additional “borrower” and assuming the obligations under the loan agreement, promissory note and related loan documents that the entity and certain other parties previously entered into with First Federal Bank or its successor Bear State Bank or Arvest Bank, as successor in interest to Bear State Bank (together, the “Lender” or the “Bank”).

On November 10, 2016, a Loan Amendment and Assumption Agreement was entered with into the Bank. Pursuant to the agreement, as subsequently amended, the Company agreed to pay the Bank monthly payments of principal and interest which currently are approximately $~~19,000~~ ~~per month, with a final payment due and payable in August 2021.~~

~~As of June 30, 2021 and December 31, 2020, the outstanding principal balance owed on the applicable note was approximately $2,018,000~~ ~~and $2,067,000, respectively. The loan currently bears an interest of~~ ~~6.00% per year. Interest expense for the three months ended June 30, 2021 and 2020 was approximately $30,000~~ ~~and $31,000, respectively. Interest expense for the six months ended June 30, 2021 and 2020 was approximately $61,000~~ ~~and $70,000~~ ~~respectively.~~

~~On July 8, 2021, the Company paid in full the building loan, and there is no outstanding balance under the building loan.~~

On April 13, 2020, the Company received $3,191,700 in loan funding from the Paycheck Protection Program (the “PPP”), established pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and administered by the U.S. Small Business Administration (“SBA”). The unsecured loan (the “PPP Loan”) is evidenced by a promissory note of the Company (the “Note”), in the principal amount of $3,191,700, to Arvest Bank (the “Bank”), the lender. The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. Subsequent guidance from the SBA and the Department of the Treasury indicated that in assessing the economic need for the loan, a borrower must take into account its current activity and ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds pursuant to the PPP Loan, and the forgiveness of the PPP Loan attendant to these funds, is dependent on the Company having initially qualified for the loan and, in the case of forgiveness, qualifying for the forgiveness of such loan based on our future adherence to the forgiveness criteria.

Under the terms of the Note and the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the Note is two years, unless sooner provided in connection with an event of default under the Note. To the extent the loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the Note (or later if a timely loan forgiveness application has been submitted), until the maturity date.

The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company may apply for and be granted forgiveness for all or part of the PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during a specified period after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that at least 60% of the loan amount is used for eligible payroll costs; the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible costs during the covered eight-week or 24-week period will qualify for forgiveness.

In December 2020, the Company submitted an application for the forgiveness of our PPP Loan. In August 2021, the Company received notification through the Bank that as of August 5, 2021, the PPP Loan, including principal and interest thereon, has been fully forgiven by the SBA and that the remaining PPP Loan balance is 0zero. The Company ~~will recognize~~recognized the amount forgiven as other ~~income for the quarter in which the Company received the notification.~~income.

On March 15, 2021, the Company entered into a Note (the “PPP2 Note”) in favor of the Bank, in the principal amount of $1,765,495 relating to funding under a Second Draw loan (the “Second Draw Loan”) pursuant to the terms of the PPP, the CARES Act, and the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act enacted in December 2020. Under the terms of the PPP2 Note and Second Draw Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. ~~If any payment on the PPP2 Note is more than 15 days late, the Bank may charge the Company a late fee of up to~~ 5~~% of the unpaid portion of the regularly scheduled payment.~~ The term of the PPP2 Note iswas five years, unless sooner provided in connection with an event of default under the PPP2 Note. The Company may prepay the Second Draw Loan at any time prior to maturity with no prepayment penalties. Under the PPP, the proceeds of the Second Draw Loan may be used to pay payroll and make certain covered interest payments, lease payments and utility payments. The Company may apply for forgiveness of some or all of the Second Draw Loan pursuant to the PPP. In order to obtain full or partial forgiveness of the Second Draw Loan, the borrower must timely request forgiveness, must provide satisfactory documentation in accordance with applicable SBA guidelines, and must satisfy the criteria for forgiveness under the PPP and applicable SBA requirements. ~~If the~~The Company ~~timely applies~~applied for forgiveness payments will be deferred in accordance with the CARES Act, as modified by the Paycheck Protection Program Flexibility Act of 2020, and we will not be obligated to make any payments of principal or interest before the date on which the SBA remits the loan forgiveness amount to the Bank or notifies the Bank that no loan forgiveness is allowed; and the Bank will then notify us of remittance by SBA of the loan forgiveness amount or notify us that the SBA determined that no loan forgiveness is allowed and the date that our first payment is due. Interest will accrue during the deferral period. There is no assurance that the Company will obtain forgiveness of the Second Draw Loan in whole or in part. Our PPP loans and applications for forgiveness of loan amounts are subject to review by SBA for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form. Accordingly, the Company may be audited or reviewed by federal or state regulatory authorities as a result of filing an application for forgiveness or otherwise. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return or repay the full amount of the applicable loan and could be subject to fines or penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations. If the Second Draw Loan is not forgiven in accordance with the terms of the PPP, the Company will be obligated to make monthly payments of principal and interest to repay the Second Draw Loan in full prior to the maturity date. If it is determined that the Company was ineligible to receive the Second Draw Loan, the Company may be required to repay the Second Draw Loan in its entirety and/or be subject to additional penalties. Should the Company apply for and receive forgiveness of some or all of the PPP2 Loan, the amount forgiven would be recognized as other income upon formal notice of forgiveness.  If we do not submit a loan forgiveness application to the Bank within 10 months after the end of our applicable covered period, as defined under the PPP and applicable regulations and guidance issued by the SBA or the U.S. Department of Treasury, then we must begin paying principal and interest after that period. The PPP2 Note contains customary events of default relating to, among other things, payment defaults, breaches of representations, warranties or covenants, defaults on other loans with the Bank, failure to disclose material fact or making materially false or misleading representations to the Bank or SBA, certain defaults on other loan agreements or agreements with creditors, bankruptcy or insolvency events, certain change of control events, material adverse changes or events, certain events that the Bank believes may materially affect the Company’s ability to pay the PPP2 Note, and certain other events. The occurrence of an event of default may result in ~~the repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment against the Company.~~

~~In September 2021, the Company submitted an application for the forgiveness of our Second Draw PPP Loan. In~~ October 2021 the Company received notification through the Bank that as of September 28, 2021, the Second Draw PPP Loan, including principal and interest thereon, ~~has been~~was fully forgiven by the ~~SBA and~~SBA. The Company recognized the amount forgiven as other income in the third quarter of 2021. However, as described further in Note 9 below, in March 2022 the Company was informed that the ~~remaining~~Civil Division of the U.S. Attorney’s Office for the Southern District of New York was investigating the Company’s Second Draw PPP Loan ~~balance is~~ and eligibility for that loan, and the Company’s financial statements for the quarter ended March 31, 2022, included a $01,850,000. contingent loss liability relating to the possible repayment of the full amount of the Second Draw PPP Loan as well as accrued interest and processing fees of the lending bank. In June 2022, following the inquiry, the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees.

Even though the PPP Loan has been forgiven and the Second Draw PPP Loan ~~have been forgiven,~~repaid, our PPP loans and applications for forgiveness of loan amounts remain subject to review and audit by SBA for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form, including without limitation the required economic necessity certification by the Company that was part of the PPP loan application process. Accordingly, the Company is subject to audit or review by federal or state regulatory authorities as a result of applying for and obtaining the PPP Loan and Second Draw PPP Loan or obtaining forgiveness of those loans. If wethe Company were to be audited or reviewed and receive an adverse determination or finding in such audit or review, weincluding a determination that the Company was ineligible to receive the applicable loan, the Company could be required to return or repay the full amount of the applicable loan and could be subject to additional fines or penalties, which could reduce ~~our~~the Company's liquidity and adversely affect our business, financial condition and results of operations. If it is determined that the Company was ineligible to receive the PPP Loan and/or the Second Draw Loan, the Company may be required to repay the PPL Loan and Second Draw Loan in its entirety and/or be subject to additional penalties.

~~As of June 30, 2021 and December 31, 2020, the outstanding unpaid principal balance of the PPP loans were $4,957,195~~ ~~and $3,191,700, respectively.~~

~~At June 30, 2021, the outstanding principal maturities of the amended long-term debts were as follows~~:

The carrying value of the Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to the short-term nature of these items. ~~Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the debt approximates fair value.~~

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

~~The~~The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value ~~hierarchy~~hierarchy: :

The fair value measurement of the warrants issued by the Company in February 2020 (the ~~"2020 Warrants"~~“2020 Warrants”) are based on significant inputs that are unobservable and thus represents a Level 3 measurement. The Company’s estimated fair value of the Warrant liability is calculated using the Black Scholes Option Pricing Model. Key assumptions at ~~June~~September 30, ~~2021~~2022 include the expected volatility of the Company’s stock of approximately 70%, the Company’s stock price at valuation date of $~~1.10~~0.199, expected dividend yield of 0.0%, expected term of 2.93 years and average risk-free interest rate of approximately ~~0.726~~4.255%. The Level 3 estimates are based, in part, on subjective assumptions. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs.

The fair value measurement of the warrants issued by the Company in ~~August 2019~~February 2020 (the ~~"2019 Warrants"~~“2020 Warrants”) ~~and the 2020 Warrants~~ are based on significant inputs that are unobservable and thus represents a Level 3 measurement. The Company’s estimated fair value of the Warrant liability is calculated using the Black Scholes Option Pricing Model. Key assumptions at December 31, ~~2020~~2021 include the expected volatility of the Company’s stock of approximately 80~~% and~~ 70% ~~for 2019 and 2020 Warrants, respectively;~~, the Company’s stock price at valuation date of $~~0.49~~0.605;, expected dividend yield of 0.0% ~~and;~~, expected term of 3.68 years and average risk-free interest rate of approximately ~~0.26~~1.038% ~~and~~ ~~0.36% for 2019 and 2020 Warrants, respectively.~~. The Level 3 estimates are based, in part, on subjective assumptions. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs.

The following table sets forth a summary of ~~the~~ changes in the fair value of the ~~Company’s~~Company's Level 3 financial instruments, which are treated as liabilities, as follows:

The Company has certain assets, such as goodwill, that are measured at fair value on a non-recurring basis and are adjusted to fair value only when the carrying values are more than the fair values. Based on market data of companies operating in the compounding and generic drug manufacturing industry, for the March 31, 2020 and December 31, 2020 goodwill impairment analysis, the Company used a discount rate of ~~26.5% and~~ ~~17.3~~%, respectively, for the income approach calculation which includes a Company specific risk premium to account for the increased risk to future cash flows in the current environment. The categorization of the framework used to price the assets is considered Level 3, due to the subjective nature of the unobservable inputs used to determine the fair value.

As discussed in Note 5, Intangible Assets And Goodwill, the Company performed an interim impairment assessment to test the carrying value of goodwill, all of which is related to the Compounded Pharmaceuticals reporting unit, as of March 31, 2020. As a result of the analysis, the carrying value of our reporting unit exceeded the fair value by approximately $~~3,143,000~~, which was recorded as goodwill impairment expense as of March 31, 2020. On December 31, 2020, the Company performed its annual impairment assessment and as a result of the analysis, the carrying value of our reporting unit exceeded the fair value by approximately $~~3,629,000, which was recorded as goodwill impairment expense on December 31, 2020. Refer to Note 5 for more information.~~

The Company has a production threshold commitment to a manufacturer of our SYMJEPI products where the Company would be required to pay for maintenance fees if it does not meet certain periodic purchase order minimums. Any such maintenance fees would be prorated as a percentage of the required minimum production threshold. Maintenance fees for the three months ended June 30, 2021 and 2020 were approximately $0 ~~and $420,000, respectively. Maintenance fees for the six months ended June 30, 2021 and 2020 were approximately $~~0 ~~and $840,000, respectively.~~

The Company may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, breach of contract claims, labor and employment claims ~~claims relating to our compounded pharmacy business,~~ and other matters. We may also become party to litigation in federal and state courts relating to opioid drugs. Any litigation could divert management time and attention from Adamis, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, we are not currently involved in any legal proceedings that we believe are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on us because of associated cost and diversion of management time.

On September 21, 2018, Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center LLC (collectively, “Nephron”) filed a lawsuit in the United States District Court for the Middle District of Florida, Orlando Division, alleging claims against our wholly owned subsidiary USC —and a USC employee who previously was an employee of Nephron. The original complaint asserted thirteen causes of action against the employee and USC alleging generally misappropriation of Nephron’s trade secrets. The plaintiffs subsequently amended their complaint to include Adamis as a defendant. After several motions to dismiss, only four claims remained from the third amended complaint: (1) misappropriation under the Federal Defend Trade Secrets Act (“DFSA”), (2) breach of contract (against the employee only), (3) misappropriation under the Florida Uniform Trade Secrets Act (“FUTSA”), and (4) tortious interference with an advantageous business relationship. The gravamen of these claims was that the employee improperly misappropriated trade secret information from the employee’s former employer, Nephron, prior to starting employment at USC and that USC improperly recruited the employee for employment at USC. The third amended complaint alleged that Adamis and USC aided in this misappropriation by “using and/or disclosing and/or retaining the same in an effort to unfairly compete against Nephron.” The third amended complaint sought actual, compensatory, consequential, special, and punitive damages, attorneys’ fees and costs, prejudgment interest, preliminary and permanent injunctive relief, and other relief. Investigations

On May 6, 2020, Adamis and USC moved for summary judgment to dismiss the three claims that remained pending against them. In October 2020, the magistrate judge presiding over the motion delivered a Report and Recommendation recommending that the court enter an order granting the motion in part and denying the motion in part. The court adopted the recommendation of the magistrate and granted in part and denied in part the motion of Adamis and USC for summary judgment. The court denied the motion for summary judgment by Adamis and USC with respect to the plaintiffs’ claims under the DFSA and FUTSA, concluding that there were triable issues of material fact that precluded the entry of summary judgment, and granted the motion for summary judgment in favor of Adamis and USC with respect to the claim for tortious interference. In March 2021, the court granted a motion by Nephron to hold Adamis and USC in civil contempt for violation of a previous consent preliminary injunction related to the hiring by USC of an employee, and ordered that Adamis and USC compensate Nephron for certain fees and expenses in the litigation relating to the matter as well as pay a fine, in an amount to be determined. A hearing on the amount of such sanctions was held on April 6, 2021, but decisions regarding sanctions were deferred until after trial. After the hearing, the court ruled on various pre-trial motions relating to the conduct of the trial. The case was set for trial on April 19, 2021.

As previously disclosed in the 2020 Form 10-K, while we continued to believe that the claims and damages sought by the plaintiff were without merit, in light of several factors including the recent hearing and outcome of decisions concerning pre-trial motions, the legal expenses of ongoing litigation and trial, the uncertainties of litigation and jury trials, and the possibility of punitive damages and other adverse awards or sanctions, on April 9, 2021, Adamis, USC and Nephron agreed to terms of settlement of the Florida litigation as well as a related case filed by Nephron against USC, Adamis and a second USC employee in the United States District Court for the District of New Jersey alleging misappropriation of trade secrets from Nephron. Under the terms of the settlement agreement entered into by Adamis, the Nephron entities and certain other individuals (the “individual parties”), and related documents entered into by the parties thereto, on May 3, 2021, the Company paid Nephron an amount equal to $~~7,900,000~~; the Company and USC, as well as the individual parties, agreed to a permanent injunction reflecting certain terms of the settlement and pursuant to which they agreed, among other things, not to retain, access, communication, use or disclose any proprietary or confidential information of Nephron and to destroy all such information in their possession or control, subject to limited exceptions; and Nephron agreed to dismissal of or withdrawal from the lawsuits and related legal proceedings. A contingent loss liability of $~~7,900,000~~ was included in the Company's consolidated balance sheet as of December 31, 2020. Pursuant to the settlement agreement, each of the parties agreed to release each other from all existing claims that any of them may have against any of the other parties that arise from or relate to the claims and liabilities asserted in the various lawsuits and agreed not to sue any of the parties on the basis of any released claim.

~~On May 11, 2021, the~~ The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review the matters brought forth in the subpoenas and certain other matters. The investigation involved, among other matters, interviews with employees and collection and review of a large number of documents. The company has taken a number of actions in response to the internal investigation, including personnel actions relating to certain USC veterinary sales employees. In addition, following the commencement of the investigation, as disclosed elsewhere in ~~this Report~~these interim condensed consolidated financial statements, the ~~company~~Company has sold assets relating to its compounding pharmacy business, ceased selling human and veterinary compounded pharmaceutical products, ~~is engaged in a process of winding~~has wound down USC’s business, and the employment of ~~substantially all~~ USC employees has ~~ended or will end in connection with the winding down of that business.~~ended. As a result, the ~~company will~~Company is no longer be engaged in the sale of human or veterinary compounded pharmaceutical products. The ~~company~~Company is also considering a number of additional actions in response to the internal investigation and the USAO investigation. As of the date of ~~this Report,~~these interim condensed consolidated financial statements, we believe that the investigation initially commenced by the Audit Committee is substantially complete. However, additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the Audit Committee’s investigation. ~~In addition to the subpoenas from the USAO, the company~~

The Company has also received requests from the U.S. Securities and Exchange Commission (“SEC”) for the voluntary production of documents and information in connection with the SEC’s investigation relating to the subject matter of the USAO’s subpoenas and certain other matters. The ~~company~~Company has produced documents and will continue to produce and provide documents in response to ~~the~~ subpoenas and ~~requests.~~requests for voluntary production of documents as needed. Additionally, on March 16, 2022, the Company was informed that the Civil Division of the USAO (“Civil Division”) was investigating the Company’s Second Draw PPP Loan application and the company’s eligibility for the Second Draw PPP Loan. The ~~company~~Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. As a result of the investigation by the Civil Division, the Company’s financial statements for the first quarter of 2022 included a $1,850,000 contingent loss liability relating to the possible repayment of the full amount of the Second Draw PPP Loan as well as accrued interest and processing fees of the lending bank. In June 2022, following the inquiry the Company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and related interest and fees. The Company previously disclosed that the lending bank waived the processing fee of approximately $63,000; however, the Company has recently been made aware by the Civil Division that the lending bank did receive a processing fee of approximately $53,000 and that it may need to be repaid. The Company is awaiting confirmation from the Civil Division on the potential repayment of the above-referenced processing fee and as to whether any additional action is required to conclude the investigation into the Second Draw PPP Loan. The Company intends to ~~cooperate~~continue cooperating with the USAO, SEC, and ~~the SEC.~~Civil Division. At this time, the ~~company~~Company is unable to predict the duration, scope, or outcome of the investigations by the USAO, SEC, Civil Division, or other ~~agencies, or determine~~agencies; what, if any, proceedings the USAO, SEC, Civil Division, or other federal or state authorities may ~~initiate,~~initiate; what, if any, remedies or remedial measures the USAO, SEC, Civil Division or other federal or state authorities may ~~seek,~~seek; or what, if any, impact the foregoing matters may have on the ~~company’s~~Company’s business, previously reported financial results, financial results included in ~~this Report,~~these interim condensed consolidated financial statements, or future financial ~~results.. We~~results. The Company could receive additional requests or subpoenas from the USAO, SEC, Civil Division, or other authorities, which may require further investigation. There can be no assurance that any discussions with the USAO, SEC or ~~USAO~~Civil Division to resolve these matters will be successful.

The foregoing matters may divert management’s attention, cause the ~~company~~Company to suffer reputational harm, require the company to devote significant financial resources, subject the ~~company~~Company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, result in fines, penalties or equitable remedies, and affect the ~~company’s~~Company’s business, previously reported financial results, financial results included in ~~this Report,~~these interim condensed consolidated financial statements, or future financial results. The occurrence of any of these events, or any determination that our activities were not in compliance with existing laws or regulations, could have a material adverse effect on the ~~company’s~~Company’s business, liquidity, financial condition, and results of operations.

OnAs previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, and in our subsequent Quarterly Reports on Form 10-Q for the first two quarters of 2022, on June 8, 2021, Jerald Hammann filed a complaint against the Company and each of its directors in the Court of Chancery of the State of Delaware, captioned Jerald Hammann v. Adamis Pharmaceuticals Corporation et al., C.A. No. 2021-0506-PAF (the “Complaint”), seeking injunctive and declaratory relief. The Complaint alleges, among other things, that the defendants (i) violated Rule 14a-5(f) and 14a-9(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with the Company’s 2021 annual meeting of stockholders—which was subsequently held on July 16, 2021 (the “2021 annual meeting”)—and disseminated false and misleading information in the Company’s proxy materials relating to the 2021 annual meeting, (ii) violated certain provisions of the Company’s bylaws relating to the 2021 annual meeting, (iii) violated section 220 of the Delaware General Corporation Law (“DGCL”) in connection with a request for inspection of books and records submitted by the plaintiff, and (iv) breached their fiduciary duties of disclosure and loyalty, including relating to establishing and disclosing the date of the Company’s 2021 annual meeting and to the Company’s determination that a solicitation notice delivered to the Company by plaintiff was not timely and was otherwise deficient. The ~~Complaint alleges, among other things, that~~ plaintiff ~~intended to initiate a proxy contest against~~has also filed various motions with the Court, which have been resolved. The Company that defendants’ conduct made it difficult or impossible for plaintiff to initiate a proxy context, and that the Company’s definitive proxy statement included false and misleading disclosures and omissions of material information. The Complaint sought injunctive relief (i) to prevent the Board, the Company, and their employees and agents from soliciting any stockholders pursuant to the Company’s proxy statement and (ii) to prevent the defendants from interfering in the effectiveness of stockholder voting for the 2021 annual meeting. The Complaint also seeks declaratory relief (i) finding that plaintiff’s solicitation notice was timely and properly submitted; (ii) directing the defendants to comply with Rules 14a-5(f) and 14a-9(a) of the Exchange Act; (iii) directing the Company to produce the materials set forth in the plaintiff’s books and records request; (iv) finding that the director defendants breached their fiduciary obligations to stockholders; and (v) finding that the director defendants engaged in self-dealing. The Complaint seeks an award of fees, costs, and expenses in this action, including attorneys’ and experts’ fees.

~~On June 10, 2021, the plaintiff~~has filed a motion for summary judgment with respect to one of the counts in the complaint and a ~~temporary restraining order~~motion to dismiss certain other counts of the plaintiff's amended complaint. Those motions are pending before the Court, and ~~for expedited proceedings, seeking~~the case continues to proceed. On October 13, 2022, the Court entered an order ~~enjoining~~scheduling oral arguments on the Company from printing or disseminating its proxy statement relating to the 2021 annual meeting or from convening the 2021 annual meeting on July 16, 2021. Following a hearing, on June 17, 2021, the Court determined that: (i) it did not have jurisdiction to consider the plaintiff’s claims relating to alleged violations of the Exchange Act; (ii) plaintiff’s claims regarding the booksmotion for summary judgment and ~~records request and alleged violations of section 220 of the DGCL should be pursued in a separate proceeding, and the Court denied the plaintiff’s~~ motion to ~~expedite~~dismiss for December 19, 2022. Trial on the ~~books and records claims; (iii) certain~~merits of the plaintiff’s claims, alleging breach of the fiduciary duty of disclosure against the individual defendants, including claims based on alleged misrepresentations and omissions in the Company’s proxy statement, were not colorable; and (iv) plaintiff’s claim alleging that the individual defendants violated their fiduciary duty by taking action purportedly intended to prevent the plaintiff from pursuing a proxy contest survived a low threshold of colorability, but the Court denied the plaintiff’s motionshould one be necessary, is currently scheduled for ~~a temporary restraining order. The Court granted in part the motion to expedite the proceedings.~~

~~The case is proceeding and the parties are currently engaged in discovery.~~March 16, 2023. The Company believes the claims in the plaintiff’s ~~Complaint~~complaint are without merit and intends to vigorously dispute them. The Company has not recorded a contingent liability related to this matter.

The Company records accruals for loss contingencies associated with legal matters when the Company determines it is probable that a loss has been or will be incurred and the amount of the loss can be reasonably estimated. Where a material loss contingency is reasonably possible and the reasonably possible loss or range of possible loss can be reasonably estimated, U.S. GAAP requires us to disclose an estimate of the reasonably possible loss or range of loss or make a statement that such an estimate cannot be made.

On December 31, 2021, we received a notice from the Nasdaq Listing Qualifications Department of The ~~company has~~NASDAQ Capital Market (“Nasdaq”) informing us that because the closing bid price of our common stock had been below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) (the “Rule”) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), we were provided an initial compliance period of 180 calendar days, or until June 29, 2022, to regain compliance. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. The notice letter also disclosed that if we do not ~~accrued any amount in respect~~regain compliance within the initial compliance period, we may be eligible for an additional 180-day compliance period. To qualify for additional time, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the ~~matters described under~~bid price requirement, and would need to provide written notice of a plan to cure the ~~headings “Investigation” or “Jerald Hammann,” since even~~deficiency during the second compliance period, including by effecting a reverse stock split if ~~it is probable that such matters may result in~~necessary. We did not regain compliance with the Rule by June 29, 2022. We requested additional time to regain compliance and provided notice to Nasdaq of our intention to cure the deficiency during the second compliance period, including by effecting a ~~material loss contingency, we cannot estimate the probable loss or the range of probable losses~~reverse stock split if necessary. On June 30, 2022, Nasdaq notified us that we ~~may incur. We are unable~~were granted an additional 180-day compliance period, or until December 27, 2022, to ~~make such an estimate because (i)~~regain compliance with ~~respect~~the Rule. The letter also indicated that if at any time before December 27, 2022, the bid price of the Company’s Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Rule. If the Company does not meet the minimum bid requirement at some time during the additional 180-day grace period, Nasdaq will provide written notification to the ~~matters described under the heading “Investigation,” we are unable to predict whether any proceedings~~Company that its shares will be ~~initiated by the USAO, SEC or other authorities arising from~~subject to delisting. At such matters, what, if any, relief, remedies or remedial measures the USAO, SEC, or other authorities may seek if proceedings are commenced, and the duration, scope, or outcome of any such proceedings, if they are commenced, (ii) litigation and other proceedings are inherently uncertain and unpredictable, and (iii) with respect to the matters described under the heading “Jerald Hammann,” the complaint seeks declaratory and injunctive relief. Because legal proceedings and investigations are uncertain and unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires significant judgments about future events, including determining both the probability and reasonably estimated amount of a possible loss or range of loss. The amount of any ultimate loss may differ from any accruals or estimates thattime, the Company may ~~make.~~appeal the delisting determination to a Nasdaq Hearings Panel. The Company would remain listed pending the Panel’s decision. There can be no assurance that if the Company does appeal a subsequent delisting determination, that such appeal would be successful. The letter and notification from Nasdaq had no immediate effect on the listing or trading of the Company’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol “ADMP.” There are no assurances that we will be able to regain compliance with the minimum bid price requirements or will otherwise be in compliance with other Nasdaq listing rules.

In January and February 2021, the Company issued common stock upon exercise of investor warrants. The warrant holders exercised for cash at exercise prices ranging from $0.70 to $1.15 per share. The Company received total proceeds of approximately $5,852,000 and the warrant holders received 8,356,000 shares of common stock.

On February 2, 2021, the Company completed the closing of an underwritten public offering of 46,621,621 shares of common stock at a public offering price of $1.11 per share, which included 6,081,081 shares pursuant to the full exercise of the over-allotment option granted to the underwriters. Net proceeds were approximately $48.4 million, after deducting approximately $3.3 million in underwriting discounts and commissions and estimated offering expenses payable by the Company.

On July 5, 2022, the Company entered into a private placement transaction with Lincoln Park Capital Fund, LLC, (or, "Lincoln Park") pursuant to which the Company issued an aggregate of 3,000 shares of Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred”), together with warrants (the "Warrants") to purchase up to an aggregate of 750,000 shares of common stock of the Company, at an exercise price of $0.47 per share (subject to adjustment as provided in the Warrants). Gross proceeds were $300,000, excluding transaction costs, fees and expenses of $15,000. The Warrants become exercisable commencing January 3, 2023 and have a term ending on January 5, 2028.

The Series C Preferred is entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of common stock, when, as and if actually paid on shares of common stock (subject to adjustments pursuant to the related Certificate of Designation.) The Series C Preferred will have no voting rights (other than the right to vote as a class on certain matters as provided in the related Certificate of Designation). However, each share of Series C Preferred entitles the holder thereof (i) to vote exclusively on the Proposal (as defined in the related documents) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal, and (ii) to 1,000,000 votes per each share of Series C Preferred.

The Series C Preferred shall, except as required by law, vote together with the common stock and any other issued and outstanding shares of preferred stock of the Company entitled to vote, as a single class; provided, however, that such shares of Series C Preferred shall, to the extent cast on the Proposal, be automatically and without further action of the holders thereof voted in the same proportion as shares of common stock (excluding any shares of common stock that are not voted) and any other issued and outstanding shares of preferred stock of the Company entitled to vote (other than the Series C Preferred or shares of such preferred stock not voted) are voted on the Proposal and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal. The Series C Preferred has a “Stated Value” of $100 per share of Series C Preferred. (i) Upon any liquidation, dissolution or winding up of the Company (a “Liquidation”), the holders of Series C Preferred are entitled to be paid in cash an amount per share of Series C Preferred equal to 110% of the Stated Value (the “Liquidation Amount”), or (ii) in the event of a “Deemed Liquidation Event” as defined in the Certificate of Designation, which generally includes certain merger transactions or a sale, lease or other disposition of all or substantially all of the assets of the Company, the holders of Series C Preferred are entitled to paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the “Available Proceeds” (as defined in the Certificate of Designation), in each case before any payment may be made to the holders of Common Stock by reason of their ownership thereof, an amount per share of Series C Preferred equal to the Liquidation Amount. Upon certain of the Deemed Liquidation Events, if the Company does not effect a dissolution within 90 days after such event, then the holders of Series C Preferred may require the Company to redeem the Series C Preferred for an amount equal to the Liquidation Amount.

The Series C Preferred is convertible into shares of common stock at the option of the holder, any time after the effective date of a reverse stock split of the outstanding shares of the Common Stock at a ratio set forth in a reverse stock split proposal by means of an amendment to the Company’s certificate of incorporation approved by the board of directors and the stockholders of the Company (a “Reverse Stock Split”), into that number of shares common stock (subject to certain beneficial ownership limitations applicable to each holder, and to compliance with the rules and regulations of the Nasdaq Capital Market) determined by dividing the Stated Value of such share of Series C Preferred by the conversion price then in effect, rounded down to the nearest whole share (with cash paid in lieu of any fractional shares). The conversion price for the Series C Preferred equals 90% of the lesser of (i) the closing sale price of the Common Stock on the trading day immediately prior to the Closing Date and (ii) the average of the closing sale prices for the common stock on the five trading days immediately prior to the closing date, subject to adjustment as provided in the certificate of designation; provided, that the conversion price may not fall below the par value per share of the common stock and may not exceed $0.60 per share. Based on the initial conversion price of $0.43 per share, the 3,000 Shares of Series C Preferred are initially convertible into approximately 697,674 shares of common stock. The conversion price is subject to adjustment as set forth in the certificate of designation for stock dividends, stock splits, reverse stock splits, and similar events. The Series C Preferred also contain redemption features by the holder at 110%, at any time after the effective date of a Reverse Stock Split and by the issuer at 105%, at any time after the effective date of a Reverse Stock Split. Additionally, in accordance with the transaction agreement, the Company filed a registration statement with the SEC, which has been declared effective, to register the resale from time to time of shares of common stock underlying the Series C Preferred and the Warrants.

The Company determined that the Series C Preferred should be classified as mezzanine equity (temporary equity outside of permanent equity), that the Series C Preferred more closely aligned with debt as the intent is for redemption by either the holder or issuer, mostly likely the issuer (the Company) due to the more favorable redemption terms. The embedded conversion feature was determined to meet the derivative scope exception. The Company did not separately account for the redemption features as the fair value of such feature is not material. The Warrants are freestanding and detachable; and the Company determined that the warrants meet the criteria for equity classification in the Company’s consolidated balance sheet. With the equity classification of both the Series C Preferred and the warrants, the $15,000 in transaction costs were allocated between the Series C Preferred and the Warrants, which netted the proceeds received. Net proceeds were allocated between the Series C Preferred and the Warrants based on their relative fair values.

Fair value for both the Series C Preferred and the related warrants were based on significant inputs that were unobservable and thus represented Level 3 measurements. Fair value for the Series C Preferred was based on the weighted value of the Reverse Stock Split approval and the value of the Reverse Stock Split rejection times the probability of each scenario as assessed by management at the time of the Series C Preferred stock issuance. Fair value of the Warrants was based on the Black-Scholes pricing model, using the following inputs: $0.53 stock price, $0.47 exercise, 5.5 years remaining expected term, 70% volatility, 0% dividend rate and 2.82% risk free rate. The relative fair value ascribed to the Series C Preferred was approximately $157,300 and the relative fair value ascribed to the Warrants was approximately $127,700.

Subsequent to the issuance of the Series C Preferred, in connection with the Company’s annual meeting of stockholders, in September 2022 the Company’s stockholders voted on a reverse stock split proposal, and the proposal was not approved. Pursuant to the Series C Preferred transaction agreements, at September 30, 2022, in the consolidated balance sheet, the Company accrued $15,000 owed to Lincoln Park resulting from the failure of the reverse stock split proposal to be approved at the meeting. Based on the failure, redemption of the Series C Preferred is not probable at September 30, 2022, and, as such, no accretion was recorded to the redemption value. The warrants are equity-classified, and, as such do not require revaluation and 750,000 warrants remain outstanding as of September 30, 2022.

The Company accounts for stock-based compensation transactions in which the Company receives employee services in exchange for restricted stock units (“RSUs”) or options to purchase common stock and the Company recognizes stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period. Stock-based compensation cost for RSUs is measured based on the closing fair market value of the Company’s common stock on the date of grant. Stock-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur and will reduce compensation cost at the time of forfeiture. Cash-settled Stock Appreciation Rights (“SARs”) provide for the cash payment of the excess of the fair market value of the Company’s common stock price on the date of exercise over the grant price. The fair value of the SARs is calculated during each reporting period and estimated using the Black-Scholes option pricing model. The SARs will vest over a period of three years and are accounted for as liability awards since they will be settled in cash. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of the Company’s common stock over the grant price is paid in cash and not in common stock. The Company accounts for forfeiture as they occur and reduces the compensation cost at the time of forfeiture.

At the Company’s 2020 annual meeting of stockholders, the stockholders approved the Company’s 2020 Equity Incentive Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards, and other forms of equity compensation (collectively “stock awards”). In addition, the 2020 Plan provides for the grant of cash awards. The initial aggregate number of shares of common stock that may be issued ~~initially~~ pursuant to stock awards under the 2020 Plan is 2,000,000 shares. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year during the term of the 2020 Plan, commencing January 1, 2021, by 5.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares of common stock determined by the Company’s board of directors before the start of a calendar year for which an increase applies. One of the provisions of the 2020 Plan is that no award may be granted, issued or made under the 2020 Plan until such time as the fair market value of the common stock, which is generally the closing sales price of the common stock on the principal stock market on which the common stock is traded, has been equal to or greater than $3.00 per share (subject to proportionate adjustment for stock splits, reverse stock splits, and similar events) for at least 10ten consecutive trading days, after which time awards may be made under the 2020 Plan without regard to any subsequent increase or decrease in the fair market value of the common stock. No awards were made pursuant to the 2020 Plan as of ~~June~~September 30, ~~2021.~~

On January 1, ~~2021,~~2022, pursuant to the 2020 Equity Incentive Plan the number of shares reserved for the issuance of stock awards increased by ~~4,692,103~~7,479,713 shares.

In June 2022, the Company issued 250,000 shares of common stock to a former executive officer of the Company pursuant to a separation agreement between the Company and the officer. The separation agreement resulted to the modification of the RSU previously issued to the officer, accelerating the RSU vesting upon his separation. As a result of this Type III modification, the Company determined the cumulative compensation cost that should have been recognized at that date as if the fair value of the modified award had been recognized from the original grant date over his requisite service period, which resulted in the reversal of approximately $540,000 in expense.

The following table summarizes the stock option activity for the ~~six~~nine months ended ~~June~~September 30, ~~2021 below:~~2022:

~~Expense related to stock options for the three months ended June 30, 2021 and 2020 was approximately $~~

~~5,000~~ ~~and $292,000, respectively; and for the six months ended June 30, 2021 and 2020, expense related to stock options was approximately $147,000~~ ~~and $722,000, respectively.~~

As of ~~June~~September 30, ~~2021,~~2022, the compensation expense related to stock options ~~have~~issued under the Company’s 2009 Equity Incentive Plan has been fully ~~amortized.~~recognized.

The aggregate intrinsic value (the difference between the Company’s closing stock price on the last trading day of the ~~period~~year and the exercise price, multiplied by the number of in-the-money options) of ~~the~~ ~~6,113,866and~~ ~~6,508,296~~ ~~stock~~all options outstanding at ~~June~~September 30, ~~2021~~2022 and ~~December 31, 2020~~2021 was $0~~, respectively.~~ .

The ~~aggregate intrinsic value of~~ ~~6,108,933~~ ~~and~~ ~~6,397,703~~ following summarizes the restricted stock ~~options exercisable at June~~unit activity for the nine months ended September 30, ~~2021 and December 31, 2020 was $~~0~~, respectively.~~2022 below:

~~Expense related to RSUs for~~As of September 30, 2022, the ~~three months ended June 30, 2021 and 2020 was approximately $793,000~~ ~~and $823,000, respectively; and for the six months ended June 30, 2021 and 2020,~~unamortized compensation expense related to RSUs was approximately $~~1,531,000~~366,000 and will be recognized over 1.17 years.

Stock-based compensation recognized as selling, general and administrative costs (or, SG&A) for three months ended September 30, 2022 and 2021, was approximately $71,000 and $~~1,612,000~~(59,000), respectively. ~~As of June~~

Stock-based compensation recognized as research and development costs (or, R&D) for three months ended September 30, 2022 and 2021, ~~the unamortized compensation expense related to RSUs options~~ was approximately $~~2,980,000~~4,000~~. The weighted-average period in years over which the remaining unamortized expense will be~~ and $212,000, respectively.

Stock-based compensation recognized is as SG&A for nine months ended September 30, 2022 and 2021, was approximately $~~1.68~~(137,000) ~~years.~~and $1,012,000, respectively.

Stock-based compensation recognized as R&D for nine months ended September 30, 2022 and 2021, was approximately $123,000 and $818,000, respectively.

The following table summarizes warrants outstanding at ~~June~~September 30, ~~2021 and December 31, 2020:~~2022:

At ~~June 31, 2021,~~September 30, 2022, the Company has reserved shares of common stock for issuance ~~following vesting~~ upon exercise of outstanding options, warrants including all of the warrants in the table above, restricted stock units and ~~upon exercise of outstanding optionsincluding options granted under the 2009 Equity Incentive Plan, and upon exercise of outstanding warrants,~~convertible preferred stock, as follows:

~~Commencing April 1, 2020, our management, including the chief executive officer, who is our chief operating decision maker (“CODM”), began managing our operations as operating in~~ 2 business segments: Drug Development and Commercialization which includes, without limitation, out-licensing the Company’s FDA approved products; and Compounded Pharmaceuticals which includes the Company’s registered outsourcing facility, based on changes to the way that management monitors performance, aligns strategies, and allocates resources. Based on these changes, we determined that each of these operating segments represented a reportable segment. While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon business units. Each segment is separately managed and is evaluated primarily upon segment net loss.

The Company ~~does not report the statement~~has a production threshold commitment to a manufacturer of cash flow and the balance sheet information by segment because, except as noted below, the Company’s CODM does not review that information. The revenues of the Drug Development and Commercialization segment for the three months and six months ended June 30, 2021 and 2020 were all from the USWM and Sandoz distribution channel.

~~The following tables present a summary of the Company’s reporting segments for the three months and six months ended June 30, 2021 and 2020, respectively (unaudited)~~:

~~The CODM is provided certain segment cash flow and balance sheet information in connection with operating and investment decisions regularly. Accordingly,~~ ~~the following segment information is presented for Drug Development and Commercialization; and Compounded Pharmaceuticals.~~

~~On July 8, 2021,~~ ~~the Company repaid to Arvest Bank, as lender, the full remaining outstanding principal and interest balance of $2,028,191~~ owed under the Company’s outstanding building and real property loan relating to USC’s building and real property, the maturity date of which was in August 2021. Following such payment, the Company does not have any outstanding indebtedness under any of the loan agreements that were assumed by the Company in connection with its previous acquisition of USC.

On July 30, 2021, the Company and its wholly-owned USC subsidiary entered into an Asset Purchase Agreement (the “USC Agreement”) effective as of July 30, 2021 (the “Effective Date”) with Fagron Compounding Services, LLC d/b/a Fagron Sterile Services (the “Purchaser”), providing for the sale and transfer by USC and the purchase by the Purchaser, effective as of the Effective Date, of certain assets of USC related to its human compounding pharmaceutical business (the “Business”), including certain customer information and information onour SYMJEPI products sold to such customers by USC (together, the “Book of Business”), including related formulations, know-how, and expertise regarding the compounding of pharmaceutical preparations, clinical support knowledge and other data and certain other information relating to the customers and products (collectively, the “Assets”). After the Effective Date, Purchaser may use the Book of Business to secure customers for its products and services and may otherwise use the Book of Business. Pursuant to the USC Agreement, the Purchaser will not assume any liabilities of USC, and the transaction does not include the sale or transfer of any USC equipment, buildings or real property, or any products, information, agreements, relationships or other assets relating to the veterinary business of USC.

~~The USC Agreement provides that the consideration payable by the Purchaser to the Company for the Assets sold and transferred will consist of the following amounts: (i) a payment of $107,500~~ ~~on the Effective Date; and (ii) monthly payments in an amount equal to (a) two (~~2.0) times the amount actually collected by Purchaser or its affiliates for sales of products or services made to certain identified customers included in the Book of Business during the 12-month period following the Effective Date (the “Payment Term”), and (b) a lower multiple of the amount actually collected by Purchaser or its affiliates for sales of products or services made to certain other customers included in the Book of Business. The Company estimated the variable consideration at approximately $~~6,385,000~~. In addition, to the extent that such product or service is supplied by USC pursuant to the supply arrangement provided for by the USC Agreement (the “Supply Agreement”), the Purchaser agreed to reimburse USC for the cost of such product or service, as set forth in the Supply Agreement. The USC Agreement provides that during the Payment Term, the Purchaser will maintain the Book of Business and use commercially reasonable efforts to maximize the consideration payable to the Company and collect amounts outstanding related to sales of products or services made to customers included in the Book of Business. However, the USC Agreement does not provide for any minimum purchase price consideration to the Company or USC. Accordingly, there is no assurance as to the amount of purchase price consideration that the Company or USC may ultimately receive as a result of the transactions contemplated by the USC Agreement. Certain of the customers included in the Book of Business may decide to not purchase products or to reduce their purchases of products from Purchaser after the Effective Date, and Purchaser may, in good faith, decide not to change its product mix from those products offered by Purchaser as of the Effective Date and may decide not to carry all of the products offered and sold by USC as part of the Business prior to the Effective Date.

The USC Agreement includes certain restrictive covenants of the Company and USC, including noncompetition provisions, pursuant to which, for a period of five years from the Effective Date (the “Restricted Period”) and subject to certain exceptions, the Company and USC have agreed, among other matters, not to solicit any Business from any customers included in the Book of Business or engage in certain other activities. Each of the USC Agreement and the Supply Agreement includes standard indemnification provisions, and a number of other covenants and agreements of the parties concerning the transactions contemplated by the USC Agreement and the Supply Agreement, including concerning cooperation and assistance, confidentiality, non-disparagement and the transfer of information and documents, compliance with laws, and personnel matters. The USC Agreement includes indemnification provisions pursuant to which the Company ~~and USC agreed~~would be required to ~~indemnify the Purchaser and~~pay for maintenance fees if it does not meet certain ~~related parties against losses incurred by~~periodic purchase order minimums. Any such ~~indemnified parties arising or resulting from certain matters including breach~~maintenance fees would be prorated as a percentage of the ~~USC Agreement by USC~~required minimum production threshold. There were no maintenance fees recorded as of September 30, 2022 and ~~third party claims~~2021.

For information concerning contingencies relating to ~~product sales~~legal proceedings, see Note 9 of the notes to ~~customers by USC before~~ the ~~Effective Date.��~~condensed consolidated financial statements.

On October 1, 2022, Ronald B. Moss, M.D., the ~~transaction,~~Chief Medical Officer of the Company, ~~will pay~~resigned as an officer and employee of the Company effective October 14, 2022.

On October 3, 2022, the Company announced that following the previously announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a ~~fee~~process to explore a ~~financial~~range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or other agreements regarding or sale of one or both of the Company’s commercial products SYMJEPI® and ZIMHI®, a merger, sale, or reverse merger of the Company, and/or seeking additional financing. As part of this process, the Company has engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor ~~of $700,000, and may pay an additional amount depending on the total consideration received by~~to assist the Company in ~~connection with advisory services relating to the transaction.~~

In light of a number of factors including the sale of assets to the Purchaser pursuant to the USC Agreement, the Board approved a restructuring process of winding down and winding up the remaining operations and business of USC and selling, transferring or disposingevaluating certain alternatives. As of the ~~remaining assets~~date of USC. The restructuring and winding down includes, without limitation, the termination of USC’s veterinary business and USC sales to veterinary customers; the termination of employment of all or substantially all employeesthis Report, we are presently engaged in the USC business (except as determined to be necessary or appropriate in connection with the Company’s and USC’s performance of their obligations under the USC Agreement and the transactions contemplated thereby, or in connection with resolving matters relating to the winding down of USC’s business), and providing such notices and making such payments to such employees as the officers of the Company determine are necessary or appropriate, including as maybe required by law or as maybe provided for pursuant to any retention agreement, severance agreement, incentive agreement, or other written agreement with such employees; the sale or other disposition from time to time of the remaining equipment, real property, buildings and tangible and intangible assets relating to USC's business that are unrelated to the USC Agreement; the termination, assignment or other resolution of agreementscommunications with third parties ~~relating to~~regarding this process concerning one or more possible transactions. There can be no assurance regarding the USC business; making regulatory filings and taking appropriate actions with federal and state regulatory authorities in connection with the winding down and winding up of USC's business; and taking such other actions as the officersschedule for completion of the ~~Company or USC (as appropriate) determine are necessary or appropriate~~strategic review process, that this strategic review process will result in ~~connection with the restructuring and the winding down and winding up of the remaining business, operations and assets of USC.~~

~~In August 2021,~~ the Company pursuing any transaction or that any transaction, if pursued, will be completed. The process of obtaining funding, or the terms of a strategic transaction, could result in significant dilution to our existing stockholders. The Company is also reviewing and ~~its wholly-owned USC subsidiary entered into an Asset Purchase Agreement effective as of August 31, 2021 with a third party buyer ("Buyer"), providing for the sale~~implementing expense reduction alternatives and ~~transfer by USC~~measures including, without limitation, employee headcount reductions and reduction or discontinuation of certain assets related to USC’s veterinary compounded pharmaceuticals business. The sale covers the transfer of all the veterinary business customers’ information belonging to USC or in USC’s control and possession (“Book of Business – Veterinary”) and USC’s know how, information and expertise regarding the veterinary business including, but not limited to, formulations, clinical support knowledge and services, other data and studies, instruction and process, documents, and information relating to customers and other business relationships (“Business Knowledge – Veterinary”). Pursuant to the agreement, the Buyer agreed to pay the Company, for any sales of products in USC’s veterinary products list or equivalent products made to the customers included in the Book of Business – Veterinary during the five-year period after the date of the agreement, an amount equal to twenty percent (20%) of the amount actually collected by Buyer on such sales during the period ending three months after the end of such five year period. The Company does not expect to receive a material amount from the variable consideration of this agreement.product development programs.

The costs associated with providing termination payments to USC employees, employee salaries and incentive payments during a transition period after the effective date of the sale of the Assets, severance or other termination benefits or payments in connection with workforce reduction and termination of employment, and payments anticipated to be made pursuant to retention agreements or incentive agreements with certain employees is approximately $~~1.6~~ million. The substantial majority of the cash payments related to personnel-related restructuring charges are paid during the third and fourth quarters of 2021. The charges that the company incurred in connection with the workforce reduction and winding down of operations of USC are actual expenses. In addition, as part of the restructuring, the company and USC intend to sell or dispose of tangible assets relating to USC’s business, including equipment, building and property. The company expects to incur commissions and other costs associated with the sale or other disposition of certain of such assets but is unable, at this time, to make a good faith determination of cost estimates, or ranges of cost estimates, associated with such future sales or dispositions of such tangible assets or other costs associated with the sale or disposition of such tangible assets.

As a result of the transactions contemplated by the USC Agreement and the restructuring activities described above, the Company has determined that its financial results for the quarter ending September 30, 2021, will include an impairment of certain assets relating to USC, including inventories, intangible assets, goodwill, fixed assets, and right of use assets. The company currently estimates approximately $~~8.2~~ million for the impairment charges of inventory, fixed assets, intangibles, goodwill and right of use assets. The impairment charges that the company expects to incur in connection with the matters described above are subject to a number of assumptions, and the actual amount of impairment charges may differ materially from those estimated by the company. In addition, the company may determine in the future that additional impairments of assets are appropriate in connection with the matters described above.

~~On August 12, 2021, the Company received notification through the Bank that the PPP Loan, including principal of $3,191,700~~ ~~and interest thereon, has been fully forgiven by the SBA and that the remaining PPP Loan balance is~~ 0 ~~effective August 5, 2021.~~

~~In October 2021, the Company received notification through the Bank that as of September 28, 2021, the Second Draw PPP Loan, including principal of $1,765,495~~ ~~and interest thereon, has been fully forgiven by the SBA and that the remaining Second Draw PPP Loan balance is~~ 0.

~~In the third quarter of 2021, approximately $776,000~~ ~~of certain inventory returned to a supplier was derecognized. In exchange for the return of inventory, the supplier provided fixed and variable consideration totaling approximately $445,000. The consideration partially offsets the inventory derecognition which resulted in a $330,000~~ loss for the three and nine months ended September 30, 2021. The Company expects to receive the variable consideration over the course of the next one to two years. The variable amount was based on the Company’s estimates and is subject to change as more information comes to light, which would result in adjustments to the loss originally recorded.

In October 2021, following the sale in July 2021 of certain assets of USC relating to USC’s human compounding pharmaceutical business and the Company’s approval of a restructuring process of winding down and winding up the remaining operations and business of USC and selling or disposing of the remaining assets of USC, the company entered into a Consent Order with the Arkansas State Board of Pharmacy to resolve an ongoing administrative proceeding before the pharmacy board, pursuant to which USC agreed to surrender its Arkansas retail pharmacy permit and wholesaler/outsourcer permit effective October 31, 2021, to pay a civil penalty of $~~75,000~~ ~~relating to violations of various Arkansas pharmacy laws and regulations and to pay $75,000~~ ~~in investigative costs of the pharmacy board.~~

On October 18, 2021, the issued a press release announcing that the FDA has approved the Company’s ZIMHI ™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. ZIMHI is a high-dose naloxone injection product FDA-approved for the treatment of opioid overdose. The approval was pursuant to the FDA’s review of the Company’s New Drug Application (“NDA”), which was resubmitted to the FDA in May 2021, pursuant to the Food, Drug & Cosmetic Act, as amended.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q (this “Report”) includes forward-looking statements. Such statements are not historical facts, but are based on our current expectations, estimates and beliefs about our business and industry. Such forward-looking statements may include, without limitation, statements about our strategies, objectives and our future achievements; the outcome of our strategic alternatives review process; our expectations for growth; estimates of future revenue; our current or future expenses, commitments, obligations or liabilities; our sources and uses of cash; our liquidity needs; our current or planned clinical trials or research and development activities; ~~anticipated completion dates for clinical trials;~~ product development timelines; anticipated dates for resumption of manufacturing concerning certain of our commercial ~~introduction of~~ products; our future products; regulatory matters; our expectations concerning the timing of regulatory actions relating to our products and product candidates; ~~anticipated dates for meetings with regulatory authorities and submissions to obtain required regulatory marketing approvals;~~ expense, profit, cash flow, or balance sheet items or any other guidance regarding future periods; the impact of broad-based business or economic disruptions, including relating to the COVID-19 pandemic, on our ongoing business and prospects; our expectations concerning the outcome of proceedings discussed in this Report under Item 1 of Part II of this Report under the caption “Legal Proceedings”; and other statements concerning our future operations and activities. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events, and they are subject to risks and uncertainties, known and unknown, that could cause actual results and developments to differ materially from those expressed or implied in such statements. In some cases, you can identify forward-looking statements by terminology, such as “believe,” “will,” “expect,” “may,” “anticipate,” “estimate,” “intend,” “plan,” “should,” and “would,” or the negative of such terms or other similar expressions. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this Report. These forward-looking statements are not guarantees of future performance and concern matters that could subsequently differ materially from those described in the forward-looking statements. Actual events or results may differ materially from those discussed in this Report. In addition, many forward-looking statements concerning our anticipated future business activities assume that we have or are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed elsewhere in this Report, we ~~may~~will require additional funding to continue operations, and there are no assurances that such funding will be available. Failure to timely obtain required funding would adversely affect and could delay or prevent our ability to realize the results contemplated by such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Because factors referred to elsewhere in this Report and in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 (sometimes referred to as the ~~“2020~~“2021 Form 10-K”) that we previously filed with the Securities and Exchange Commission, including without limitation the “Risk Factors” section in this Report and in the ~~2020~~2021 Form 10-K, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this Report. Important risks and factors that could cause actual results to differ materially from those in these forward-looking statements are disclosed in this Report including, without limitation, under the headings “Part II, Item 1A. Risk Factors,” and “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our ~~2020~~2021 Form 10-K, including, without limitation, under the headings “Part I, Item 1A. Risk Factors,” “Part I, Item 1. Business,” and “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as in our subsequent filings with the Securities and Exchange Commission, press releases and other communications.

Unless the context otherwise requires, the terms “we,” “our,” ~~"the company"~~“the company” and “the Company” refer to Adamis Pharmaceuticals Corporation, a Delaware corporation, and its subsidiaries.

Investors and others should note that we may announce material information to our investors using our website (www.adamispharmaceuticals.com), SEC filings, press releases, public conference calls and webcasts, as well as social media and blogs. We use these channels as a means of disclosing material non-public information and making disclosures pursuant to Regulation FD, and to communicate with our members and the public about our company. It is possible that the information we post on our website or social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on our website, social media channels and blogs listed on our investor relations website.

Adamis Pharmaceuticals Corporation (“we,” “us,” “our,” “Adamis” or the “company”) is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Our products and product candidates in the allergy, respiratory, and opioid overdose markets include: ~~SYMJEPI™~~SYMJEPI (epinephrine) Injection 0.3mg, which was approved by the U.S. Food and Drug Administration, or FDA, in 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; SYMJEPI (epinephrine) Injection 0.15mg, which was approved by the FDA in September 2018, for use in the treatment of anaphylaxis for patients weighing 33-65 pounds; ~~ZIMHI™~~ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL, which was approved by the FDA in October 2021 for the treatment of opioid overdose; and Tempol, an investigational drug. In June 2020, we entered into a license agreement with a third party to license rights under patents, patent applications and related know-how of the licensor relating to Tempol. The exclusive license includes the worldwide use under the licensed patent rights and related rights for the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection, as well as the use of Tempol as a therapeutic for reducing radiation-induced dermatitis in patients undergoing treatment for cancer. We ~~have~~ commenced Phase 2/3 clinical trial start-up activities to examine the safety and efficacy of Tempol in ~~COVID-19 patients~~high risk subjects with early ~~in the~~COVID-19 infection and on September 2, 2021, we announced the initiation of patient dosing in the trial. ~~Our goal~~In February 2022 we announced the enrollment and dosing of more than 100 subjects in the Phase 2/3 trial, and on March 14, 2022, we announced that the Data Safety Monitoring Board, or DSMB, overseeing the Phase 2/3 clinical trial met to evaluate the clinical and safety data from the first planned interim analysis and, following its evaluation, recommended that the study continue without modification. The DSMB is composed of subject matter experts and can unblind the data to ~~create low cost therapeutic alternatives to existing treatments. Consistent across all specialty pharmaceuticals product lines, we intend to submit NDAs under Section 505(b)(2),~~determine the treatment effects of the ~~U.S. Food, Drug~~subjects in the trial. On June 1, 2022, we announced that the DSMB had met again to evaluate interim clinical and safety data for the trial and based on an interim review of the data, determined that the study can continue as planned.

On September 21, 2022, we announced that the DSMB’s third interim analysis of the Phase 2/3 clinical trial, which was the first interim review where the DSMB evaluated the primary efficacy endpoint, determined that the trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. The DSMB conducting the interim review recommended that the study be halted early due to lack of efficacy. The DSMB noted that no safety concerns were identified in the subjects that received Tempol. Based on the recommendation from the DSMB, we have halted the trial and have stopped further development of Tempol.

On October 3, 2022, we announced that following the previously announced halting of our Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, we have initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value. Potential alternatives that may be explored or evaluated include a partnership or other agreement regarding or sale of one or both of the company’s commercial products SYMJEPI^® and ZIMHI^®, a merger, sale, or reverse merger of the company, and/or seeking additional financing. As part of this process, we have engaged the investment bank Raymond James & ~~Cosmetic Act,~~Associates, Inc. to act as ~~amended,~~strategic advisor to assist us in evaluating certain alternatives. As of the date of this Report, we are presently engaged in communications with third parties regarding this process concerning one or ~~FDCA,~~more possible transactions. There can be no assurance regarding the timing for completion of the strategic review process, that this strategic review process will result in the company pursuing any transaction or ~~Section 505(j) Abbreviated New Drug Applications,~~that any transaction, if pursued, will be completed. The process of obtaining funding, or ~~ANDAs,~~the terms of a strategic transaction, could result in significant dilution to our existing stockholders. We have implemented expense reduction measures including, without limitation, employee headcount reductions and the ~~FDA, whenever possible, in order to potentially reduce the time to market and to save on costs, compared to those associated with Section 505(b)(1) NDAs for new drug products.~~reduction or discontinuation of certain product development programs.

Our US Compounding Inc. subsidiary, or USC, which we acquired in April 2016 and which iswas registered as a human drug compounding outsourcing facility under Section 503B of the FDCA and the U.S. Drug Quality and Security Act, or DQSA, ~~provides~~provided prescription compounded medications, including compounded sterile preparations and nonsterile compounds, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States. ~~USC's product offerings broadly include, among others, corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables.~~ In July 2021, we sold certain assets relating to USC’s human compounding pharmaceutical business and approved a restructuring process to wind down the remaining USC business and sell, liquidate or otherwise dispose of the remaining USC assets. Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer selling compounded pharmaceutical or veterinary products.

On June 15, 2017, the FDA approved our SYMJEPI (epinephrine) Injection 0.3mg product for the emergency treatment of allergic reactions (Type I) including anaphylaxis. SYMJEPI (epinephrine) Injection 0.3mg is intended to deliver a dose of epinephrine, which is used for emergency, immediate administration in acute anaphylactic reactions to insect stings or bites, allergic reaction to certain foods, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis for patients weighing 66 pounds or more. On September 27, 2018, the FDA approved our lower dose SYMJEPI (epinephrine) Injection 0.15mg product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis in patients weighing 33 to 6665 pounds.

In July 2018, we entered into a Distribution and Commercialization Agreement, or the Sandoz Agreement, with Sandoz Inc., or Sandoz, to commercialize both of our SYMJEPI products. In January 2019, we announced that Sandoz had launched SYMJEPI (epinephrine) 0.3 mg Injection in the U.S. market, initially available in the institutional setting. On July 9, 2019, we announced the full launch (institutional and retail) by Sandoz of both dose forms of theOur SYMJEPI injection ~~products.~~products were fully launched in July 2019 by our then-commercialization partner Sandoz Inc.

~~On May 11, 2020, we announced that we entered into an agreement,~~Our SYMJEPI products are currently marketed and sold by USWM, LLC, or ~~the Termination Agreement,~~USWM or US WorldMeds, with ~~Sandoz to terminate the Sandoz Agreement and simultaneously announced that~~which we entered into an exclusive distribution and commercialization agreement, or the USWM Agreement, ~~with USWM, LLC, or USWM or US WorldMeds,~~in May 2020 for the United States commercial rights for the SYMJEPI products, as well as for our ZIMHI product. Under the terms of the USWM Agreement, ~~we appointed~~ USWM asis the exclusive distributor of SYMJEPI in the United States and related territories, or ~~the~~ Territory, ~~effective upon the termination of the Sandoz Agreement,~~ and ~~of the ZIMHI product if approved by the FDA for marketing, and granted~~ USWM has an exclusive license under our patent and other intellectual property rights and know-how to market, sell, and otherwise commercialize and distribute the products in the Territory, in partial consideration of an initial payment of $1,000,000 by USWM and potential additional regulatory and commercial based milestone payments. There can be no assurances that any of these milestones will be met or that any milestone payments will be paid to us. We retain rights to the intellectual property subject to the USWM Agreement and to commercialize both products outside of the Territory. In addition, we may continue to use the licensed intellectual property (excluding certain of the licensed trademarks) to develop and commercialize other products (with certain exceptions), including products that utilize our Symject™ syringe product platform.

The USWM Agreement provides that, after deducting the supply price and subject to certain other deductions and adjustments, including an allocation for USWM sales and distribution expenses from net sales of the products, USWM will pay to us 50% of the net profit from net sales, as each such term is defined in the USWM Agreement, of the product in the Territory to third parties, determined on a quarterly basis. We will be the supplier of the products to USWM, and USWM will order and pay us a supply price for quantities of products ordered. The agreement does not include minimum payments to us by USWM, minimum requirements for sales of product by USWM or, with certain exceptions, minimum purchase commitments by USWM.

On March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The four lots were recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. The recall is being conducted with the knowledge of the FDA and USWM is handling the entire recall process for the company, with company oversight. As of the date of this Report, neither USWM nor we have received, or are aware of, any adverse events related to this recall.

SYMJEPI is manufactured and tested for us by Catalent Belgium S.A. For the manufacture of SYMJEPI, the company utilizes “Ready-to-Fill,” or RTF, syringes that consist of a pre-assembled glass syringe barrel with a staked-in stainless steel needle. During routine inspection of epinephrine pre-filled syringe batches, a small number of syringes with clogged needles were identified. An initial investigation suggested a syringe component issue as the likely cause of the observed needle clogging. Further investigation confirmed the steel used in one specific stainless steel needle batch as the root cause for the clogged syringes observed. The company and the manufacturer have developed corrective and preventive actions. New RTF syringes, which have been manufactured using a different batch of steel for their needles, are being sourced. The company is committed to returning SYMJEPI to the market after all stakeholders are satisfied that these corrective actions should prevent a repeat of the observed failure in future batches. Catalent has now resumed operations at its Belgium facility and as of the date of this Report is scheduled to manufacture a new batch of SYMJEPI during November 2022. Assuming no additional interruptions or delays, we believe that batch should ship to our third party commercial partner for final assembly in early 2023 and, although there can be no assurances concerning the timing, we anticipate having SYMJEPI relaunched and commercially available before the end of the first quarter of 2023.

Naloxone is an opioid antagonist used to treat narcotic overdoses. Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.

On December 31, 2018, we filed an NDA with the FDA relating to our higher dose naloxone injection product, ZIMHI, for the treatment of opioid overdose. ~~On November 22, 2019, we received a~~Following the receipt of two Complete Response ~~Letter,~~Letters, or ~~CRL,~~CRLs, from the FDA regarding our NDA for ~~ZIMHI. A CRL is issued by the FDA’s Center for Drug Evaluation~~ZIMHI and ~~Research when it has completed its review of a file and questions remain that preclude the approval~~our resubmissions of the NDA, in its current form. The CRL stated that the FDA determined that it could not approve the NDA in its present form and provided recommendations needed for resubmission. In December 2019, we provided responses to the FDA to the comments included in the CRL and subsequently held a Type A meeting with the FDA to discuss the company’s response to the CRL and the process and timeline for resubmission of the NDA to the FDA. On May 15, 2020, we resubmitted to the FDA the NDA for ZIMHI. On November 13, 2020, we received a second CRL from the FDA regarding the resubmitted NDA. We submitted responses to the deficiencies identified in the CRL and held a Type A meeting with the FDA to discuss the CRL and the company’s responses, and on ~~May 13, 2021, we resubmitted the NDA for ZIMHI to the FDA. On~~ October 18, 2021, we ~~issued a press release announcing~~announced that the FDA had approved ZIMHI for the treatment of opioid overdose. ~~The company’s~~On March 31, 2022, our commercial partner USWM ~~has indicated that it is preparing for~~and the company issued a press release announcing the commercial launch of ZIMHI. USWM has indicated to the company that initial feedback from the field has been positive. A recently launched website enables institutional customers to order and receive product directly. USWM has indicated to the company that progress has continued in adding ZIMHI ~~anticipated~~ to beformularies for payors and PBMs, and that in many states ZIMHI has been added to the ~~first quarter of 2022.~~

standing orders, which permits pharmacies to dispense ZIMHI without a prescription.

On June 12, 2020, we entered into a license agreement with ~~Matrix Biomed, Inc.,~~a third party entity, or the Licensor, to license rights under patents, patent applications and related know-how of Licensor relating to Tempol, an investigational drug. The exclusive license includes the worldwide use under the licensed patent rights and related rights of Tempol for the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection. In addition, the exclusive license includes the use of Tempol as a therapeutic for reducing radiation-induced dermatitis in patients undergoing treatment for cancer. In consideration for the Licensor providing the rights under its patent rights and related know-how relating to Tempol within the licensed fields, we paid Licensor $250,000 and also issued to the Licensor 1,000,000 shares of our Series B Convertible Preferred Stock, which had been converted into an equal number of shares of our common stock.

Tempol is a redox cycling nitroxide that promotes the metabolism of many reactive oxygen species and improves nitric oxide bioavailability. It has been studied extensively in animal models of oxidative stress and inflammation. Overall, Tempol acts as both a super-oxide dismutase mimetic and also has demonstrated anti-inflammatory, anticoagulant activity and antiviral activity. Inflammation and oxidative stress occur in various disease states including COVID-19. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS). Many published articles describing animal models of ARDS show Tempol caused a decrease in lung inflammation and preserved lung pathology associated with acute and chronic lung injury. In animal models, Tempol has been shown to decrease proinflammatory cytokines (cytokine storm), and through its antioxidant activity has been shown to decrease the harmful effects of ROS. In addition, Tempol has been shown to decrease platelet aggregation, a problem observed in many COVID-19 patients. More recently, Tempol has been shown to have antiviral activity against the virus that causes COVID-19 in-vitro and may have synergy with the antiviral ~~Remdesivir.~~

In July 2020, we submitted to the FDA a pre-IND package which provided a protocol for a Phase 2/3 study examining Tempol in COVID-19 patients, and the FDA provided comments regarding the prospective use of Tempol in a randomized placebo controlled trial. In January 2021, we submitted an IND to the FDA for the investigational use of Tempol for the treatment of COVID-19. On February 22, 2021, we announced that the FDA notified the company that the agency had completed the safety review of the IND and concluded that the company may proceed with the proposed clinical investigation and trial described in the IND. The goal of the study titled, "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection," is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. In addition to safety, the study will examine markers of inflammation and the rate of hospitalization for patients taking Tempol versus placebo early in COVID-19 infection. On June 11, 2021, we announced that clinical trial start-up activities were underway, that the company was carrying out those activities with a large clinical research organization, that commenced activities included site identification and initiation, data base production, vendor management, and the establishment of an independent data safety monitoring board of infectious disease experts, who will review the safety and efficacy of the trial, and that clinical trial drug product and placebo have also been obtained. On September 2, 2021, we announced the initiation of patient dosing in the trial. Our trial requires individuals with moderate COVID-19 symptoms to be unvaccinated and have co-morbidities such as heart disease, as those patients typically have worse outcomes, requiring hospitalization. We have experienced enrollment challenges primarily as a result of the decrease in COVID-19 infections and increased immunizations in the United States. To mitigate this challenge, we are in the process of undertaking the steps required to open new sites across the U.S., and enrollment rates may also be affected by any increase in COVID-19 during this coming winter. New site activation requires multiple steps and can take many weeks to complete. In addition, we intend to consider sites outside of the United States in geographic locations where vaccination rates are lower, and COVID19 rates are higher. Absent unexpected developments, the company intends to announce the interim analysis of interim results for the clinical trial after 50 eligible subjects have completed day 21of the trial protocol and the appropriate analysis has been performed and reviewed by the Data Safety Monitoring Board (DSMB).

remdesivir. On January 28, 2021, we announced that in collaboration with the Human Immune Monitoring Center at Stanford University we conducted a study to investigate the effects of Tempol on immune cells from COVID-19 patients, and that preliminary data from that study showed that Tempol ~~decreased~~decreases cytokines from stimulated cells from COVID-19 patients. ~~On August 24, 2021, we announced that an article reporting on the study and study results was published in the peer reviewed journal~~ ~~Clinical Immunology~~. In March 2021, we announced that in studies conducted at Galveston National Laboratory, or GNL, University of Texas Medical Branch, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2) showed decreased inflammation in the lungs when treated with Tempol compared to ~~controls. We intend~~controls, and on March 22, 2022, we announced that in studies conducted at the GNL, hamsters challenged with high levels of the Omicron variant of the SAR-CoV-2 virus, resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to ~~continue~~controls.

In January 2021, we submitted an IND to ~~explore~~ the ~~availability of government and/or non-government funding to help support study~~FDA for the ~~efficacy~~investigational use and proposed Phase 2/3 clinical trial of Tempol ~~as a therapeutic~~for the treatment ~~for COVID-19. We also continue to explore options regarding~~of COVID-19, with the ~~funding and design~~goal of ~~a clinical~~the study to examine the ~~effects~~safety and activity of Tempol in COVID-19 patients early in the infection. In addition to safety, the study examined markers of inflammation and the rate of hospitalization for ~~other~~patients taking Tempol versus placebo early in COVID-19 infection. On June 11, 2021, we announced the start-up of the Phase 2/3 clinical ~~indications~~trial and by February 2022 we announced the enrollment and dosing of more than 100 subjects in the Phase 2/3 trial. On March 14, 2022, we announced that the DSMB, which is composed of infectious disease experts that oversee and review the safety and efficacy of the trial, met to evaluate the clinical and safety data from the first planned interim analysis and, following its evaluation, recommended that the study continue without modification. During the trial and interim review process, the company did not have access to unblinded trial data and did not have access to unblinded data until the final study data was compiled and reviewed. The DSMB met again on May 31, 2022, to evaluate interim clinical and safety data for the trial and based on an interim review of the data, determined that the study can continue as planned. On September 12, 2022, we announced that the clinical trial reached the initial planned enrollment of 248 subjects.

On October 27, 2022, we received a communication from the Licensor asserting that the license agreement between the Licensor and us relating to Tempol has terminated by virtue of alleged noncompliance by us with certain financial covenants contained in the agreement. We dispute, and do not agree, that the agreement has terminated. We are also evaluating potential claims against the Licensor including ~~but not limited~~possible breach of its obligations under the agreement, and we intend to vigorously defend our rights relating to the ~~treatment~~agreement. We do not believe that the agreement or any termination of ~~methamphetamine use disorder, and are engaged in additional activities intended~~the agreement is material to ~~support an IND to begin such a study.~~the Company’s current or presently anticipated future business, financial conditions or results of operations.

On July 30, 2021, the ~~Company~~company and its wholly-owned USC subsidiary entered into an Asset Purchase Agreement, ~~(the “USC Agreement”)~~or the USC Agreement, effective as of July 30, 2021, ~~(the “Effective Date”)~~or the Effective Date, with Fagron Compounding Services, LLC d/b/a Fagron Sterile Services (the “Purchaser”), providing for the sale and transfer by USC and the purchase by the Purchaser, effective as of the Effective Date, of certain assets of USC related to its human compounding pharmaceutical business, ~~(the “Business”),~~or the Business, including certain customer information and information on products sold to such customers by USC, ~~(together,~~together, the “Book of ~~Business”),~~Business,” including related formulations, know-how, and expertise regarding the compounding of pharmaceutical preparations, clinical support knowledge and other data and certain other information relating to the customers and products, ~~(collectively,~~collectively referred to as the ~~“Assets”).~~“Assets.” After the Effective Date, Purchaser may use the Book of Business to secure customers for its products and services and may otherwise use the Book of Business. Pursuant to the USC Agreement, the Purchaser ~~will~~did not assume any liabilities of USC, and the transaction did not include the sale or transfer of any USC equipment, buildings or real property, or any products, information, agreements, relationships or other assets relating to the veterinary business of USC.

The USC Agreement provides that the consideration payable by the Purchaser to the ~~Company~~company for the Assets sold and transferred ~~will consist~~consisted of the following amounts: (i) a payment of $107,500 on the Effective Date; and (ii) monthly payments in an amount equal to (a) two (2.0) times the amount actually collected by Purchaser or its affiliates for sales of products or services made to certain identified customers included in the Book of Business during the 12-month period following the Effective Date, ~~(the~~or the “Payment ~~Term”),~~Term.” and (b) a lower multiple of the amount actually collected by Purchaser or its affiliates for sales of products or services made to certain other customers included in the Book of Business. In addition, to the extent that such product or service is supplied by USC pursuant to the supply arrangement provided for by the USC Agreement (the “Supply Agreement”), the Purchaser agreed to reimburse USC for the cost of such product or service, as set forthThe final payment amount due from Fagron, recorded in the Supply Agreement. The USC Agreement provides that during the Payment Term, the Purchaser will maintain the Book of Business and use commercially reasonable efforts to maximize the consideration payable to the Company and collect amounts outstanding related to sales of products or services made to customers included in the Book of Business. However, the USC Agreement does not provide for any minimum purchase price consideration to the Company or USC. Accordingly, there is no assurance as to the amount of purchase price consideration that the Company or USC may ultimately receive as a result of the transactions contemplated by the USC Agreement. Certain of the customers included in the Book of Business may decide to not purchase products or to reduce their purchases of products from Purchaser after the Effective Date, and Purchaser may, in good faith, decide not to change its product mix from those products offered by Purchaser as of the Effective Date and may decide not to carry all of the products offered and sold by USC as part of the Business prior to the Effective Date.

company's condensed consolidated balance sheet at September 30, 2022, was approximately $248,000. The USC Agreement includes certain restrictive covenants of the ~~Company~~company and USC, including noncompetition provisions, pursuant to which, for a period of five years from the Effective Date (the “Restricted Period”) and subject to certain exceptions, the Company and USC have agreed, among other matters, not to solicit any Business from any customers included in the Book of Business or engage in certain other activities. Each of the USC Agreement and the Supply Agreement includesprovisions. The transaction agreements include standard indemnification provisions, and a number of other covenants and agreements of the parties concerning the transactions contemplated by the USC Agreement and the Supply Agreement, including concerning cooperation and assistance, confidentiality, non-disparagement and the transfer of information and documents, compliance with laws, and personnel matters. The USC Agreement includes indemnification provisions pursuant to which the Company and USC agreed to indemnify the Purchaser and certain related parties against losses incurred by such indemnified parties arising or resulting from certain matters including breach of the USC Agreement by USC and third party claims relating to product sales to customers by USC before the Effective Date. In connection with the transaction, the Company accrued a $700,000 liability for a transaction fee payable to a financial advisor of $700,000 as of September 30, 2021.agreements.

In light of a number of factors including the sale of assets to the Purchaser pursuant to the USC Agreement, in August 2021 the Board approved a restructuring process of winding down the remaining operations and business of USC and selling, transferring or disposing of the remaining assets of USC. Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer selling compounded pharmaceutical or veterinary products. The restructuring and winding down includes, without limitation, the termination of USC’s veterinary business and USC sales to veterinary customers; the termination of employment of all or substantially all employees engaged in the USC business (except as determined to be necessary or appropriate in connection with the ~~Company’s~~company’s and USC’s performance of their obligations under the USC Agreement and the transactions contemplated thereby, or in connection with resolving matters relating to the winding down of USC’s business), and providing such notices and making such payments to such employees as the officers of the ~~Company~~company determine are necessary or appropriate, including as maybe required by law or as maybe provided for pursuant to any retention agreement, severance agreement, incentive agreement, or other written agreement with such employees; the sale or other disposition from time to time of the remaining equipment, real property, buildings and tangible and intangible assets relating to ~~USC's~~USC’s business that are unrelated to the USC Agreement; the termination, assignment or other resolution of agreements with third parties relating to the USC business; making regulatory filings and taking appropriate actions with federal and state regulatory authorities in connection with the winding down and winding up of ~~USC's~~USC’s business; and taking such other actions as the officers of the ~~Company~~company or USC (as appropriate) determine are necessary or appropriate in connection with the restructuring and the winding down and winding up of the remaining business, operations and assets of USC. ~~In August 2021, the~~The company has sold and ~~USC entered into an asset purchase agreement with a third party buyer providing for the sale and transfer by USC~~disposed of certain customer information and other assets related to USC’s veterinary compounded pharmaceuticals business, ~~in consideration for~~and will continue the ~~payment~~process of selling or otherwise disposing of the remaining assets relating to USC’s business.

In connection with the ~~company by~~winding down of the ~~buyer~~USC business, we incurred significant expenses and made a number of payments. The substantial majority of cash payments related to personnel-related restructuring charges, including without limitation costs associated with providing termination payments to USC employees, employee salaries and incentive payments during a ~~percentage of amounts actually collected by the buyer on sales of certain veterinary products to veterinary customers covered by the agreement over the five year~~transition period after the effective date of the ~~agreement.~~ sale of the Assets pursuant to the USC Agreement, severance or other termination benefits or payments in connection with workforce reduction and termination of employment, and payments pursuant to retention agreements or incentive agreements with certain employees, were made during the third and fourth quarters of 2021 and were approximately $1.6 million. In addition, as part of the winding down of USC’s business, we have incurred other costs. We also expect to incur commissions and other costs associated with the sale or other disposition of certain USC tangible assets such as building, property and certain equipment.

As a result of the transactions contemplated by the USC Agreement and the restructuring activities described above, the company’s financial results for the third and fourth quarters of 2021 include approximately $8.6 million for the impairment charges of inventory, fixed assets, intangibles, goodwill and right of use assets. The impairment charges that the company incurred and expects to incur in connection with the matters described above are subject to a number of assumptions, and the actual amount of impairment charges may differ materially from those estimated by the company. In addition, the company may determine in the future that additional impairments of assets are appropriate in connection with the matters described above.

The financial statements included elsewhere herein for the ~~six~~three and nine months ended ~~June~~September 30, ~~2021, and our financial statements for the year ended December 31, 2020 and 2019,~~2022, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. However, as of June 30, 2021, we had cash and cash equivalents and restricted cash of approximately $40.6 million, an accumulated deficit of approximately $257.0 million, and liabilities of approximately $17.0 million. We have incurred substantial recurring losses from continuing operations, have used, rather than provided, cash in our continuing operations, and are dependent on additional financing to fund operations. We incurred a net loss of approximately $23.2 million and $37.1 million for the nine months ended September 30, 2022 and 2021. As of September 30, 2022, we had cash and cash equivalents of approximately $2.4 million, an accumulated deficit of approximately $301.2 million and liabilities of approximately $9.1 million. These conditions raise substantial doubt about our ability to continue as a going concern. The financial statements included elsewhere herein do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. In January and February 2021, the company issued common stock upon exercise of investor warrants, and the company received a total of approximately $5,852,000 and the warrant holders received 8,356,000 shares of common stock. On February 2, 2021, the company completed the closing of an underwritten public offering of 46,621,621 shares of common stock at a public offering price of $1.11 per share, which included 6,081,081 shares pursuant to the full exercise of the over-allotment option granted to the underwriters, resulting in net proceeds of approximately $48.4 million. In March 2021, we received approximately $1.8 million of debt funding that we obtained under the Second Draw Loan pursuant to the terms of the PPP, the CARES Act, and the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act enacted in December 2020. However, we may need additional funding in the future to continue operations, satisfy our obligations, including any expenses that may arise in the future relating to matters in Part II, Item 1 - Legal Proceedings, fund the future expenditures that we believe will be required to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates.

The above conditions raise substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements included elsewhere herein for the six months ended June 30, 2021, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. In preparing these condensed consolidated financial statements, consideration was given to our future business as described elsewhere herein, which may preclude us from realizing the value of certain assets. Our unaudited condensed consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. Without additional funds in the future from debt or equity financing, sales of assets, sales or out-licenses of intellectual property, products, product candidates or technologies, or from a business combination or a similar transaction, after expenditure of our existing cash resources and revenues from existing agreements and sales of prescription compounded formulations, we would exhaust our resources and be unable to continue operations.

Our management intends to attempt to secure additional required funding through equity or debt financing if available, seeking to enter into a partnership or other strategic agreement regarding, or sales or out-licensing of, our commercial products, product candidates or intellectual property assets ~~consideration that we may receive from~~or other assets including assets used in connection with the ~~Purchaser pursuant to our asset purchase agreement~~former USC business, revenues relating to ~~certain assets of USC~~supply and sale of ~~other assets used in the USC business,~~SYMJEPI and ZIMHI products and share of net profits received relating to sales in the U.S. of our SYMJEPI and ZIMHI products, seeking partnerships or commercialization agreements with other pharmaceutical companies or third parties to co-develop and fund research and development or commercialization efforts of our products, from a merger, reverse merger or other business combination, or similar transactions. As part of this process, we have engaged the investment bank Raymond James & Associates, Inc. to act as strategic advisor to assist us in evaluating certain alternatives. As of the date of this Report, we are presently engaged in communications with third parties regarding this process concerning one or more possible transactions. However, there can be no assurance regarding the timing of the strategic review process or that we will be able to obtain any sources of funding. As of the date of this Report, we have a limited number of authorized shares available for issuance in funding transactions involving issuances of equity securities. Such additional funding may not be available, may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. There is no assurance that we will be successful in obtaining the necessary funding to sustain our operations or meet our business objectives. In addition, obtaining funding, or the terms of a strategic transaction, could result in significant dilution to our existing stockholders. If we do not obtain required ~~additional equity or debt~~ funding, our cash resources will be depleted in the near term and we ~~could~~would be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business ~~relationships, at least until additional funding is obtained.~~relationships. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection, dissolution or liquidation, or other alternatives that could result in our stockholders losing some or all of their investment in us. We have implemented expense reduction measures including, without limitation, employee headcount reductions and the reduction or discontinuation of certain product development programs.

Any funding that we may receive during the remainder of fiscal 2022 or thereafter is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, and for general working capital purposes.

Our consolidated results of operations are presented for the three months and nine months ended September 30, 2022 and 2021. Certain financial results (revenues and expenses) relating to the business formerly conducted by USC are reflected in Note 2, Discontinued Operations and Assets Held for Sale, of the notes to the consolidated financial statements appearing elsewhere in this Report. Unless otherwise noted, the discussion below, and the revenue and expense amounts discussed below, are based on and relate to the continuing operations of the company, which we sometimes refer to as our drug development and commercialization business.

Revenues.Revenues~~. Consolidated revenues~~ were approximately ~~$4,011,000~~$1,506,000 and ~~$3,926,000~~$760,000 for the three months ended ~~June~~September 30, 2022 and 2021, ~~and 2020,~~ respectively. ~~Consolidated revenues increased approximately $85,000~~The $746,000 increase in revenue for the ~~second~~third quarter of ~~2021 compared~~2022 was primarily attributable to approximately $1,306,000 of sales of ZIMHI to USWM recognized in that quarter (which was not yet FDA approved during the same period of 2021) and an increase of approximately $562,000 in recognition of deferred revenue due to the ~~comparable period~~Company's reassessment of ~~2020.~~

~~Revenues~~performance obligations met under the USWM Agreement, offset primarily by a decrease in SYMJEPI sales of ~~our Drug Development~~approximately $736,000 due to the manufacturing hold and ~~Commercialization business conducted by Adamis were approximately $1,275,000 and $721,000~~voluntary product recall announced in March 2022. Additionally, revenues for the three months ended ~~June~~September 30, ~~2021 and 2020, respectively. Revenue relating to~~2022, were reduced by additional product recall costs of approximately $388,000, which were recorded as contra-revenue. As disclosed elsewhere in this Report, including above under the ~~sales of~~heading “General - SYMJEPI (epinephrine) Injection ~~0.3mg and 0.15mg increased approximately $554,000 primarily due~~Product,” the manufacturing of SYMJEPI continues to ~~the sales and marketing initiatives of our new distribution partner, USWM, when compared with the comparable 2020 period.~~

~~Revenues of our Compounded Pharmaceuticals business conducted through USC were approximately $2,736,000 and $3,205,000 for the three months ended June 30, 2021 and 2020, respectively.~~be on hold. The decline was primarily due to a decline in sale of USC’s human products resulting primarily from restrictions on outpatient surgery and other medical procedures due to the COVID-19 pandemic, and to a lesser extent a decline in sales of veterinary products. The COVID-19 outbreak has adversely affected revenues from sales of USC products, in part due to reductions or cancellations of elective surgeries and reduction in office visits to physicians’ offices, healthcare facilities or clinics by patients,Company and the ~~resulting decreased demand by USC’s customers~~manufacturer have developed corrective and preventive actions. New RTF syringes, which have been manufactured using a different batch of steel for ~~certain~~their needles, are being sourced. Catalent has now resumed operations at its Belgium facility and as of ~~USC’s products,~~the date of this Report is scheduled to manufacture a new batch of SYMJEPI during November 2022. Assuming no additional interruptions or delays, we believe that batch should ship to our third party commercial partner for final assembly in early 2023 and, ~~will likely continue to adversely affect revenues from sales~~although there can be no assurances concerning the timing, we anticipate having SYMJEPI relaunched and commercially available before the end of ~~USC products for a period~~the first quarter of ~~time which cannot be predicted. Moreover, COVID-19 has restricted USC from utilizing traditional sales and marketing efforts, such as regular sales visits to customers, in generating revenues.~~2023.

Cost of ~~Goods Sold.~~ ~~Consolidated cost of~~ goods ~~sold was approximately $3,871,000 and $4,684,000 for the three months ended June 30, 2021 and 2020, respectively.~~sold. Our cost of goods sold includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, shipping and handling costs, the write-off of obsolete inventory and other related expenses. ~~The gross margin (loss) percentage for three months ended June 30, 2021~~Consolidatedcost of goods sold was approximately ~~4% compared to approximately (19%)~~$1,648,000 and $1,566,000 for the three months ended ~~June~~September 30, ~~2020.~~

~~Cost of goods sold of our Drug Development~~2022 and ~~Commercialization business conducted by Adamis was approximately $1,796,000 and $1,840,000~~2021, respectively. The gross loss for the three months ended ~~June~~September 30, ~~2021~~2022 was approximately $142,000 compared to approximately $806,000 for the three -months ended September 30, 2021. The $82,000 increase in cost of goods sold in the third quarter of 2022 was primarily due to an increase in direct material costs of approximately $1,199,000 related to ZIMHI production, offset primarily by a decrease in direct material costs and ~~2020, respectively. The gross loss percentage~~obsolescence and wastage charges related to SYMJEPI production of approximately $795,000 due to its continuing manufacturing hold and voluntary product recall. Additionally, for the three months ended ~~June~~September 30, 2021 a loss on derecognition of inventory of $330,000 was ~~approximately 41% compared~~recorded due to ~~approximately 155% for~~a return of inventory to our supplier. The supplier agreed to repurchase the inventory at an amount lower than our cost. There was no return of inventory during the three months ended ~~June~~September 30, 2020. Cost of goods sold for the second quarter of the 2021 period compared to the comparable period of 2020 decreased primarily due to the decrease of approximately $374,000 for depreciation, maintenance fees and other related expenses associated with the production of SYMJEPI, offset by increases of approximately $330,000 in direct materials largely driven by increased sales of SYMJEPI.2022.

Cost of goods sold of our Compounded Pharmaceuticals business conducted through USC was approximately $2,075,000 and $2,844,000 for the three months ended June 30, 2021 and 2020, respectively. The gross margin percentage for the three months ended June 30, 2021 was approximately 24% compared to approximately 11% for the three months ended June 30, 2020. Materials costs, compensation and other employee benefits, product devices, testing, freight, and other related expenses decreased approximately $769,000 due to the reduction in consumer demand for certain USC products as a result of the COVID-19 pandemic.

Selling, General and Administrative Expenses. Selling, general and administrative, or SG&A, expenses consist primarily of ~~depreciation~~consulting and ~~amortization,~~employee compensation, professional fees which include legal, accounting and audit fees, ~~consulting~~ and ~~employee compensation. Consolidated~~depreciation and amortization expenses. SG&A expenses for the three months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 were approximately ~~$7,132,000~~$2,508,000 and ~~$5,653,000,~~$4,794,000, respectively.

The $2,286,000 decrease in SG&A expenses ~~of our Drug Development and Commercialization business conducted by Adamis for~~during the three months ended ~~June~~September 30, ~~2021 and 2020 were approximately $4,935,000 and $3,009,000, respectively. The increase~~2022, was primarily ~~attributable~~due to ~~an increase~~a decrease in ~~professional fees~~legal expenses of approximately ~~$2,346,000, partially offset by an~~$1,220,000 related principally to the ongoing investigations, a decrease of approximately ~~$243,000 decrease in depreciation and amortization as~~$792,000 primarily related to a ~~result~~financial advisor fee related to the sale of ~~the write-off of the DPI intangible asset in the fourth quarter of 2020 that eliminated amortization expense in future periods,~~certain USC assets to Fagron and a decrease of approximately ~~$177,000 of compensation~~$514,000 related ~~expenses largely attributed~~ to ~~decreased stock~~ compensation expenses asprincipally resulting from a ~~result~~reversal of ~~the completion~~bonus accrual expenses, offset by an increase of ~~vesting of a significant amount of option grants through February 2021.~~

approximately $240,000 in other SG&A ~~expenses of our Compounded Pharmaceuticals business conducted through USC for the three months ended June 30, 2021~~costs primarily insurance, IT and 2020 were approximately $2,197,000 and $2,644,000, respectively. Approximately $200,000 of the decrease in SG&A expenses for second quarter of 2021 compared to the second quarter in 2020 year was attributable to decreases in selling expenses primarily due to the reduction of commission payments, marketing expenses and other related expenses as a direct effect of the reduction in revenue, approximately $68,000 of the decrease was due to reductions in professional fees and consulting expenses, approximately $55,000 of the decrease was attributable to a reduction in bad debt expense. Additionally, there was an approximately $124,000 decrease attributable to lower expense for licensing and permits, property taxes, and other administrative items.recruiting expenses.

Research and ~~Development Expenses~~development expenses.. Our research and development, or R&D, costs are expensed as incurred. Non-refundable advance payments for goods and services to be used in future research and development activities are recorded as an asset and are expensed when the research and development activities are performed. ~~Consolidated research and development~~R&D expenses were approximately ~~$2,233,000~~$1,978,000 and ~~$3,086,000~~$4,620,000 for the three months ended ~~June~~September 30, 2022 and 2021, ~~and 2020, respectively.~~

Research and development expenses of our Drug Development and Commercialization business conducted by Adamis were approximately $2,197,000 and $2,926,000 for the three months ended June 30, 2021 and 2020, respectively. ~~Approximately $656,000 of the~~The $2,642,000 decrease in R&D expenses during the quarter-ended September 30, 2022, was principally due to a decrease in development spending for ~~the three months ended June 30, 2021, compared to the comparable 2020 period was~~Tempol of approximately $1,144,000, a decrease in development spending for ZIMHI of approximately $1,088,000 and a decrease of approximately $464,000 related to ~~decreased~~compensation expense principally resulting from a reversal of bonus accrual expenses, offset by approximately $54,000 related to increased development spending on ~~Tempol,~~ SYMJEPI ~~ZIMHI,~~ and other projects. In addition, wages, benefits, and other compensation expenses for research and development employees decreased approximately $73,000 during the three months ended June 30, 2021, compared to the comparable 2020 period, largely attributed to decreased stock compensation expenses as a result of the completion of vesting of a significant amount of option grants through February 2021.

Research and development expenses of our Compounded Pharmaceuticals business conducted through USC were approximately $36,000 and $160,000 for the three months ended June 30, 2021 and 2020, respectively. USC’s R&D ~~expenses for the three months ended June 30, 2021, compared to the comparable 2020 period, decreased due to the reduction of new product testing.~~projects.

~~Impairment Expense, Contract Costs.~~Other Income (Expense). Impairment expenses of contract costs for the three months ended June 30, 2021 and 2020 were approximately $0 and $1,750,000, respectively. As a result of entering into the Termination Agreement with Sandoz, our financial results for the three months ending June 30, 2020, included an impairment of the Adamis capitalized cost to obtain a contract of $1,750,000.

~~Impairment Expense, Construction in Progress.~~ Impairment expenses of construction in progress for the three months ended June 30, 2021 and 2020 were approximately $9,000 and $0, respectively. In the second quarter of 2021, USC determined that certain in-process development costs related to its website design no longer had value and was thus impaired.

~~Other Expense.~~ Other Income (Expenses) consists primarily of interest income, interest expense, and changes to the fair value of warrant liabilities. Other income (expense) for the three months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 was approximately ~~$81,000~~$357,000 and ~~$1,678,000,~~$5,052,000, respectively. The $4,695,000 decrease in other income ~~(expense) during~~for the ~~three-month period in 2021, compared to the same period in 2020,~~three months ended September 30, 2022, was primarily due to no gain recorded in the ~~decrease~~consolidated statement of ~~other expense~~operations for the quarter-ended September 30, 2022, related to the forgiveness of the PPP loan debts, whereas in the comparable quarter in 2021 there was gain recorded of approximately ~~$1,618,000~~$5,010,000 related to the forgiveness of debt. Additionally, there was a gain of approximately $278,000 recorded during the three months ended September 30, 2022, due to change in estimate of variable consideration related to the sale of certain assets to Fagron, pursuant to the USC Agreement.

Loss from Discontinued Operations. The company recorded a net loss from discontinued operations, after taxes, of approximately $128,000 and $7,193,000 related to its US Compounding Inc. subsidiary for the three months ended September 30, 2022 and 2021. The $7,065,000 decrease in net loss from discontinued operations was due to management's decision to discontinue the operations of USC in the third quarter of 2021. The $128,000 net loss from discontinued operations in the third quarter of 2022, primarily related to SG&A expenses as the company continues the wind-down of USC. The main components of the third quarter loss in 2021 were asset impairments totaling approximately $8,167,000 primarily related to adjustments associated with the ~~change in fair value~~winding down of ~~warrants, a decrease~~the business of USC. Also contributing to that loss was gross loss of approximately ~~$9,000~~$1,177,000, approximately $2,499,000 of other operating expenses, partially offset by approximately $4,637,000 of gain from the sale of non-financial asset to Fagron, approximately $8,000 for interest income, and other income of approximately $5,000.

Revenues. Revenues were approximately $2,605,000 and $3,368,000 for the nine months ended September 30, 2022 and 2021, respectively. The $763,000 decrease in ~~other income,~~revenue for the nine months ended September 30, 2022 was primarily attributable to approximately $2,355,000 of sales of ZIMHI to USWM recognized in that period (which was not yet FDA approved during the same period of 2021) and an increase of ~~interest expense~~approximately $562,000 in recognition of deferred revenue due to the Company's reassessment of performance obligations met under the USWM Agreement, offset by a decrease in SYMJEPI sales of approximately ~~$12,000.~~

~~Six Months Ended June~~$3,292,000. No revenues relating to SYMJEPI were reported during the nine months ended September 30, ~~2021~~2022, due to the manufacturing hold and ~~2020~~

~~Revenues~~~~. Consolidated~~the voluntary product recall announced in March 2022. Additionally, revenues ~~were approximately $8,120,000 and $8,590,000~~ for the ~~six~~nine months ended ~~June~~September 30, ~~2021 and 2020, respectively. Consolidated revenues decreased~~2022, were reduced by additional product recall costs of approximately ~~$470,000~~$388,000, which were recorded as contra-revenue. As disclosed elsewhere in this Report, including above under the ~~first six months of 2021 compared to the comparable period of 2020.~~

Revenues of our Drug Development and Commercialization business conducted by Adamis were approximately $2,608,000 and $1,229,000 for the six months ended June 30, 2021 and 2020, respectively. Revenue relating to the sales ofheading “General - SYMJEPI (epinephrine) Injection ~~0.3mg and 0.15mg increased approximately $1,379,000 primarily due to~~Product,” the ~~sales and marketing initiatives~~manufacturing of ~~our new distribution partner, USWM, when compared with the comparable 2020 period.~~

~~Revenues of our Compounded Pharmaceuticals business conducted through USC were approximately $5,512,000 and $7,361,000 for the six months ended June 30, 2021 and 2020, respectively.~~SYMJEPI is currently on hold. The decline was primarily due to a decline in sale of USC’s human products resulting primarily from restrictions on outpatient surgery and other medical procedures due to the COVID-19 pandemic, and to a lesser extent a decline in sales of veterinary products. The COVID-19 outbreak has adversely affected revenues from sales of USC products, in part due to reductions or cancellations of elective surgeries and reduction in office visits to physicians’ offices, healthcare facilities or clinics by patients,company and the ~~resulting decreased demand by USC’s customers~~manufacturer have developed corrective and preventive actions. New RTF syringes, which have been manufactured using a different batch of steel for ~~certain~~their needles, are being sourced. Catalent has now resumed operations at its Belgium facility and as of ~~USC’s products,~~the date of this Report is scheduled to manufacture a new batch of SYMJEPI during November 2022. Assuming no additional interruptions or delays, we believe that batch should ship to our third party commercial partner for final assembly in early 2023 and, ~~will likely continue to adversely affect revenues from sales~~although there can be no assurances concerning the timing, we anticipate having SYMJEPI relaunched and commercially available before the end of ~~USC products for a period~~the first quarter of ~~time which cannot be predicted. Moreover, COVID-19 has restricted USC from utilizing traditional sales and marketing efforts, such as regular sales visits to customers, in generating revenues.~~2023.

Cost of Goods Sold.~~Consolidated cost of goods sold was approximately $7,513,000 and $8,371,000 for the six months ended June 30, 2021 and 2020, respectively.~~ Our cost of goods sold includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, shipping and handling costs, the write-off of obsolete inventory and other related expenses. ~~The gross margin percentage for six months ended June 30, 2021 was approximately 7% compared to approximately 3% for the six months ended June 30, 2020.~~

Cost of goods sold ~~of our Drug Development and Commercialization business conducted by Adamis~~ was approximately ~~$3,642,000~~$3,706,000 and ~~$3,573,000~~$5,207,000 for the ~~six months~~nine-months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. The gross loss ~~percentage~~ for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 was approximately ~~40%~~$1,101,000 compared to approximately ~~191%~~$1,839,000 for the ~~six months~~nine-months ended ~~June~~September 30, ~~2020. Cost~~2021. The $1,501,000 decrease in cost of goods sold for the ~~quarter ended June~~nine-month period ending September 30, ~~2021 compared~~2022, was primarily due to a decrease of direct material costs and obsolescence and wastage of approximately $3,213,000 related to SYMJEPI resulting from the lack of production due to the ~~comparable period of 2020 increased approximately $855,000~~manufacturing hold and voluntary product recall, offset by an increase in direct materials costs ~~which~~of approximately $2,258,000 related to ZIMHI product manufactured during the nine-month period of 2022. Additionally, for the nine months ended September 30, 2021 a loss on derecognition of inventory of $330,000 was ~~largely~~recorded due to ~~increased sales~~a return of ~~SYMJEPI, partially offset primarily by a decrease~~inventory to our supplier. The supplier agreed to repurchase the inventory at an amount lower than our cost. There was no return of ~~approximately $786,000 for depreciation, maintenance fees and other related expenses associated with~~inventory during the ~~production of SYMJEPI.~~

~~Cost of goods sold of our Compounded Pharmaceuticals business conducted through USC was approximately $3,871,000 and $4,798,000 for the six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively. The gross margin percentage for the six months ended June 30, 2021 was approximately 30% compared to approximately 35% for the six months ended June 30, 2020. Materials costs, compensation and other employee benefits, product devices, testing, freight, and other related expenses decreased approximately $927,000 due to the reduction in consumer demand for certain USC products as a result of the COVID-19 pandemic. 2022.

Selling, General and Administrative Expenses.Selling, general and administrative, or SG&A, expenses consist primarily of depreciation and amortization, professional fees which include legal, accounting and audit fees, consulting and employee compensation. ~~Consolidated~~ SG&A expenses for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 were approximately ~~$13,051,000~~$10,096,000 and ~~$11,707,000,~~$13,247,000, respectively.

The $3,151,000 decrease in SG&A during the nine months ended September 30, 2022, was primarily due to a decrease in legal expenses of ~~our Drug Development~~approximately $2,138,000 principally related to the ongoing investigations and Commercialization business conducted by Adamis for the six months ended June 30, 2021 and 2020 were approximately $8,452,000 and $6,312,000, respectively. The increase was primarily attributable to professional fees of approximately $2,933,000, partially offset by an approximately $486,000 decrease in depreciation and amortization as a result of the write-off of the DPI intangible asset in the fourth quarter of 2020 that eliminated amortization expense in future periods, a decrease of approximately ~~$270,000 of compensation related expenses largely attributed to decreased stock~~$1,279,000 in compensation expenses, ~~as a result~~offset by an increase in other SG&A costs of approximately $267,000 primarily insurance, IT and recruiting expenses. The decrease in compensation expenses during the ~~completion of vesting of a significant amount of option grants through February 2021, and an approximately $37,000 decrease for other administrative expenses.~~

~~SG&A expenses of our Compounded Pharmaceuticals business conducted through USC for the six~~nine months ended ~~June~~September 30, ~~2021 and 2020 were approximately $4,599,000 and $5,395,000, respectively. Approximately $525,000 of the decrease in SG&A expenses for the six months ended June 30, 2021~~2022, compared to the ~~six months ended June 30, 2020~~same period in 2021, was ~~attributable to decreases in selling expenses primarily~~ due to the ~~reduction~~reversal of ~~commission payments, marketing~~bonus accrual expenses and ~~other related expenses as~~ a ~~direct effect~~lower stock-based compensation expense resulting primarily from the modification of ~~the reduction~~certain outstanding equity awards in ~~revenue, approximately $94,000 of the decrease was attributable~~connection with accelerated vesting pursuant to a ~~reduction~~separation agreement, offset mainly by employment separation payments made during the first half of G&A employee compensation expenses, approximately $60,000 of the decrease was attributable to a reduction in bad debt expense, and approximately $117,000 of the decrease was attributable to lower licensing and permits expenses, property tax expense, and other administrative expenses.2022.

Research and Development ~~Expenses~~Expenses.. Our research and development, or R&D, costs are expensed as incurred. Non-refundable advance payments for goods and services to be used in future research and development activities are recorded as an asset and are expensed when the research and development activities are performed. ~~Consolidated research and development~~R&D expenses were approximately ~~$4,494,000~~$9,520,000 and ~~$5,123,000~~$9,067,000 for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively.

Research and development expenses of our Drug Development and Commercialization business conducted by Adamis were approximately $4,446,000 and $4,963,000 for the six months ended June 30, 2021 and 2020, respectively. Approximately $218,000 of the decrease The $453,000 increase in R&D expenses for the six months ended June 30, 2021, compared to the comparable 2020 period was related to decreased development spending on Tempol, ZIMHI, and other projects. In addition, wages, benefits, and other compensation expenses for research and development ~~employees decreased~~for the nine-month period ending September 30, 2022, was principally due to an increase of approximately ~~$299,000 during~~$2,756,000 in development costs for Tempol resulting from the ~~six months ended June 30, 2021, compared~~progression of our Phase 2/3 clinical trial relating to Tempol, offset by a decrease of approximately $1,140,000 in ZIMHI development costs, a decrease of $404,000 in SYMJEPI and other R&D projects development costs and a decrease of approximately $758,000 in compensation expenses principally related to the ~~comparable 2020 period, largely attributed to decreased stock~~reversal of bonus accrual expenses and lower stock-based compensation expenses ~~as a result of the completion of vesting of a significant amount of option grants through February 2021.~~

Research and development expenses of our Compounded Pharmaceuticals business conducted through USC were approximately $48,000 and $160,000 for the six months ended June 30, 2021 and 2020, respectively. USC’s R&D expenses for the six months ended June 30, 2021, compared to the comparable 2020 period, decreased due to the ~~reduction~~modification of ~~new product testing.~~

~~Impairment Expense, Goodwill.~~ Impairment expenses of goodwill for the six months ended June 30, 2021 and 2020 were approximately $0 and $3,143,000, respectively. In light of events associated with the global spread of COVID-19 and other factors, the company performed a goodwill impairment review as of March 31, 2020, and recorded a charge of approximately $3,143,000 for impairment of goodwill during the first quarter of 2020.

~~Impairment Expense, Contract Costs.~~ Impairment expenses of contract costs for the six months ended June 30, 2021 and 2020 were approximately $0 and $1,750,000, respectively. As a result of entering into the Termination Agreement with Sandoz, our financial results for the six months ending June 30, 2020, included an impairment of the Adamis capitalized cost to obtain a contract of $1,750,000.

~~Impairment Expense, Construction in Progress.~~ ~~Construction in progress impairment expenses for the six months ended June 30, 2021 and 2020 were approximately $9,000 and $0, respectively. In the second quarter of 2021, USC determined that~~ certain ~~in-process development costs related to its website design no longer had value and was thus impaired.~~outstanding equity awards.

Other Income (Expense). Other Income (Expenses) consists primarily of interest income, interest expense, ~~and~~ changes to the fair value of warrant ~~liabilities.~~liabilities, and other transactions. Other income (expense) for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021 was approximately ($~~7,746,000)~~2,079,000) and ~~$1,333,000~~$(2,635,000), respectively. The $556,000 decrease in other ~~income (expense)~~expenses during the ~~six-month period in 2021,~~nine months ended September 30, 2022, compared to the same period in ~~2020,~~2021, was primarily ~~due~~attributable to ~~the increase of other~~a decrease in expense ~~of approximately $9,050,000~~primarily associated with the change in fair value of warrants ~~a decrease~~ of approximately ~~$16,000~~$7,668,000, an increase in other income ~~and~~of approximately $500,000 from insurance proceeds, offset by an increase in expense related to the contingent loss accrual associated with the Second Draw PPP Loan, or PPP2 Loan of approximately $1,787,000 and additional expense of approximately $919,000 due to change in estimate of variable consideration related to the sale of certain assets to Fagron, pursuant to the USC Agreement. The decrease in variable consideration was due to lower level of sales by Fagron to covered customers covered in the USC Agreement, in part due to certain supply and materials difficulties and increased competitive conditions. Additionally, during the nine months ended September 30, 2022, there was approximately $63,000 of gain recorded in the consolidated statement of operations related to the forgiveness of the PPP2 Loan repayment, whereas in the comparable period of 2021, a gain of approximately $5,010,000 was recorded related to the forgiveness of the PPP loan debts.

Loss from Discontinued Operations. The Company recorded a net loss from discontinued operations of approximately $354,000 and $10,266,000 for the nine months ended September 30, 2022 and 2021, respectively. The $9,912,000 decrease in net loss from discontinued operations was primarily due to management's decision to discontinue the operations of USC, offset by a gain on the sale of non-financial assets of USC during the same period of 2021. The $354,000 net loss from discontinued operations for the nine months ended September 30, 2022, primarily related to SG&A expenses as the company continues the wind-down of USC. The main components of the loss for the nine months ended September 30,2021 were asset impairments totaling approximately $8,176,000 primarily related to adjustments associated with the winding down of the business of USC, approximately $7,145,000 of SG&A and R&D operating expenses, and approximately $71,000 of interest expense, partially offset by approximately $4,637,000 of gain from the sale of non-financial asset to Fagron, approximately ~~$13,000.~~$463,000 gross profit on sales and approximately $26,000 of other income.

We have incurred net losses from our continuing and discontinued operations of approximately ~~$24.7~~$23.2 million and ~~$20.2~~$37.1 million for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. Since inception, and through ~~June~~September 30, ~~2021,~~2022, we have an accumulated deficit of approximately ~~$257.0~~$301.2 million. Since inception and through ~~June~~September 30, ~~2021,~~2022, we have financed operations principally ~~through debt financing and~~ through public and private issuances of common stock, preferred stock and ~~warrants. In January~~warrants and February 2021, the company issued common stock upon exercise of investor warrants, the company received a total of approximately $5,852,000 and the warrant holders received 8,356,000 shares of common stock. On February 2, 2021, the company completed the closing of an underwritten public offering of 46,621,621 shares of common stock at a public offering price of $1.11 per share, which included 6,081,081 shares pursuant to the full exercise of the over-allotment option granted to the underwriters, resulting in net proceeds of approximately $48.4 million.through debt financing.

~~However, we may~~We will need additional funding in the near future to satisfy our existing and future obligations and ~~fund the future expenditures that we believe will be required~~liabilities and working capital needs, to support commercialization of our products, and ~~conduct the clinical and regulatory work, studies and trials~~for other purposes. We intend to ~~develop our product candidates, including without limitation relating~~seek to ~~our Tempol product candidates. We may finance~~satisfy future cash needs primarily through proceeds from equity or debt financings if available, loans, ~~share of profits anticipated to be received~~a partnership or other agreement regarding our commercial products, revenues relating to sales ~~in the U.S.~~ of our SYMJEPI and ZIMHI products, sales or out-licensing of intellectual property assets ~~out-licensing transactions, and/~~or ~~collaborative agreements with corporate partners.~~other assets, products, product candidates or technologies, a merger, sale or reverse merger of the Company, or other strategic transaction. As described elsewhere in this Report, we have initiated and are engaged in a review of strategic alternatives. However, there is no assurance that the Company will be successful in obtaining the necessary funding to sustain its operations or meet its business objectives.

As of ~~June~~September 30, ~~2021,~~2022, we had cash and cash equivalents ~~and restricted cash~~ of ~~$40,648,554.~~approximately $2.4 million. Total assets were approximately ~~$63.7~~$12.1 million and ~~$30.9~~$38.3 million as of ~~June~~September 30, ~~2021~~2022 and December 31, ~~2020~~2021, respectively. Current assets exceeded current liabilities by approximately ~~$32.7~~$1.2 million as of ~~June~~September 30, ~~2021.~~2022.

Net cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, was approximately ~~$21.3~~$(24.4) million and ~~$9.4~~$(31.1) million, respectively. Net cash used in operating activities ~~increased~~decreased primarily due to the ~~increase~~decrease in operating losses, offset by product recall payments of approximately $2.0 million, an approximately $1.4 million severance payment made in connection with a separation agreement in 2022 and an approximately $1.8 million repayment of the ~~payment of contingent loss liability in 2021~~Second Draw PPP Loan principal and such related interest and fees, as compared to ~~2020.~~ 2021. As part of our previously announced strategic review process, we have implemented expense reduction measures including, without limitation, employee headcount reductions and reduction or discontinuation of certain product development programs.

Net cash ~~used in~~provided by (used in) investing activities was approximately ~~$848,000~~$3.3 million and ~~$911,000~~$(0.9) million for ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. The net cash provided by investing activities for the nine months ended September 30, 2022, was primarily due to payments received from Fagron from the sale of USC assets, and net cash used in investing activities ~~decreased~~for both periods were primarily due to the purchase of capital equipment, with more capital equipment purchased in ~~process research and development license during~~ the ~~six~~nine months ended ~~June~~September 30, ~~2020~~2021, compared to the ~~six months ended June 30, 2021.~~same period in 2022.

Net cash provided inby financing activities was approximately ~~$56.0~~$0.3 million and ~~$9.4~~$54.0 million for the ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 and ~~2020,~~2021, respectively. Net cash ~~flows~~ provided by financing activities ~~increased~~ for the ~~period~~nine months ended ~~June~~September 30, ~~2021 primarily~~2022, was due to proceeds from the issuance of Series C Preferred Stock, as compared to proceeds from the issuance of common stock in an underwritten public offering, exercise of investor warrants and proceeds from the Second Draw PPP Loan during the nine months ended September 30, 2021.

PPP Loans. As discussed in Note 7 to the financial statements included elsewhere herein, we applied for and obtained loan funding under the PPP ~~generating net proceeds of approximately $56.0 million, offset by payment of loans and finance leases of approximately $51,000. In~~pursuant to the ~~six months ended of 2020, net cash used in financing activities consisted of issuance of common stock and the initial draw of~~ PPP Loan ~~generating net proceeds of approximately $9.4 million, offset by payment of loans~~ and ~~finance leases of approximately $53,000.~~

~~In connection with our acquisition of USC~~PPP Note in ~~2016, we assumed approximately $5,722,000~~the principal amount of ~~debt obligations under two loan agreements~~$3,191,700, the balance of which has been forgiven, and related loan documents relating to the building, real property and equipment that certain third parties agreed to transfer to the company or USC in connection with the merger transaction, as well as the two loan agreements to which USC is a party, a working capital loan and an equipment loan, and related loan documents evidencing loans previously made to USC, and we agreed to become an additional co-borrower under the loan agreement and related documents, such documents as amended referred to as the “Loan Documents.” The lender in all of the Loan Documents was First Federal Bank and/or its successor Bear State Bank (together with Arvest Bank, as successor in interest to Bear State Bank, referred to as “Lender” or the “Bank”). All amounts owed under the working capital loan and the equipment loan have previously been paid and there are no outstanding balances under those Loan Documents, and the working capital loan has not been renewed or extended. Periodic interest and principal payments under the building loan agreement are approximately $19,000 per month, with a final payment of all outstanding amounts due and payable in August 2021. At June 30, 2021, our aggregate indebtedness under the building loan agreement was approximately $2,018,000, which we paid in full in July 2021. There is no outstanding balance under the building loan or any of the other Loan Documents.

In April 2020, we secured an approximately $3.2 million Paycheck Protection Program (PPP) loan provided for by the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, and administered by the SBA. The unsecured loan, or the PPP Loan, is evidenced by a promissory note of the company, or the PPP Note, to Arvest Bank, the Lender. Under the terms of the PPP Note and the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the PPP Note is two years, unless sooner provided in connection with an event of default under the PPP Note. To the extent the loan amount is not forgiven under the PPP, we are obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Note (or later if a timely loan forgiveness application has been submitted), until the maturity date. The CARES Act and the PPP provide a mechanism for a borrower to apply for forgiveness of up to the full amount borrowed. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by us during the eight-week or 24-week period after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that at least 60% of the loan amount is used for eligible payroll costs; the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible costs during the covered eight-week or 24-week period will qualify for forgiveness.

~~In December 2020, we submitted an application for the forgiveness of our~~Second Draw PPP Loan and on August 12, 2021, we received notification through the Bank that the PPP Loan, including principal and interest thereon, has been fully forgiven by the SBA and that the remaining PPP Loan balance is zero. The company will recognize the amount forgiven as other income for the quarter in which the company received the notification.

~~On March 15, 2021, we entered into a Note, or the~~ PPP2 Note ~~in favor of the Bank,~~ in the principal amount of $1,765,495, ~~relating to funding~~the balance of which was also initially forgiven. However, as a result of the investigation by the Civil Division described elsewhere under ~~a Second Draw loan, or~~ the ~~Second Draw Loan, pursuant~~heading “Legal Proceedings” and in Note 9 to the ~~terms of the PPP, the CARES Act, and the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act enacted~~consolidated financial statements included elsewhere herein, in December 2020. Under the terms of the PPP2 Note and Second Draw Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. If any payment on the PPP2 Note is more than 15 days late, the Bank may chargeJune 2022, the company paid a ~~late fee~~total of ~~up to 5% of the unpaid portion of the regularly scheduled payment. The term of the PPP2 Note is five years, unless sooner provided~~$1,787,417 in ~~connection with an event of default under the PPP2 Note. We may prepay the Second Draw Loan at any time prior to maturity with no prepayment penalties. Under the PPP, the proceeds~~repayment of the Second Draw PPP Loan ~~may be used to pay payroll~~principal and ~~make certain covered~~related interest ~~payments, lease payments~~ and ~~utility payments. We may apply~~fees. Our PPP loans and applications for forgiveness of ~~some or all of the Second Draw Loan pursuant~~loan amounts remain subject to the PPP. In order to obtain full or partial forgiveness of the Second Draw Loan, we must timely request forgiveness, must provide satisfactory documentation in accordance with applicable SBA guidelines,future review and must satisfy the criteria for forgiveness under the PPP and applicable SBA requirements. If we timely apply for forgiveness, payments will be deferred in accordance with the CARES Act, as modified by the Paycheck Protection Program Flexibility Act of 2020, and we will not be obligated to make any payments of principal or interest before the date on which the SBA remits the loan forgiveness amount to the Bank or notifies the Bank that no loan forgiveness is allowed; and the Bank will then notify us of remittanceaudit by SBA ~~of the loan forgiveness amount,~~ or notify us that the SBA determined that no loan forgiveness is allowed and the date that our first payment is due. Interest will accrue during the deferral period. There is no assurance that we will obtain forgiveness of the Second Draw Loan in wholeother federal or ~~in part. Our PPP loans are subject to review by SBA~~state regulatory authorities for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form. ~~Accordingly, the company may be audited or reviewed by federal or state regulatory authorities as a result of filing an application for forgiveness or otherwise.~~ If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return or repay the full amount of the applicable loan and could be subject to additional fines or penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations. If the Second Draw Loan is not forgiven in accordance with the terms of the PPP, we will be obligated to make monthly payments of principal and interest to repay the Second Draw Loan in full prior to the maturity date. If it is determined that the company was ineligible to receive the Second Draw Loan, we may be required to repay the Second Draw Loan in its entirety and/or be subject to additional penalties. Should the company apply for and receive forgiveness of some or all of the PPP2 Loan, the amount forgiven would be recognized as other income upon formal notice of forgiveness.  If we do not submit a loan forgiveness application to the Bank within 10 months after the end of our applicable covered period, as defined under the PPP and applicable regulations and guidance issued by the SBA or the U.S. Department of Treasury, then we must begin paying principal and interest after that period. The PPP2 Note contains customary events of default relating to, among other things, payment defaults, breaches of representations, warranties or covenants, defaults on other loans with the Bank, failure to disclose material fact or making materially false or misleading representations to the Bank or SBA, certain defaults on other loan agreements or agreements with creditors, bankruptcy or insolvency events, certain change of control events, material adverse changes or events, certain events that the Bank believes may materially affect the company’s ability to pay the PPP2 Note, and certain other events. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing by us, or filing suit and obtaining judgment against us.

On August 12, 2021, we received notification through the Bank that as August 5, 2021, the PPP Loan drawn on April 13, 2020, including principal of $3,191,700 and interest thereon, has been fully forgiven by the SBA and that the remaining PPP Loan balance is zero. In October 2021, we received notification through the Bank that as of September 28, 2021, the Second Draw PPP Loan, including principal of $1,765,495 and interest thereon, has been fully forgiven by the SBA and that the remaining PPP2 Loan balance is zero.

Even though the PPP Loan and the Second Draw PPP Loan have been forgiven, our PPP loans and applications for forgiveness of loan amounts remain subject to review and audit by SBA for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form, including without limitation the required economic necessity certification by the Company that was part of the PPP loan application process. Accordingly, the Company is subject to audit or review by federal or state regulatory authorities as a result of applying for and obtaining the PPP Loan and Second Draw PPP Loan or obtaining forgiveness of those loans. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return or repay the full amount of the applicable loan and could be subject to fines or penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations. If it is determined that the Company was ineligible to receive the PPP Loan and/or the Second Draw Loan, the Company may be required to repay the PPL Loan and Second Draw Loan in its entirety and/or be subject to additional penalties.

As noted above under the heading “Going Concern and Management Plan,” through ~~June~~September 30, ~~2021, Adamis has~~2022, we have incurred substantial losses. We will be required to obtain additional cash resources in the near term in order to support our operations and activities. The availability of ~~any~~ required additional funding cannot be assured. As of the date of this Report, we have a limited number of authorized shares available for issuance in funding transactions involving the issuance of equity securities. In addition, an adverse outcome in legal or regulatory proceedings in which we are or in the future could be involved could adversely affect our liquidity and financial position. See Note 9 of the notes to our consolidated financial statements included elsewhere herein. If we doare not able to obtain additional required ~~additional~~ equity or debt funding or funding from other sources, our cash resources could be depleted and we could be required to materially reduce or suspend ~~operations.~~operations, or seek dissolution and liquidation, or bankruptcy protection. No assurance can be given as to the timing or ultimate success of obtaining future funds. Even if we are successful in obtaining required additional funding to permit us to continue operations at the levels that we desire, substantial time may pass before we realize additional significant revenues from our commercial products or obtain regulatory marketing approval for any additional ~~specialty~~ pharmaceutical products and begin to realize revenues from sales of such additional ~~products, and during this period Adamis could require additional funds.~~products. No assurance can be given as to the timing or ultimate success of obtaining any required future funding. The company will be required to devote additional cash resources, which could be significant, in order to continue development and commercialization of our product candidates and to support our other operations and activities. AsIn addition, as a result of the COVID-19 pandemic and actions taken to slow its spread, national or global developments, inflation or other economic considerations or other factors, there can be no assurance that deterioration in credit and financial markets will not occur, which would make it more difficult, or more costly or dilutive, to obtain any necessary debt or equity financing.

As disclosed elsewhere in this Report, including in Part II, Item 1, “Legal Proceedings,” on May 11, 2021, each of the company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the company and USC. The Audit Committee of the Board ~~has~~ engaged outside counsel to conduct an independent internal investigation to review these and other matters. In addition to the subpoenas from the USAO, the company has also received requests from the SEC for the voluntary production of documents and information relating to the subject matter of the USAO’s subpoenas and certain other ~~matters.~~matters in connection with the SEC’s investigation. The company has produced documents and will continue to produce and provide documents in response to the subpoenas and requests. The company intends to cooperate with the USAO the SEC and the ~~SEC.~~Civil Division. At this time, the company is unable to predict the duration, scope, or outcome of the investigations by the USAO, SEC, Civil Division or other agencies, or determine what, if any, proceedings the USAO, SEC, Civil Division or other federal or state authorities may initiate, what, if any, remedies or remedial measures the USAO, SEC, the Civil Division, or other federal or state authorities may seek, or what, if any, impact the foregoing matters may have on the company’s business, previously reported financial results, financial results included in this Report, or future financial results. The foregoing matters may divert management’s attention, cause the company to suffer reputational harm, require the company to devote significant financial resources, subject the company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, result in fines, penalties, equitable remedies, and affect the company’s business, previously reported financial results, financial results included in this Report, or future financial results. The occurrence of any of these events could have a material adverse effect on the company’s business, financial condition and results of operations.

Based on our current and anticipated level of operations, we do not believe that our cash, cash equivalents and short-term investments, together with anticipated revenues from operations and cash inflows from other sources, and amounts that we expect to receive as a result of our sales of assets relating to our former USC business, will be sufficient to meet our anticipated operating expenses, capital expenditures and obligations for at least 12 months from the date of this Report. We anticipate that before the end of 2022, we will require additional funding to sustain operations, satisfy our obligations and liabilities, fund our ongoing operations, or for other purposes. We may seek to raise additional funds or seek funding from a variety of sources including proceeds from equity or debt financings if available, loans, revenues relating to sales of our SYMJEPI and ZIMHI products, sales or out-licensing of intellectual property assets or other assets, products, product candidates or technologies, during the remainder of 2022, and thereafter. As of the date of this Report, we have a limited number of authorized shares available for issuance in funding transactions involving the issuance of equity securities. Additional required capital may not be available on a timely basis, on favorable terms, or at all, and such funding, if raised, may not be sufficient to meet our obligations or enable us to continue to implement our long-term business strategy. In addition, obtaining additional funding or entering into other strategic transactions could result in significant dilution to our stockholders. If we do not receive required funding and are not able to engage in a merger, sale, reverse merger or other strategic transaction, we would likely be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection.

As of September 30, 2022, we had an operating lease for office space for our offices in San Diego, California, with a remaining term expiring in November 2023. Monthly rent through the remaining term of the lease is approximately $32,000 per month. We also have a lease agreement for space located in Conway, Arkansas, relating to the compounding pharmaceutical products business formerly conducted by our USC subsidiary, with a current term expiring December 31, 2023. As a result of the sale of assets pursuant to the USC Agreement and the winding down of USC’s remaining business, the company will not need the leased property. Monthly rent for the remaining term of this lease is approximately $10,800 per month. See Note 6 of the notes to the consolidated financial statements included elsewhere herein for additional information about our lease obligations.

We have entered into arrangements with clinical sites and clinical research organizations, or CROs, for the conduct of our clinical trials. We make payments to these clinical sites and CROs based in part on the number of eligible patients enrolled, the length of their participation in the clinical trials and activities undertaken by the clinical sites and CROs. At this time, due to the variability associated with clinical site agreements, CRO agreements and manufacturing agreements, we are unable to estimate with certainty the future costs we will incur, including in connection with the close-out of the Phase 2/3 clinical trial relating to Tempol which was halted following the DSMB's September 2022 recommendation, but such expenses may be material. In addition, we have entered into agreements and arrangements with third parties for the manufacture and supply of clinical and commercial materials and drug products, including for our SYMJEPI and ZIMHI products and our halted clinical trial for our Tempol product candidate. In some of our agreements with manufacturers, we have a production threshold commitment where we would be required to pay for maintenance fees if we do not meet certain periodic purchase order minimums. Maintenance fees for the three months and nine months ended September 30,2022 were $0. Under certain of these agreements, we may be subject to penalties in the event that we prematurely terminate these agreements. We intend to use our current financial resources to fund our obligations under these commitments.

As disclosed elsewhere in this Report, on March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level, due to the potential clogging of the needle preventing the dispensing of epinephrine. USWM is handling the entire recall process for the company, with company oversight. SYMJEPI is manufactured and tested for us by Catalent Belgium S.A. The ultimate costs of the recall and the allocation of costs of the recall, including the costs to us resulting from the recall, are unknown as of the date of this Report; however, the recall could cause the company to suffer reputational harm, depending on the resolution of matters relating to the recall could result in the company incurring financial costs and expenses which could be material, could adversely affect the supply of SYMJEPI products until manufacturing is resumed, and depending on the resolution of matters relating to the recall could have a material adverse effect on our business, financial condition, and results of operations.

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The company’s critical accounting policies and estimates ~~previously disclosed~~included in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021, filed with the SEC on March 31, 2022, have not ~~significantly~~materially changed.

Recent accounting pronouncements are disclosed in Note 1 to the ~~accompanying~~condensed consolidated financial statements ofincluded in this Quarterly Report on Form 10-Q.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving their objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this ~~report.~~Report. Based on the foregoing, our chief executive officer and chief financial officer concluded that ~~as of June 30, 2021,~~ our disclosure controls and procedures were ~~in design and operation, not~~ effective at the reasonable assurance level~~, due to the presence~~ as of ~~a material weakness in internal control over financial reporting as described below.~~ A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

~~As required by Rule~~ There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) ~~and Rule~~or 15d-15(d) of the Exchange Act ~~our management, including our principal executive officer and our principal financial officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes~~that occurred during the ~~period covered by this Report~~quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ~~Based on that evaluation,~~

Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting

Because of their inherent limitations, our ~~principal executive officer~~disclosure controls and ~~principal financial officer concluded that except as described below~~procedures and ~~other~~ ~~than the material weakness and the remediation measures described in this Item 4,~~ ~~there~~ ~~were no changes in our internal controls over financial reporting during the quarter ended June 30, 2021 that materially affected, or were reasonably likely to materially affect, our~~ ~~internal control over financial reporting.~~ We have not experienced any material impact to our internal controls over financial reporting as a result of the COVID-19 pandemic despite the fact that some of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the impact of the COVID-19 pandemic on our internal controls to reduce or minimize the impact on their design and operating effectiveness.

~~Based on the material weakness described below, management has concluded that as of March 31, 2021,~~ our internal control over financial reporting ~~was~~may not ~~effective. We identified a weakness relating to~~prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls ~~over adherence to certain company policies~~ and procedures ~~relating~~and our internal control over financial reporting is subject to ~~hiring, monitoring and supervision~~risks, including that the controls may become inadequate because of ~~USC’s sales personnel and~~changes in conditions or that the ~~activities~~degree of ~~such personnel, which were not strictly implemented and observed. We also identified a weakness in controls regarding inadequate oversight by senior management to ensure~~ compliance with ~~and adherence to company~~our policies ~~and~~or procedures ~~by USC sales personnel and to ensure performance of adequate monitoring and supervision of personnel. This control deficiency was assessed as a material weakness as of June 30, 2021.~~

Notwithstanding the material weakness described above, our management has concluded that the unaudited financial statements included in this Report are fairly stated in all material respects in accordance with U.S. GAAP for each of the periods presented herein.

We may from time to time become party to actions, claims, suits, investigations or proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, ~~claims relating to our compounded pharmacy business,~~ breach of contract claims, labor and employment claims and other matters. We may also become party to litigation in federal and state courts relating to opioid drugs. Any litigation could divert management time and attention from Adamis, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, we are not currently involved in any legal proceedings that we believe are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on us because of associated cost and diversion of management time.

On September 21, 2018, Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center LLC (collectively, “Nephron”) filed a lawsuit in the United States District Court for the Middle District of Florida, Orlando Division, alleging claims against our wholly owned subsidiary USC —and a USC employee who previously was an employee of Nephron. The original complaint asserted thirteen causes of action against the employee and USC alleging generally misappropriation of Nephron’s trade secrets. The plaintiffs subsequently amended their complaint to include Adamis as a defendant. After several motions to dismiss, only four claims remained from the third amended complaint: (1) misappropriation under the Federal Defend Trade Secrets Act (“DFSA”), (2) breach of contract (against the employee only), (3) misappropriation under the Florida Uniform Trade Secrets Act (“FUTSA”), and (4) tortious interference with an advantageous business relationship. The gravamen of these claims was that the employee improperly misappropriated trade secretFor additional information from the employee’s former employer, Nephron, prior to starting employment at USC and that USC improperly recruited the employee for employment at USC. The third amended complaint alleged that Adamis and USC aided in this misappropriation by “using and/or disclosing and/or retaining the same in an effort to unfairly compete against Nephron.” The third amended complaint sought actual, compensatory, consequential, special, and punitive damages, attorneys’ fees and costs, prejudgment interest, preliminary and permanent injunctive relief, and other relief.

On May 6, 2020, Adamis and USC moved for summary judgment to dismiss the three claims that remained pending against them. In October 2020, the magistrate judge presiding over the motion delivered a Report and Recommendation recommending that the court enter an order granting the motion in part and denying the motion in part. The court adopted the recommendation of the magistrate and granted in part and denied in part the motion of Adamis and USC for summary judgment. The court denied the motion for summary judgment by Adamis and USC with respect to the plaintiffs’ claims under the DFSA and FUTSA, concluding that there were triable issues of material fact that precluded the entry of summary judgment, and granted the motion for summary judgment in favor of Adamis and USC with respect to the claim for tortious interference. In March 2021, the court granted a motion by Nephron to hold Adamis and USC in civil contempt for violation of a previous consent preliminary injunction related to the hiring by USC of an employee, and ordered that Adamis and USC compensate Nephron for certain fees and expenses in the litigation relating to the matter as well as pay a fine, in an amount to be determined. A hearing on the amount of such sanctions was held on April 6, 2021, but decisions regarding ~~sanctions were deferred until after trial. After the hearing, the court ruled on various pre-trial motions relating to the conduct of the trial. The case was set for trial on April 19, 2021.~~

As previously disclosed in the 2020 Form 10-K, while we continue to believe that the claims and damages sought by the plaintiff were without merit, in light of several factors including the recent hearing and outcome of decisions concerning pre-trial motions, the legal expenses of ongoing litigation and trial, the uncertainties of litigation and jury trials, and the possibility of punitive damages and other adverse awards or sanctions, on April 9, 2021, Adamis, USC and Nephron agreed to terms of settlement of the Florida litigation as well as a related case filed by Nephron against USC, Adamis and a second USC employee in the United States District Court for the District of New Jersey alleging misappropriation of trade secrets from Nephron. Under the terms of the settlement agreement entered into by Adamis, the Nephron entities and certain other individuals (the “individual parties”), and related documents entered into by the parties thereto, on May 3, 2021, the company paid Nephron an amount equal to $7,900,000;proceedings involving the company and ~~USC, as well as~~ the ~~individual parties, agreed to a permanent injunction reflecting certain terms~~proceedings discussed below, please see the discussion of legal proceedings in Note 9--Legal Matters, of the ~~settlement and pursuant~~notes to our consolidated financial statements included elsewhere in this Report, which they agreed, among other things, not to retain, access, communication, use or disclose any proprietary or confidential information of Nephron and to destroy all such information in their possession or control, subject to limited exceptions; and Nephron agreed to dismissal of or withdrawal from the lawsuits and related legal proceedings. Pursuant to the settlement agreement, each of the parties agreed to release each other from all existing claims that any of them may have against any of the other parties that arise from or relate to the claims and liabilities asserted in the various lawsuits and agreed not to sue any of the parties on the basis of any released claim.discussion is incorporated herein by reference.

On May 11, 2021, the ~~company~~Company and USC each received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (“USAO”). The USAO issued the subpoenas in connection with a ~~criminal~~grand jury investigation and requested a broad range of documents and materials relating to, among other matters, certain veterinary products sold by USC, certain practices, agreements, and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the ~~company~~Company and USC. ~~On May 11, 2021, the~~The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review the matters brought forth in the subpoenas and certain other matters. The investigation involved, among other matters, interviews with employees and collection and review of a large number of documents. The company has taken a number of actions in response to the internal investigation, including personnel actions relating to certain USC veterinary sales employees. In addition, following the commencement of the investigation, as disclosed elsewhere in ~~this Report~~these interim condensed consolidated financial statements, the ~~company~~Company has sold assets relating to its compounding pharmacy business, ceased selling human and veterinary compounded pharmaceutical products, ~~is engaged in a process of winding~~has wound down USC’s business, and the employment of ~~substantially all~~ USC employees has ~~ended or will end in connection with the winding down of that business.~~ended. As a result, the ~~company will~~Company is no longer be engaged in the sale of human or veterinary compounded pharmaceutical products. The ~~company~~Company is also considering a number of additional actions in response to the internal investigation and the USAO investigation. As of the date of this Report, ~~we believe~~the Company believes that the investigation initially commenced by the Audit Committee is substantially complete. However, additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the Audit Committee’s investigation. ~~In addition to the subpoenas from the USAO, the company~~

The Company has also received requests from the U.S. Securities and Exchange Commission (“SEC”) for the voluntary production of documents and information in connection with the SEC’s investigation relating to the subject matter of the USAO’s subpoenas and certain other matters. The ~~company~~Company has produced documents and will continue to produce and provide documents in response to ~~the~~ subpoenas and ~~requests.~~requests for voluntary production of documents as needed. Additionally, on March 16, 2022, the Company was informed that the Civil Division of the USAO (“Civil Division”) was investigating the Company’s Second Draw PPP Loan application and the company’s eligibility for the Second Draw PPP Loan. The ~~company~~Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. As a result of the investigation by the Civil Division, the Company’s financial statements for the first quarter of 2022 included a $ 1,850,000 contingent loss liability relating to the possible repayment of the full amount of the Second Draw PPP Loan as well as accrued interest and processing fees of the lending bank. In June 2022, following the inquiry the Company paid a total of $ 1,787,417 in repayment of the Second Draw PPP Loan principal and related interest and fees. The Company previously disclosed that the lending bank waived the processing fee of approximately $63,000; however, the Company has recently been made aware by the Civil Division that the lending bank did receive a processing fee of approximately $53,000 and that it may need to be repaid. The Company is awaiting confirmation from the Civil Division on the potential repayment of the above-referenced processing fee and as to whether any additional action is required to conclude the investigation into the Second Draw PPP Loan. The Company intends to ~~cooperate~~continue cooperating with the USAO, SEC, and ~~the SEC.~~Civil Division. At this time, the ~~company~~Company is unable to predict the duration, scope, or outcome of the investigations by the USAO, SEC, Civil Division, or other ~~agencies, or determine~~agencies; what, if any, proceedings the USAO, SEC, Civil Division, or other federal or state authorities may ~~initiate,~~initiate; what, if any, remedies or remedial measures the USAO, SEC, Civil Division or other federal or state authorities may ~~seek,~~seek; or what, if any, impact the foregoing matters may have on the ~~company’s~~Company’s business, previously reported financial results, financial results included in ~~this Report,~~these interim condensed consolidated financial statements, or future financial ~~results.. We~~results. The Company could receive additional requests or subpoenas from the USAO, SEC, Civil Division, or other authorities, which may require further investigation. There can be no assurance that any discussions with the USAO, SEC or ~~USAO~~Civil Division to resolve these matters will be successful. The foregoing matters may divert management’s attention, cause the ~~company~~Company to suffer reputational harm, require the company to devote significant financial resources, subject the ~~company~~Company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, result in fines, penalties or equitable remedies, and affect the ~~company’s~~Company’s business, previously reported financial results, financial results included in ~~this Report,~~these interim condensed consolidated financial statements, or future financial results. The occurrence of any of these events, or any determination that our activities were not in compliance with existing laws or regulations, could have a material adverse effect on the ~~company’s~~Company’s business, liquidity, financial condition, and results of operations.

As a result of the investigation by the Civil Division, the company’s financial statements for the first quarter of 2022 included a $1,850,000 contingent loss liability relating to the possible repayment of the full amount of the Second Draw PPP Loan as well as accrued interest and processing fees of the lending bank. In ~~October 2021,~~June 2022, following the ~~sale~~inquiry, the company paid a total of $1,787,417 in ~~July~~repayment of the Second Draw PPP Loan principal and such related interest and fees.

On December 31, 2021, we received a notice from the Nasdaq Listing Qualifications Department of ~~certain assets~~The NASDAQ Capital Market (“Nasdaq”) informing us that because the closing bid price of our Common Stock had been below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) (the “Rule”) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), we were provided an initial compliance period of 180 calendar days, or until June 29, 2022, to regain compliance. To regain compliance, the closing bid price of our Common Stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. The notice letter also disclosed that if we do not regain compliance within the initial compliance period, we may be eligible for an additional 180-day compliance period. To qualify for additional time, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of a plan to cure the deficiency during the second compliance period, including by effecting a reverse stock split if necessary. We did not regain compliance with the Rule by June 29, 2022. We requested additional time to regain compliance and provided notice to Nasdaq of our intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split if necessary. On June 30, 2022, Nasdaq notified us that we were granted an additional 180-day compliance period or until December 27, 2022, to regain compliance with the Rule. The notice also indicated that if at any time before December 27, 2022, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Rule. If the Company does not meet the minimum bid requirement at some time during the additional 180-day grace period, Nasdaq will provide written notification to the Company that its shares will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. The Company would remain listed pending the Panel’s decision. There can be no assurance that if the Company does appeal a subsequent delisting determination, that such appeal would be successful. The letter and notification from Nasdaq had no immediate effect on the listing or trading of the Company’s ~~USC subsidiary relating~~shares, which will continue to ~~USC’s human compounding pharmaceutical business and~~trade on the ~~Company’s approval of a restructuring process of winding down~~Nasdaq Capital Market under the ~~remaining operations and business of USC and selling or disposing of the remaining assets of USC, the Company entered into a Consent Order~~symbol “ADMP.” There are no assurances that we will be able to regain compliance with the ~~Arkansas State Board of Pharmacy to resolve an ongoing administrative proceeding before~~minimum bid price requirements or will otherwise be in compliance with other Nasdaq listing rules.

As previously disclosed in our Annual Report on Form 10-K for the ~~pharmacy board, pursuant to which USC agreed to surrender its Arkansas retail pharmacy permit and wholesaler/outsourcer permit effective October~~year ended December 31, 2021, ~~to pay a civil penalty of $75,000 relating to violations of various Arkansas pharmacy laws~~ and ~~the pharmacy board’s regulations, and to pay $75,000~~ in ~~investigative costs of the pharmacy board.~~

~~In response to the company’s May 2021 Form 12b-25 disclosure that it would be unable to file in a timely manner its~~our subsequent Quarterly ~~Report~~Reports on Form 10-Q for the quarter ended March 31, 2021 due to the need for additional time to address matters relating to the USAO’s subpoenas, Nasdaq sent the company a letter determining that the company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1). We submitted a plan to regain compliance. In August, we received a notification letter from Nasdaq notifying us that because we had not filed our Quarterly Reportfirst two quarters of 2022, on Form 10-Q for the period ended June 30, 2021, as well as the Form 10-Q for the period ended March 31, 2021 (together, the “Form 10-Qs”), we did not comply with NASDAQ Listing Rule 5250(c)(1). Nasdaq subsequently requested that we submit an updated plan to regain compliance, which we submitted, and Nasdaq granted an exception of up to November 22, 2021, to regain compliance. With this Report and the filing of the Form 10-Qs, the company believes it has returned to full compliance.

On June 8, 2021, Jerald Hammann filed a complaint against the Company and each of its directors in the Court of Chancery of the State of Delaware, captioned Jerald Hammann v. Adamis Pharmaceuticals Corporation et al., C.A. No. 2021-0506-PAF (the “Complaint”), seeking injunctive and declaratory relief. The Complaint alleges, among other things, that the defendants (i) violated Rule 14a-5(f) and 14a-9(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with the Company’s 2021 annual meeting of stockholders—which was subsequently held on July 16, 2021 (the “2021 annual meeting”)—and disseminated false and misleading information in the Company’s proxy materials relating to the 2021 annual meeting, (ii) violated certain provisions of the Company’s bylaws relating to the 2021 annual meeting, (iii) violated section 220 of the Delaware General Corporation Law (“DGCL”) in connection with a request for inspection of books and records submitted by the plaintiff, and (iv) breached their fiduciary duties of disclosure and loyalty, including relating to establishing and disclosing the date of the Company’s 2021 annual meeting and to the Company’s determination that a solicitation notice delivered to the Company by plaintiff was not timely and was otherwise deficient. The ~~Complaint alleges, among other things, that~~ plaintiff ~~intended to initiate a proxy contest against~~has also filed various motions with the Court, which have been resolved. The Company that defendants’ conduct made it difficult or impossible for plaintiff to initiate a proxy context, and that the Company’s definitive proxy statement included false and misleading disclosures and omissions of material information. The Complaint sought injunctive relief (i) to prevent the Board, the Company, and their employees and agents from soliciting any stockholders pursuant to the Company’s proxy statement and (ii) to prevent the defendants from interfering in the effectiveness of stockholder voting for the 2021 annual meeting. The Complaint also seeks declaratory relief (i) finding that plaintiff’s solicitation notice was timely and properly submitted; (ii) directing the defendants to comply with Rules 14a-5(f) and 14a-9(a) of the Exchange Act; (iii) directing the Company to produce the materials set forth in the plaintiff’s books and records request; (iv) finding that the director defendants breached their fiduciary obligations to stockholders; and (v) finding that the director defendants engaged in self-dealing. The Complaint seeks an award of fees, costs, and expenses in this action, including attorneys’ and experts’ fees.

You should consider carefully the following information about the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q and in our other public filings in evaluating our business. The risk factors set forth below with an asterisk (*) next to the title contain substantive changes to the risk factors associated with our business previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~ 2021. Our business, financial condition, results of operations and future prospects could be materially and adversely affected by these risks if any of them actually occurs. In these circumstances, the market price of our common stock would likely decline. The risks and uncertainties described below are not the only ones we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business.

The business of Adamis Pharmaceuticals Corporation (“we,” “us,” “our,” “Adamis,” or the “company”) is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled “Risk Factors.” These risks include, but are not limited to, the following:

*There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain further financing.

Our consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in our consolidated financial statements for the year ended December 31, ~~2020,~~2021, included in our ~~annual report~~Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, and in the consolidated financial statements ~~accompanying~~included in this Report, we have sustained substantial recurring losses from operations. In addition, we have used, rather than provided, cash in our continuing operations. ~~Additional funding may be required to develop~~As of September 30, 2022, we had cash and commercialize our products and product candidates, conduct research, development and trials relating to our product candidates, fund our ongoing operations and satisfy our obligations and liabilities. Without obtaining additional funding if required, it would be unlikely for us to continue as a going concern.cash equivalents of approximately $2.4 million. The above conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue in existence. Uncertainty concerning our ability to continue as a going concern, among other factors, may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent, among other factors, on our ability to successfully develop and commercialize products, the market acceptance and success of our products and our ability to obtain additional required funding in the near term and ~~there~~thereafter. If we cannot continue as a viable entity, we might be required to reduce or cease operations or seek dissolution and liquidation or bankruptcy protection, and our stockholders would likely lose most or all of their investment in us.

We incurred significant net losses for the nine months ended September 30, 2022, and for the years ended December 31, 2021 and December 31, 2020. As of September 30, 2022, we had cash and cash equivalents of approximately $2.4 million. Our continued operations and the development of our business will require additional capital. Based on our current and anticipated level of operations, we do not believe that our cash, cash equivalents and short-term investments, together with anticipated revenues from operations and amounts that we expect to receive as a result of our sales of assets relating to our former USC business or from other sources, will be sufficient to meet our anticipated operating expenses, liabilities and obligations for at least 12 months from the date of this Report. Before the end of 2022, as well as thereafter, we will require additional funds to sustain operations, satisfy our obligations and liabilities, fund our ongoing operations, or for other purposes, and we intend to seek additional funds during the fourth quarter of 2022 and/or thereafter. There are no assurances that ~~such~~required funding will be available at all or will be available in sufficient amounts or on reasonable terms. Without additional funds, if required, from debt or equity financings, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions or sources, we will exhaust our resources and will be unable to continue operations. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.

We incurred significant net losses for the years ended December 31, 2020 and December 31, 2019 and for the quarters of 2021 reflected in the financial statements included elsewhere in this Report. The development of our business may in the future require additional capital to help fund the development and commercialization of our products and product candidates, conduct research, development and trials relating to our product candidates, fund our ongoing operations and satisfy our obligations and liabilities. In addition to product revenues, we have historically relied upon sales of our equity or debt securities to fund our operations. As of the date of this Report, we have a limited number of authorized shares available for issuance in any funding transactions involving the issuance of equity securities. We currently have no available balance in our credit facility or committed sources of capital, and a number of factors may limit or prevent our current ability to access capital ~~markets.~~markets to obtain any required equity or debt funding. Delays in obtaining, or the inability to obtain, required funding ~~could~~from debt or equity financings, sales of assets, sales or out-licenses of intellectual property assets, products, product candidates or technologies, or other transactions or sources, would materially and adversely affect our ability to ~~develop~~satisfy our liabilities and ~~commercially introduce products and cause us to be unable to comply with~~ our obligations under outstanding ~~instruments. In addition,~~instruments, and would materially and adversely affect our ~~previously announced sale of Assets pursuant~~ability to the USC Agreement relating to the human compounding pharmaceuticals business of our USC subsidiary, together with our previously announced restructuring process of winding down, winding up and disposing of the remaining operations, business and assets of USC, will result in the company not receiving revenues in the future from sales of products by USC, other than the consideration receivable by the company pursuant to the terms of the USC Agreement or from other agreements or arrangements relating to the sale or disposition of the remaining USC assets.

Our ability to obtain required debt or equity financing ~~if required~~or funds from other transactions will be subject to a number of factors, including without limitation market conditions, our capitalization, our operating performance and investor sentiment. The terms of any such funding, or the terms of any strategic transaction that we might enter into, could result in significant dilution to our stockholders. If we are unable to raise additional ~~capital~~funds when required or on acceptable terms, we may have to significantly ~~delay, scale back or discontinue the development or commercialization of one or more of our product candidates,~~ restrict our operations or obtain funds by entering into agreements on unattractive terms, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, and which could result in additional dilution to our stockholders. If we do not have sufficient funds to continue operations, we could be required to seek dissolution and liquidation, bankruptcy protection or other alternatives that would likely result in our stockholders losing some or all of their investment in us.

*Statements in this Report concerning our future plans and operations are dependent on our ability to secure adequate funding and the absence of unexpected delays or adverse developments. We may not be able to secure required funding.

The statements contained in this Report concerning future events or developments or our future activities, such as concerning current or planned clinical trials, anticipated research and development activities, anticipated dates for commencement of clinical trials, anticipated completion dates of clinical trials, anticipated meetings with the FDA or other regulatory authorities concerning our product candidates, anticipated dates for submissions to obtain required regulatory marketing approvals, anticipated dates for commercial introduction of products, anticipated outcome of any legal proceedings in which we are involved, the possibility of entering into a strategic transaction regarding our products or a merger, reverse merger or other strategic transaction, and other statements concerning our future operations and activities, are forward-looking statements that in each instance assume that we have or are able to obtain sufficient funding to support such activities and continue our operations and planned activities in a timely manner. There can be no assurance that this will be the case. Also, such statements assume that there are no significant unexpected developments or events that delay or prevent such activities from occurring. Failure to timely obtain any required additional funding, or unexpected developments or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could adversely affect our business, financial condition and results of operations.

We have restated our unaudited condensed consolidated financial statements for the interim periods of 2020, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on our business, financial condition and stock price.

On April 14, 2021, we concluded that, because of a misapplication of valuation principles used to determine the amount of our non-cash warrant liabilities and the associated gain or loss recognized as a result of the change in the fair value of the warrant liabilities, relating to warrants that we issued in August 2019 (the “2019 Warrants”) and February 2020 (the “2020 Warrants” and, together with the 2019 Warrants, the “Warrants”), our previous quarterly and year-to-date unaudited condensed consolidated financial statements for the periods ended March 31, 2020, June 30, 2020 and September 30, 2020 (the “Affected Periods”), should no longer be relied upon. As a result, we restated our unaudited condensed consolidated financial statements for the Affected Periods. The issues identified were all non-cash and did not impact our revenues, operating expenses, operating loss, cash and cash equivalents, assets, liquidity or cash position for the Affected Periods or the year ended December 31, 2020. As a result of the foregoing matters, or if we determine in the future that other financial restatements are required, we may become subject to additional risks and uncertainties, including, among others, unanticipated costs for accounting and legal fees, the increased possibility of legal proceedings, shareholder lawsuits, governmental agency investigations, and inquiries by the Nasdaq Stock Market or other regulatory bodies, which could cause investors to lose confidence in our reported financial information and could subject us to civil or criminal penalties, shareholder class actions or derivative actions. We could face monetary judgments, penalties or other sanctions that could have a material adverse effect on our business, financial condition and results of operations and could cause our stock price to decline. If any such actions occur, they will, regardless of the outcome, consume a significant amount of management’s time and attention and may result in additional legal, accounting, insurance and other costs. If we do not prevail in any such proceedings, we could be required to pay substantial damages or settlement costs. In addition, ~~the~~any restatement ~~and~~or related matters could impair our reputation. Each of these occurrences could have a material adverse effect on our business, results of operations, financial condition and stock price.

*We have incurred losses since our inception, and we anticipate that we will continue to incur losses. We may never achieve or sustain profitability.

We incurred significant net losses for the ~~years~~nine months ended ~~December 31, 2020 and December 31, 2019 and for the quarters of 2021~~September 30, 2022, as reflected in the financial statements included elsewhere in this ~~Report.~~Report, and for the years ended December 31, 2021 and December 31, 2020. We expect that these losses may continue as we continue our research and development activities, ~~seek regulatory approvals for~~support commercialization of our ~~product candidates~~approved products, and ~~seek~~continue to ~~commercialize any approved products.~~conduct our business. These losses will cause, among other things, our stockholders’ equity and working capital to decrease. Any future earnings and cash flow from operations of our business are dependent on our ability to further develop our products and on revenue and profitability from sales of products.

There can be no assurance that we will be able to generate sufficient product revenue and amounts payable to us under our commercialization agreement relating to our SYMJEPI and ZIMHI products or other commercialization agreements that we may enter into to become profitable at all or on a sustained basis. We expect to have quarter-to-quarter fluctuations in revenue and expenses, some of which could be significant, due in part to variations in expenses and activities relating to research, development, clinical trials, marketing and manufacturing. If our product candidates fail in clinical trials or do not gain regulatory approval, or if our products do not achieve market acceptance, we may never become profitable. As we commercialize and market products, we ~~will need to~~may incur expenses for product marketing and brand awareness and conduct significant research, development, testing and regulatory compliance activities that, together with general and administrative expenses, could result in substantial operating losses for the foreseeable future. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

* We have received grand jury subpoenas issued in connection with a criminal investigation and are subject to other investigations.

As we have previously disclosed, on May 11, 2021, each of the company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. Additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the investigation. The company has also received requests from the Securities and Exchange Commission (“SEC”) for the voluntary production of documents and information relating to the subject matter of the USAO’s subpoenas and certain other matters in connection with the SEC's investigation. The company has produced documents and will continue to produce and provide documents in response to the subpoenas and requests as needed. Additionally, on March 16, 2022, we were informed that the Civil Division of the USAO (“Civil Division”) is investigating the company’s Second Draw PPP Loan application disclosed in previous reports. The Audit Committee of the Board engaged outside counsel to conduct an internal inquiry into the matter. In June 2022, following the inquiry the company paid a total of $1,787,417 in repayment of the Second Draw PPP Loan principal and such related interest and fees. The company intends to continue cooperating with the USAO, SEC, and Civil Division. At this time, the company is unable to predict the duration, scope, or outcome of the investigations by the USAO, SEC, Civil Division, or other agencies; what, if any, proceedings the USAO, SEC, Civil Division, or other federal or state authorities may initiate; what, if any, remedies or remedial measures the USAO, SEC, Civil Division or other federal or state authorities may seek; or what, if any, impact the foregoing matters may have on the company’s business, previously reported financial results, financial results included in this Report, or future financial results. We could receive additional requests from the USAO, SEC, Civil Division, or other authorities, which may require further investigation. There can be no assurance that any discussions with the USAO, SEC or Civil Division to resolve these matters will be successful. The foregoing matters may divert management’s attention, cause the company to suffer reputational harm, require the company to devote significant financial resources, subject the company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, result in fines, penalties or equitable remedies, and affect the company’s business, previously reported financial results, financial results included in this Report, or future financial results. The occurrence of any of these events could have a material adverse effect on the company’s business, financial condition and results of operations.

* Our PPP loans may be audited or reviewed by federal or state regulatory authorities. We repaid our Second Draw PPP Loan

We applied for and obtained loan funding ~~of $3,191,700~~ under the PPP pursuant to the PPP Loan and PPP Note, the balance of which has been forgiven, and under the Second Draw PPP Loan and PPP2 Note in the principal amount of $1,765,495, the balance of which ~~has also been~~was initially forgiven. However, ~~even though~~in connection with an investigation by the ~~PPP Loan and the~~Civil Division, in June 2022 we paid a total of $1,787,417 in repayment of our Second Draw PPP Loan ~~have been forgiven, our~~principal and related interest and fees. Our PPP loans and applications for forgiveness of loan amounts remain subject to future review and audit by SBA for compliance with program requirements set forth in the PPP Interim Final Rules and in the Borrower Application Form, including without limitation the required economic necessity certification by the ~~Company~~company that was part of the PPP loan application process. Accordingly, the ~~Company~~company is subject to audit or review by federal or state regulatory authorities as a result of applying for and obtaining the PPP Loan and Second Draw PPP Loan or obtaining forgiveness of those loans. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return or repay the full amount of the applicable loan and could be subject to additional fines or penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations. If it is determined that the Company was ineligible to receive the PPP Loan and/or the Second Draw Loan, the Company may be required to repay the PPL Loan and Second Draw Loan in its entirety and/or be subject to additional penalties, which could reduce our liquidity and adversely affect our business, financial condition and results of operations.

*We may never commercialize additional product candidates that are subject to regulatory approval or earn a profit.

Except for our SYMJEPI and ZIMHI products, we have not received regulatory approval for any drugs or products. Since our fiscal 2010 year, except for revenues from sales of compounded pharmacy formulations after our acquisition of USC in 2016 and amounts that we have received and may receive in the future pursuant to our commercialization agreements relating to our SYMJEPI and ZIMHI products, we have not generated commercial revenue from marketing or selling any drugs or other products. We expect to incur substantial net losses for the foreseeable future. We may never be able to commercialize any additional product candidates that are subject to regulatory approval or be able to generate revenue from sales of such products. Because of the risks and uncertainties associated with developing and commercializing our specialty pharmaceuticals and other product candidates, we are unable to predict when we may commercially introduce such products, the extent of any future losses or when we will become profitable, if ever.

*We have received a grand jury subpoena issued in connection with a criminal investigation.

As we have previously disclosed, on May 11, 2021, each of the company and its USC subsidiary received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of New York (the “USAO”) issued in connection with a criminal investigation, requesting a broad range of documents and materials relating to, among other matters, certain veterinary products sold by the company’s USC subsidiary, certain practices, agreements and arrangements relating to products sold by USC, including veterinary products, and certain regulatory and other matters relating to the company and USC. The Audit Committee of the Board engaged outside counsel to conduct an independent internal investigation to review these and other matters. Additional issues or facts could arise or be determined, which may expand the scope, duration, or outcome of the investigation. In addition to the subpoena from the USAO, the Company has also received requests from the Securities and Exchange Commission (“SEC”) for the voluntary production of documents and information relating to the subject matter of the USAO’s subpoenas and certain other matters. The company has produced documents and will continue to produce and provide documents in response to the subpoenas and requests. The company intends to cooperate with the USAO and the SEC. At this time, the company is unable to predict the duration, scope, or outcome of the investigations by the USAO, SEC, or other agencies, or determine what, if any, proceedings the USAO, SEC, or other federal or state authorities may initiate, what, if any, remedies or remedial measures the USAO, SEC, or other federal or state authorities may seek, or what, if any, impact the foregoing matters may have on the company’s business, previously reported financial results, financial results included in this Report, or future financial results. We could receive additional requests from the USAO, SEC, or other authorities, which may require further investigation. There can be no assurance that any discussions with the SEC or USAO to resolve these matters will be successful. The foregoing matters may divert management’s attention, cause the company to suffer reputational harm, require the company to devote significant financial resources, subject the company and its officers and directors to civil or criminal proceedings, and depending on the resolution of the matters or any proceedings, result in fines, penalties, equitable remedies, and affect the company’s business, previously reported financial results, financial results included in this Report, or future financial results. The occurrence of any of these events could have a material adverse effect on the company’s business, financial condition and results of operations.

~~Many of our potential products and technologies are in early stages of development,~~ ~~or have been discontinued or are suspended~~.

The development of new pharmaceutical products is a highly risky undertaking. In addition, development of some of our potential product candidates has been discontinued or suspended. Our potential products may require significant additional research and development before any commercial introduction. There can be no assurance that any future research, development or clinical trial efforts will result in viable products or meet efficacy standards. Future clinical or preclinical results may be negative or insufficient to allow us to successfully develop and market our product candidates. Obtaining needed data and results may take longer than planned or may not be obtained at all. Any such delays or setbacks could have a material adverse effect on our ability to achieve our financial goals.

*Our development plans concerning our products and product candidates are affected by many factors, the outcome of which are difficult to predict.

The development of new pharmaceutical products is a highly risky undertaking. Our potential products may require significant additional research and development before any commercial introduction. Our product development plans concerning our products and product candidates ~~and the anticipated dates for development and introduction of products in our product pipeline,~~ are affected by many factors, many of which are difficult to predict. Some of the factors that could affect our development plans for our products and product candidates include: general market conditions and developments in the marketplace including the introduction of potentially competing new products by our competitors; the availability of adequate funding to support product development efforts and sales and marketing efforts for approved products; the outcome of discussions with the FDA concerning the regulatory pathway for our products and the number and kind of clinical trials that the FDA will require before the FDA will consider regulatory approval of the applicable product; the time required to conduct required clinical trials and unexpected delays in the anticipated timing of the commencement, conduct or completion of clinical trials; the outcome and results of clinical trials; the FDA’s review and acceptance of NDAs that we may file concerning our product candidates; any unexpected difficulties in licensing or sublicensing intellectual property rights that may be required for other components of the product; patent infringement lawsuits relating to Paragraph IV certifications as part of any Section 505(b)(2) or ANDA filings; any unexpected difficulties in the ability of our suppliers to timely supply quantities for commercial launch of the product; and our ability to successfully market and sell our products or enter into commercialization arrangements with third parties to market our products. There can be no assurance that any future research, development or clinical trial efforts will result in viable products or meet efficacy standards. Future clinical or preclinical results may be negative or insufficient to allow us to successfully develop and market our product candidates. Obtaining needed data and results may take longer than planned or may not be obtained at all. Any such delays or setbacks could have a material adverse effect on our ability to achieve our financial goals.

*Business or economic disruptions or global health concerns, including the COVID-19 pandemic, could harm our business.

Business or economic disruptions or global health concerns, such as the COVID-19 pandemic, could adversely affect our business. The novel strain of coronavirus and the related COVID-19 pandemic, which the World Health Organization announced in January 2020 was a global health emergency and which has continued, ~~through 2020 and is continuing,~~ has spread throughout most of the world including the United States. The outbreak ~~has~~ resulted in extended shutdowns of businesses in the United States and elsewhere and has had ripple effects on businesses and activities around the world.

The COVID-19 outbreak and continued spread of COVID-19, including the identification of novel strains of COVID-19, has affected and may continue to affect our operations, our customers and third parties on which we rely. Restrictions on outpatient surgeries and other medical procedures due to the COVID-19 pandemic, in part due to reductions or cancellations of elective surgeries and reductions in office visits to physicians’ offices, healthcare facilities or clinics by patients, decreased demand from USC’s customers for certain of USC’s products and adversely affected revenues from sales of USC products in 2020 and ~~may continue to adversely affect revenues from sales of products to customers covered by the USC Agreement.~~2021. In addition, we could experience delays in obtaining products or services from our third party manufacturers or suppliers as a result of the impact of the COVID-19 pandemic on such parties. The pandemic and related matters also could result in interruptions or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines relating to our NDAs or other actions relating to our products or product candidates, or could result in delays relating to patient enrollment or the conduct of clinical trials that we undertake. The outbreak and any preventative or protective actions that we, our customers, our respective manufacturers, suppliers or other third parties with which we have business relationships, or governments may take in respect of the coronavirus and COVID-19 pandemic could disrupt our business and the business of our customers or third parties with which we have business relationships. The extent to which the COVID-19 pandemic will continue to impact our business is difficult to predict and subject to change, and will depend on future developments, which are highly uncertain and cannot be predicted, including without limitation the severity of the disease and duration of the outbreak, travel restrictions and social distancing requirements in the United States and other countries, future mutations and variations of the coronavirus, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and address its impact. ~~Global health concerns, such as coronavirus, could also result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate.~~ In addition, a severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making purchases or payments for our products. Any of the foregoing could harm our business. In addition, the COVID-19 pandemic has resulted in significant governmental measures being implemented to control the spread of the virus, including, at various times, quarantines, shelter-in-place or work-from-home orders or policies, travel restrictions, social distancing and business shutdowns. The effects of such measures ~~may~~could negatively impact productivity of our employees and disrupt our business activities, the magnitude of which will depend, in part, on the length and severity of the restrictions and our ability to conduct business in the ordinary course. Although we have taken precautions intended to avoid the spread of the coronavirus among our employees, ~~it is possible that one or more members of~~ our ~~workforce~~operations could be ~~diagnosed with~~adversely affected by outbreaks of COVID-19 ~~which could adversely impact~~among our ~~operations. As of the date of this Report, we cannot presently predict the long-term impact to the scope and severity of potential business or disruptions, but if~~employees. If we, our customers, or any of the third parties with whom we engage, including the suppliers, manufacturers, regulators and other third parties with whom we conduct business or have business relationships, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner presently anticipated could be materially and negatively impacted.

We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain, or may experience delays in obtaining, regulatory approval, or may not be successful in commercializing our planned and future products.

Like many companies our size, we do not have the ability to conduct preclinical or clinical studies for our product candidates without the assistance of third parties who conduct the studies on our behalf. These third parties are often toxicology facilities and clinical research organizations, or CROs, that have significant resources and experience in the conduct of pre-clinical and clinical ~~studies. The toxicology facilities conduct the pre-clinical safety~~ studies, ~~as well as associated tasks connected with these studies. The CROs typically perform patient recruitment, project management, data management, statistical analysis,~~ and ~~other reporting functions. We~~we intend to rely on such third parties ~~to conduct~~in connection with any future pre-clinical or clinical trials ~~of our product candidates and to use third party toxicology facilities and CROs for our pre-clinical and clinical studies.~~that we may conduct. We may also rely on academic institutions or clinical research organizations to conduct, supervise or monitor some or all aspects of clinical trials involving our ~~products.~~

Our reliance on these third parties for development activities will reduce our control over these activities. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, we may be required to replace them, and our clinical trials may be extended, delayed or terminated. Although we believe there are a number of third-party contractors that we could engage to continue these activities, replacing a third-party contractor may result in a delay of the affected trial.

* If there are injuries or deaths associated with use of our products, or if there is a product recall affecting one or more of our products, we may be exposed to significant liabilities.

The production, manufacturing, labeling of pharmaceutical products and compounded pharmaceutical preparations is inherently risky. We could be adversely affected if any of our products, or the formulations or other products previously sold by USC, prove to be, or are asserted to be, harmful to patients. There are a number of factors that could result in the injury or death of a patient who receives one of our products or one of the compounded formulations previously sold by USC, including quality issues, manufacturing or labeling flaws, improper packaging or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, safety alert, or other proceedings or actions, relating to one or more of such products. On March 21, 2022, we announced a voluntary recall of four lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes, due to the potential clogging of the needle preventing the dispensing of epinephrine. As of the date of this Report, the manufacturing of SYMJEPI is currently on hold. There can be no assurance concerning the timing of resumption of manufacturing or resupplying USWM with product to enable a relaunch of SYMJEPI. The recall may have an adverse effect on the amount or the timing of our revenues, and on our financial results and liquidity, for fiscal quarters in 2022 or thereafter. In addition, current or future insurance coverage may prove insufficient to cover any liability claims brought against USC or us with respect to the SYMJEPI recall, products previously sold by USC, or other matters. If adverse events or deaths or a product recall, either voluntarily or as required by the FDA or a state board of pharmacy, were associated with our products, or one of the formulations or compounds previously sold by USC, we could become subject to product and professional liability lawsuits or other proceedings, including enforcement actions by state and federal authorities or other healthcare self-regulatory bodies or product liability claims or lawsuits. In addition, such matters could result in indemnification claims by third parties or claims relating to the product recall or associated expenses, including third parties that have purchased our SYMJEPI products or that may purchase our ZIMHI product, or to which we have sold certain assets of USC, including claims pursuant to our agreements with third parties. Any of the foregoing matters could result in a material adverse effect on our business, results of operations, financial condition and liquidity.

Delays in the commencement or completion of clinical testing of our product candidates could result in increased costs and delay our ability to generate significant revenues.

The actual timing of commencement and completion of clinical trials can vary substantially from our anticipated timing due to factors such as funding limitations, scheduling ~~conflicts~~conflicts with participating clinicians and clinical institutions, and the rate of patient enrollment. Clinical trials involving our product candidates may not commence or be completed as forecast. Delays in the commencement or completion of clinical testing could significantly impact our product development costs. ~~We do not know whether current or planned clinical trials will begin on time or be completed on schedule, if at all.~~ The commencement of clinical trials can be delayed for a variety of reasons, including delays in:

	●	obtaining required funding;
	●	obtaining regulatory approval to commence a clinical trial;
	●	reaching agreement on acceptable terms with prospective contract research organizations and clinical trial sites;
	●	obtaining sufficient quantities of clinical trial materials for product candidates;
	●	obtaining institutional review board approval to conduct a clinical trial at a prospective site;
	●	recruiting participants for a clinical trial; and
	●	delays related to the impact of the COVID-19 pandemic.

In addition, once a clinical trial has begun, it may be suspended or terminated by us or the FDA or other regulatory authorities due to a number of factors, including:

	●	failure to conduct the clinical trial in accordance with regulatory requirements;
	●	inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
	●	failure to achieve certain efficacy and/or safety standards; or
	●	lack of adequate funding to continue the clinical trial.

Clinical trials require sufficient participant enrollment, which is a function of many factors, including the size of the target patient population, the nature of the trial protocol, the proximity of participants to clinical trial sites, the availability of effective treatments for the relevant disease, the eligibility criteria for our clinical trials and competing trials. Delays in enrollment can result in increased costs and longer development times. Our failure to enroll participants in our clinical trials could delay the completion of the clinical trials beyond current expectations. In addition, the FDA could require us to conduct clinical trials with a larger number of participants than we may project for any of our product candidates. As a result of these factors, we may not be able to enroll a sufficient number of participants in a timely or cost-effective manner.

Furthermore, enrolled participants may drop out of clinical trials, which could impair the validity or statistical significance of the clinical trials. A number of factors can influence the discontinuation rate, including, but not limited to: the inclusion of a placebo in a trial; possible lack of effect of the product candidate being tested at one or more of the dose levels being tested; adverse side effects experienced, whether or not related to the product candidate; and the availability of numerous alternative treatment options that may induce participants to withdraw from the trial.

*We may be required to suspend, repeat or terminate our clinical trials if the trials are not well designed, do not meet regulatory requirements or the results are negative or inconclusive, which may result in significant negative repercussions on business and financial condition.

Before regulatory approval for a potential product can be obtained, we must undertake clinical testing on humans to demonstrate the tolerability and efficacy of the product. We cannot assure you that we will obtain authorization to permit any product candidates that are in the preclinical development phase to enter the human clinical testing phase. In addition, we cannot assure you that any authorized preclinical or clinical testing will be completed successfully within any specified time period by us, or without significant additional resources or expertise to those originally expected to be necessary. For example, in September 2022, the DSMB evaluated interim data for our Phase 2/3 trial relating to our Tempol product candidate and determined that the trial did not achieve its primary end point, and we subsequently stopped the trial and development work concerning Tempol. We cannot assure you that ~~such~~any testing or clinical trials will show potential products to be safe and efficacious or that any such product will be approved for a specific indication. Further, the results from preclinical studies and early clinical trials may not be indicative of the results that will be obtained in later-stage clinical trials. In addition, we or regulatory authorities may suspend clinical trials at any time on the basis that the participants are being exposed to unacceptable health risks.

We are subject to the risk of clinical trial and product liability lawsuits.

The testing of human health care product candidates entails an inherent risk of allegations of clinical trial liability, while the marketing and sale of approved products entails an inherent risk of allegations of product liability and associated adverse publicity. We currently maintain liability insurance. However, such insurance policies are expensive, may not provide sufficient coverage, and may not be available in the future on acceptable terms, or at all. As we conduct ~~additional~~ clinical trials and introduce products into the United States market, the risk of adverse events increases and our requirements for liability insurance coverage are likely to increase. We are subject to the risk that substantial liability claims from the testing or marketing of pharmaceutical products could be asserted against us in the future. There can be no assurance that we will be able to obtain or maintain insurance on acceptable terms, particularly in overseas locations, for clinical and commercial activities or that any insurance obtained will provide adequate protection against potential liabilities. An inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could inhibit our business.

Moreover, our current and future coverages may not be adequate to protect us from all of the liabilities that we may incur. If losses from liability claims exceed our insurance coverage, we may incur substantial liabilities that exceed our financial resources. In addition, a product or clinical trial liability action against us would be expensive and time-consuming to defend, even if we ultimately prevailed. If we are required to pay a claim, we may not have sufficient financial resources and our business and results of operations may be harmed. A product liability claim brought against us in excess of our insurance coverage, if any, could have a material adverse effect upon our business, financial condition and results of operations.

We do not have commercial-scale manufacturing capability, and we lack commercial manufacturing experience. We will likely rely on third parties to manufacture and supply our product candidates for which we will be seeking FDA approval.

WeExcept for our facilities at USC that were previously utilized to prepare compounded formulations, we do not own or operate manufacturing facilities for clinical or commercial production of pharmaceutical products and product candidates, we do not have any experience in drug formulation or manufacturing, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. Accordingly, we expect to depend on third-party contract manufacturers for the foreseeable future. Any performance failure on the part of our contract manufacturers could delay clinical development, regulatory approval or commercialization of our current or future product candidates, or result in product recalls or shortages or manufacturing halts or delays, depriving us of potential product revenue and resulting in additional losses. Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our existing and potential products. Any business interruptions resulting from geopolitical actions, including war and terrorism, adverse public health developments such as the outbreak of the COVID-19 coronavirus, or natural disasters including earthquakes, typhoons, floods and fires, could adversely affect our supply chain. These risks and uncertainties are compounded in the presence of the COVID-19 pandemic. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to our manufacturers or suppliers could delay shipment of any of our products, increase our cost of goods sold and result in lost sales.

The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production.

These problems can include difficulties with production costs and yields, quality control (including stability of the product candidate and quality assurance testing), shortages of qualified personnel, and compliance with strictly enforced federal, state and foreign regulations. If our third-party contract manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations or under applicable regulations, our ability to provide product candidates to patients in our clinical trials or commercially would be jeopardized. If we file an application for marketing approval of the product and the FDA grants marketing approval, any delay or interruption in the supply of product could delay the commercial launch of the product or impair our ability to meet demand for the product. Difficulties in supplying products for clinical trials could increase the costs associated with our clinical trial programs and, depending upon the period of delay, require us to commence new trials or qualify new manufacturers at significant additional expense, possibly causing commercial delays or termination of the trials.

Our products can only be manufactured in a facility that has undergone a satisfactory inspection by the FDA and other relevant regulatory authorities. For these reasons, we may not be able to replace manufacturing capacity for our products quickly if we or our contract manufacturer(s) were unable to use manufacturing facilities as a result of a fire, natural disaster (including an earthquake), equipment failure, or other difficulty, or if such facilities were deemed not in compliance with the regulatory requirements and such non-compliance could not be rapidly rectified. An inability or reduced capacity to manufacture our products could have a material adverse effect on our business, financial condition, and results of operations.

*We are subject to substantial government regulation, which could materially adversely affect our business. If we do not receive regulatory approvals, we may not be able to develop and commercialize our technologies.

We need FDA approval to market our products in the United States that are subject to regulatory approval, and similar approvals from foreign regulatory authorities to market products outside the United States. The production and marketing of such products and potential products and our ongoing research and development, pre-clinical testing and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities in the United States and will face similar regulation and review for overseas approval and sales from governmental authorities outside of the United States. The regulatory review and approval process, which may include evaluation of preclinical studies and clinical trials of our products that are subject to regulatory review, as well as the evaluation of manufacturing processes and contract manufacturers’ facilities, is lengthy, expensive and uncertain. We have limited experience in filing and pursuing applications necessary to gain regulatory approvals. ~~Many of the product~~Product candidates ~~that we are currently developing~~usually must undergo rigorous pre-clinical and clinical testing and an extensive regulatory approval process before they can be marketed. This process makes it longer, more difficult and more costly to bring our potential products to market, and we cannot guarantee that any of our potential products will be approved. Many products for which FDA approval has been sought by other companies have never been approved for marketing. In addition to testing and approval procedures, extensive regulations also govern marketing, manufacturing, distribution, labeling, and record-keeping procedures. If we or our collaboration partners do not comply with applicable regulatory requirements, such violations could result in non-approval, suspensions of regulatory approvals, civil penalties and criminal fines, product seizures and recalls, operating restrictions, injunctions, and criminal prosecution.

Regulatory authorities generally have substantial discretion in the approval process and may either refuse to accept an application, or may decide after review of an application that the data submitted is insufficient to allow approval of the proposed product, as we have experienced with previous CRLs that we have received from the FDA. If regulatory authorities do not accept or approve our applications, they may require that we conduct additional clinical, preclinical or manufacturing studies and submit that data before regulatory authorities will reconsider such application. We may need to expend substantial resources to conduct further studies to obtain data that regulatory authorities believe is sufficient. Depending on the extent of these studies, acceptance or approval of applications may be delayed by several years, or may require us to expend more resources than we may have available. It is also possible that additional studies may not suffice to make applications approvable. If any of these outcomes occur, we may be forced to abandon our applications for approval.

Failure to obtain FDA or other required regulatory approvals, or withdrawal of previous approvals, would adversely affect our business. Even if regulatory approval of a product is granted, this approval may entail limitations on uses for which the product may be labeled and promoted, or may prevent us from broadening the uses of products for different applications.

Following regulatory approval of any of our drug candidates, we will be subject to ongoing regulatory obligations and restrictions, which may result in significant expense and limit our ability to commercialize our potential products.

With regard to our drug candidates that are approved by the FDA or by another regulatory authority, we are held to extensive regulatory requirements over product manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the drug candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the drug candidate, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market. In addition, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or elsewhere. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs and our business could suffer.

We intend to pursue Section 505(b)(2) regulatory approval filings with the FDA for our products where applicable. Such filings involve significant costs, and we may also encounter difficulties or delays in obtaining regulatory approval for our products. Similar difficulties or delays may also arise in connection with any Abbreviated New Drug Applications that we may file.

We submitted a Section 505(b)(2) NDA regulatory filing to the FDA in connection with our approved SYMJEPI products, we submitted Section 505(b)(2) NDA regulatory filings to the FDA in connection with our ZIMHI (naloxone) Injection product, ~~candidate,~~ and we may pursue Section 505(b)(2) NDA filings with the FDA in connection with one or more ~~other~~future product ~~candidates.~~candidates that we may develop. A Section 505(b)(2) NDA is a special type of NDA that enables the applicant to rely, in part, on the FDA’s findings of safety and efficacy of an existing previously approved product, or published literature, in support of its application. Section 505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Such filings involve significant filing costs, including filing fees.

To the extent that a Section 505(b)(2) NDA relies on published literature relating to a previously approved drug product or the FDA’s prior findings of safety and effectiveness for a previously approved drug product, where the underlying studies were not conducted by or for the applicant and the applicant lacks a right of reference or use to the underlying data, the Section 505(b)(2) applicant must submit in its Section 505(b)(2) application a patent certification or statement with respect to any patents that are subject to the Orange Book listing requirement in connection with the previously approved product on which the applicant’s application relies. Specifically, the applicant must certify for each such patent that, in relevant part, (1) the required patent information has not been filed; (2) the patent has expired; (3) the patent has not expired, but will expire on a particular date and approval is not sought until after patent expiration; or (4) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. Alternatively, with respect to a method of use patent, the applicant may submit a statement that the patent does not claim a use for which the applicant is seeking approval. A certification that the new product will not infringe the previously approved product’s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification. If the applicant does not challenge the listed patents through a Paragraph IV certification or submit a statement that a method of use patent does not claim a use for which the applicant is seeking approval, the FDA will not approve the Section 505(b)(2) NDA application until all the listed patents for the previously approved product have expired. Further, the FDA will also not approve a Section 505(b)(2) NDA until any applicable non-patent exclusivity, such as, for example, five-year exclusivity for obtaining approval of a new chemical entity, three-year exclusivity for an approval based on new clinical trials, or pediatric exclusivity, listed in the Orange Book for the referenced product, has expired.

If the Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA for 30 months beginning on the date the patent holder receives notice, unless, before the end of the 30-month period, a court determines that the patent is invalid, unenforceable or not infringed; a court enters a settlement order or consent decree stating that the patent is invalid, unenforceable, or not infringed; the patent owner or exclusive licensee consents to approval of the Section 505(b)(2) NDA; or the court enters an order of dismissal without a finding of infringement.

If we rely in our Section 505(b)(2) regulatory filings on published literature relating to a previously approved drug product or the FDA’s prior findings of safety and effectiveness for a previously approved drug product where the underlying studies were not conducted by or for us and we lack a right of reference or use to the underlying data, and that involves patents referenced in the Orange Book, then we will need to make the patent certifications or the Paragraph IV certification described above. If we make a Paragraph IV certification and the holder of the previously approved product that we referenced in our application initiates patent litigation within the time periods described above, then any FDA approval of our 505(b)(2) application would be delayed until the earlier of 30 months, resolution of the lawsuit, or the other events described above. Accordingly, our anticipated dates relating to review and approval of a product that was subject to such litigation would be delayed. In addition, we would incur the expenses, which could be material, involved with any such patent litigation. As a result, we may invest a significant amount of time and expense in the development of our product only to be subject to significant delay and patent litigation before our product may be commercialized, if at all.

In addition, even if we submit a Section 505(b)(2) application, such as we may submit for other future products, that relies on published literature relating to a previously approved drug product or the FDA’s prior findings of safety and effectiveness for a previously approved drug product where there are no patents referenced in the Orange Book for such other product with respect to which we have to provide certifications, we are subject to the risk that the FDA could disagree with our reliance on the particular previously approved product that we chose to rely on, conclude that such previously approved product is not an acceptable reference product, and require us instead to rely as a reference product on another previously approved product that involves patents referenced in the Orange Book, requiring us to make the certifications described above and subjecting us to additional delay, expense and the other risks described above.

Similarly, if we submit one or more ANDA applications to the FDA pursuant to Section 505(j) of the FDCA in connection with one or more of our product candidates, we could encounter generally similar difficulties or delays, including difficulties or delays resulting from the Paragraph IV certification process or from any clinical trials that might be required in connection with any such ANDAs.

*If we fail to obtain acceptable prices or appropriate reimbursement for our products, our ability to successfully commercialize our products will be impaired.

Government and insurance reimbursements for healthcare expenditures play an important role for all healthcare providers, including physicians and pharmaceutical companies such as Adamis, that plan to offer various products in the United States and other countries in the future. Physicians and patients may decide not to order our products unless third-party payors, such as managed care organizations as well as government payors such as Medicare and Medicaid, pay a substantial portion of the price of the products. Market acceptance and sales of our specialty pharmaceutical products and potential products will depend in part on the extent to which reimbursement for the costs of such products will be available from government health administration authorities, private health coverage insurers, managed care organizations, and other organizations. In the United States, our ability to have our products eligible for Medicare, Medicaid or private insurance reimbursement will be an important factor in determining the ultimate success of our products. If, for any reason, Medicare, Medicaid or the insurance companies decline to provide reimbursement for our products, our ability to commercialize our products would be adversely affected.

Third-party payors may challenge the price of medical and pharmaceutical products. Reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that our product candidates are:

	●	not experimental or investigational;
	●	effective;
	●	medically necessary;
	●	appropriate for the specific patient;
	●	cost-effective;
	●	supported by peer-reviewed publications; and
	●	included in clinical practice guidelines.

If purchasers or users of our products and related treatments are not able to obtain appropriate reimbursement for the cost of using such products, they may forego or reduce such use. Significant uncertainty exists as to the reimbursement status of newly approved pharmaceutical products, and there can be no assurance that adequate third-party coverage will be available for any of our products. Even if our products are approved for reimbursement by Medicare, Medicaid and private insurers, of which there can be no assurance, the amount of reimbursement may be reduced at times or even eliminated, which could have a material adverse effect on our business, financial condition and results of operations.

Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably.

In both the United States and certain foreign jurisdictions, there have been and are expected to be a number of legislative and regulatory changes to the healthcare system in ways that could impact our ability to sell our products profitably, including the Patient Protection and Affordable Care Act, or ACA. Given the enactment of these laws and other federal and state legislation and regulations relating to the healthcare system, their impact on the biotechnology and pharmaceutical industries and our business is uncertain. The U.S. Congress continues to consider issues relating to the healthcare system, and future legislation or regulations may affect our ability to market and sell products on favorable terms, which would affect our results of operations, as well as our ability to raise capital, obtain additional collaborators or profitably market our products. Such legislation or regulation may reduce our revenues, increase our expenses or limit the markets for our products. In particular, we expect to experience pricing pressures in connection with the sale of our products due to the influence of health maintenance and managed health care organizations and additional legislative proposals.

We are subject to a variety of federal, state and local laws and regulations relating to the general healthcare industry, which are subject to frequent change.

Participants in the healthcare industry, including the company and, before the winding down of its business as described elsewhere in this Report, USC, are subject to a variety of federal, state, and local laws and regulations. Laws and regulations in the healthcare industry are extremely complex and, in many instances, industry participants do not have the benefit of significant regulatory or judicial interpretation. Such laws and regulations are subject to change and often are uncertain in their application. There can be no assurance that we will not be subject to scrutiny or challenge under one or more of these laws or regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could adversely affect our business, financial condition or results of operations.

In addition, we are subject to the federal anti-kickback statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service reimbursable under a federal healthcare program, or purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under a federal healthcare program. We are also subject to state anti-kickback laws and regulations. Violations of the anti-kickback statutes can result in imprisonment, civil or criminal fines, and fines and disciplinary actions relating to our state licensure. Any violation or alleged violation of such federal or state laws could harm our reputation, customer relationships or otherwise have a material adverse effect on our business, financial condition and results of operations.

We have limited sales, marketing and distribution experience.

We have limited experience in the sales, marketing, and distribution of pharmaceutical products. There can be no assurance that we will be able to establish sales, marketing, and distribution capabilities or make arrangements with collaborators or others to perform such activities or that such efforts will be successful. If we decide to market any products directly ourselves, we would be required to either acquire or internally develop a marketing and sales force with technical expertise and with supporting distribution capabilities. The acquisition or development of a sales, marketing and distribution infrastructure would require substantial resources, which may not be available to us or, even if available, could divert the attention of our management and key personnel and have a negative impact on further product development efforts.

We may seek to enter into arrangements to develop and commercialize our products. These collaborations, even if secured, may not be successful.

We have entered and sought to enter into arrangements with third parties regarding development or commercialization of some of our products or product candidates and may in the future seek to enter into collaborative arrangements to develop and commercialize ~~some of~~ our products or potential products both in North America and international markets. There can be no assurance that we will be able to negotiate commercialization or collaborative arrangements on favorable terms or at all or that our current or future collaborative arrangements will be successful. The amount and timing of resources such third parties will devote to these activities may not be within our control. There can be no assurance that such parties will perform their obligations as expected. There can be no assurance that our collaborators will devote adequate resources to our products.

*Even if they are approved and commercialized, if our potential products are unable to compete effectively with current and future products targeting similar markets as our potential products, our commercial opportunities will be reduced or eliminated.

The markets for our SYMJEPI products and ZIMHI product, and ~~our~~for other product candidates that we may develop, are intensely competitive and characterized by rapid technological progress. We face competition from numerous sources, including major biotechnology and pharmaceutical companies worldwide. Many of our competitors have substantially greater financial and technical resources, and development, production and marketing capabilities, than we do. Our SYMJEPI ~~competes~~products compete with a number of other currently marketed epinephrine products for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Our ZIMHI product ~~will compete~~competes with a number of other currently marketed products utilizing naloxone, for the treatment of acute opioid overdose. Our Tempol product candidate for use in treatment of COVID-19, if successfully developed, approved and commercialized, will compete with a number of other current and future products and therapies for use in the treatment of COVID-19. Certain companies have established technologies that may be competitive with our product candidates and any future products that we may develop or acquire. Some of these products may use different approaches or means to obtain results, which could be more effective or less expensive than our products for similar indications. In addition, many of these companies have more experience than we do in pre-clinical testing, performance of clinical trials, manufacturing, and obtaining FDA and foreign regulatory approvals. They may also have more brand name exposure and expertise in sales and marketing. We also compete with academic institutions, governmental agencies and private organizations that are conducting research in the same fields.

Competition among these entities to recruit and retain highly qualified scientific, technical and professional personnel and consultants is also intense. As a result, there is a risk that one or more of our competitors will develop a more effective product for the same indications for which we are developing a product or, alternatively, bring a similar product to market before we can do so. Failure to successfully compete will adversely impact the ability to raise additional capital and ultimately achieve profitable operations.

Our product candidates may not gain acceptance among physicians, patients, or the medical community, thereby limiting our potential to generate revenue, which will undermine our future growth prospects.

Even if our pharmaceutical product candidates are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product candidate by physicians, health care professionals and third-party payors, and our profitability and growth will depend on a number of factors, including:

	●	the ability to provide acceptable evidence of safety and efficacy;
	●	pricing and cost effectiveness, which may be subject to regulatory control;
	●	our ability to obtain sufficient third-party insurance coverage or reimbursement;
	●	effectiveness of our or our ~~collaborators',~~collaborators’ sales and marketing strategy;
	●	relative convenience and ease of administration;
	●	the prevalence and severity of any adverse side effects; and
	●	availability of alternative treatments.

If any product candidate that we develop does not provide a treatment regimen that is at least as beneficial as the current standard of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will likely not achieve market acceptance and we will not generate sufficient revenues to achieve profitability.

If we suffer negative publicity concerning the safety of our products in development, our sales may be harmed and we may be forced to withdraw such products.

If concerns should arise about the safety of any of our products that are marketed, regardless of whether or not such concerns have a basis in generally accepted science or peer-reviewed scientific research, such concerns could adversely affect the market for these products. Similarly, negative publicity could result in an increased number of product liability claims, whether or not these claims are supported by applicable law.

*Our failure to adequately protect or to enforce our intellectual property rights or secure rights to third party patents could materially harm our proprietary position in the marketplace or prevent the commercialization of our products.

Our success depends in part on our ability to obtain and maintain protection in the United States and other countries for the intellectual property covering or incorporated into our technologies and products. The patents and patent applications in our existing patent portfolio are either owned by us or licensed to us. Our ability to protect our product candidates from unauthorized use or infringement by third parties depends substantially on our ability to obtain and maintain, or license, valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain and enforce patents is uncertain and involves complex legal and factual questions for which important legal principles are unresolved.

There is a substantial backlog of patent applications at the United States Patent and Trademark Office, or USPTO. There can be no assurance that any patent applications relating to our products or methods will be issued as patents, or, if issued, that the patents will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide a competitive advantage. We may not be able to obtain patent rights on products, treatment methods or manufacturing processes that we may develop or to which we may obtain license or other rights. Even if we do obtain patents, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against our competitors or their competitive products or processes. Patents and intellectual property that we own or license may not afford us the rights that we anticipate. It is possible that no patents will be issued from any pending or future patent applications owned by us or licensed to us. Others may challenge, seek to invalidate, infringe or circumvent any patents we own or license. Alternatively, we may in the future be required to initiate litigation against third parties to enforce our intellectual property rights. The defense and prosecution of patent and intellectual property claims are both costly and time consuming, even if the outcome is favorable to us. Any adverse outcome could subject us to significant liabilities, require us to license disputed rights from others, or require us to cease selling our future products.

In addition, many other organizations are engaged in research and product development efforts that may overlap with our products. Such organizations may currently have, or may obtain in the future, legally blocking proprietary rights, including patent rights, in one or more products or methods under development or consideration by us. These rights may prevent us from commercializing technology, or may require us to obtain a license from the organizations to use the technology. We may not be able to obtain any such licenses that may be required on reasonable financial terms, if at all, and we cannot be sure that the patents underlying any such licenses will be valid or enforceable. As with other companies in the pharmaceutical industry, we are subject to the risk that persons located in other countries will engage in development, marketing or sales activities of products that would infringe our patent rights if such activities were conducted in the United States.

Our patents also may not afford protection against competitors with similar technology. We may not have identified all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our product candidates, by preventing the patentability of our products or by covering the same or similar technologies that may affect our ability to market or license our product candidates. In addition, many companies have encountered difficulties in protecting and defending their intellectual property rights in foreign jurisdictions. If we encounter such difficulties or are otherwise precluded from effectively protecting our intellectual property rights in either the United States or foreign jurisdictions, our business prospects could be substantially harmed. In addition, we may not have adequate cash funding to devote the resources that might be necessary to prepare or pursue patent applications, either at all or in all jurisdictions in which we might desire to obtain patents, or to maintain already-issued patents.

We may become involved in patent litigation or other intellectual property proceedings relating to our future product approvals, which could result in liability for damages or delay or stop our development and commercialization efforts.

The pharmaceutical industry has been characterized by significant litigation and other proceedings regarding patents, patent applications, trademarks, and other intellectual property rights. The situations in which we may become parties to such litigation or proceedings may include any third parties initiating litigation claiming that our products infringe their patent or other intellectual property rights, or that one of our trademarks or trade names infringes the third party’s trademark rights; in such case, we will need to defend against such proceedings. For example, the field of generic pharmaceuticals is characterized by frequent litigation that occurs in connection with the regulatory filings under Section 505(b)(2) of the FDCA and attempts to invalidate the patent of the reference drug.

The costs of resolving any patent litigation or other intellectual property proceeding, even if resolved in our favor, could be substantial. Many of our potential competitors will be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other intellectual property proceedings may also consume significant management time.

In the event that a competitor infringes upon our patent or other intellectual property rights, enforcing those rights may be costly, difficult, and time-consuming. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time-consuming and could divert our management’s attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patent or other intellectual property rights against a challenge. If we are unsuccessful in enforcing and protecting our intellectual property rights and protecting our products, it could materially harm our business.

*If we determine that our intangible assets have become impaired in the future, our total assets and earnings could be adversely affected.

Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Goodwill and indefinite lived intangible assets are not amortized but rather are evaluated for impairment annually or more frequently, if indicators of impairment exist. Finite lived intangible assets are evaluated for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If the impairment evaluations for goodwill and intangible assets indicate the carrying amount exceeds the estimated fair value, an impairment loss is recognized in an amount equal to that excess. As of March 31, 2020, in light of recent events associated with the global spread of COVID-19 and other factors, we performed a goodwill impairment interim review and recorded a charge of approximately $3,143,000 for impairment of goodwill during the first quarter of 2020. As of December 31, 2020, with the continued decline in revenue during 2020 primarily attributable to the COVID-19 pandemic and other factors affecting our Compounded Pharmaceutical reporting unit, we performed a goodwill impairment review and recorded an additional charge of approximately $3,629,000 for impairment of goodwill in 2020. For the year ended December 31, 2020, total goodwill impairment charge recorded was approximately $6,772,000. In addition, as of December 31, 2020, in light of the time and costs involved in further product development efforts and competitive conditions in the relevant markets related to the Taper DPI intellectual property, and our determination not to devote any further substantial financial resources to development of this product candidate or pursue further development efforts regarding this product candidate, we recorded an impairment charge of approximately $2,913,000 for the year ended December 31,2020. . In addition, a result of the transactions contemplated by the USC Agreement and the restructuring activities relating to USC described elsewhere in this Report, the company has determined that its financial results for the quarter ending September 30, 2021, will include an impairment of certain assets relating to USC, including inventories, intangible assets, goodwill, fixed assets, and right of use assets. If in the future we determine that our intangible assets have become impaired, our total assets, financial results, and earnings could be adversely affected.

We are subject to certain data privacy and security requirements, which are very complex and difficult to comply with at times. Any failure to ensure adherence to these requirements could subject us to fines and penalties, and damage our reputation.

We are required to comply, as applicable, with numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, which govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who may prescribe products we may sell in the future and from whom we may obtain patient health information are subject to privacy and security requirements under HIPAA and comparable state laws. These laws could create liability for us or increase our cost of doing business, and any failure to comply could result in harm to our reputation, and potentially fines and penalties.

There are significant limitations on our ability in the future to utilize any net operating loss carryforwards for federal and state income tax purposes.

At December 31, ~~2020,~~2021, we had federal and state net operating loss carryforwards, or NOLs, and credit carryforwards which, subject to certain limitations, we may use to reduce future taxable income or offset income taxes due. Insufficient future taxable income will adversely affect our ability to utilize these NOLs and credit carryforwards. Pursuant to Internal Revenue Code Section 382, the annual use of the NOLs and research and development tax credits could be limited by any greater than 50% ownership change during any three-year testing period. As noted in Note 2120 of the notes to the audited consolidated financial statements of the company appearing in the ~~company's Annual Report on~~2021 Form 10-K, ~~for the year ended December 31, 2020,~~ our existing NOLs are subject to limitations arising from previous ownership changes, and if we undergo additional ownership changes, our ability to use our NOLs could be further limited by Section 382 of the Code. As a result of these limitations, we may be materially limited in our ability to utilize our NOLs and credit carryforward.

~~Our limited operating history may make it difficult to evaluate our business and our future viability.~~

We have a limited operating history on which to base an evaluation of our business and prospects. We are subject to the risks associated with early stage companies with a limited operating history, including without limitation: the possible need for additional financing; the uncertainty of research and development efforts resulting in successful commercial products, as well as the marketing and customer acceptance of such products; unexpected issues with the FDA or other federal or state regulatory authorities; regulatory setbacks and delays; unexpected delays in commercialization of products; competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; fluctuations in expenses; and dependence on corporate partners and collaborators. Any failure to successfully address these risks and uncertainties could seriously harm our business and prospects. We may not succeed given the technological, marketing, strategic and competitive challenges we will face. The likelihood of our success must be considered in light of the expenses, difficulties, complications, problems and delays frequently encountered in connection with the growth of a new business, the continuing development of new drug technologies, and the competitive and regulatory environment in which we operate or may choose to operate in the future.

Risks Related to Our Former Compounding Pharmacy Business

*We have sold a substantial portion of the assets of USC and are ~~engaged in a restructuring process of~~ winding down the remaining business of USC and selling or otherwise disposing of the remaining assets of USC. There is no assurance regarding the proceeds that we may receive from the sale or disposition of any assets of USC. We may incur significant costs in connection with such ~~restructuring and~~ winding down activities.

As previously disclosed in our reports with the SEC and as disclosed elsewhere in this Report, pursuant to the USC Agreement we have sold and transferred certain ~~Assets to the Purchaser~~assets relating to the human compounding pharmaceutical business of USC and have agreed to a variety of restrictive covenants preventing us from engaging in certain business and competitive activities relating to the human compounding pharmaceutical business. The remaining operations and business ~~and we~~activities of USC have ~~also approved a restructuring process of winding~~been wound down and ~~winding up the remaining business of USC~~terminated, and ~~selling, transferring or disposing of the~~ remaining assets ~~of USC. As a result, upon completion of that process we~~relating to USC’s business have been sold or will be sold or otherwise transferred or disposed of. Effective October 31, 2021, USC surrendered its Arkansas retail pharmacy permit and wholesaler/outsourcer permit and is no longer be engaged in the human or veterinary compounding pharmaceutical business. The Purchase Agreement provides for payment of consideration over time based on future sales of products by the Purchaser. There is no assurance regarding the proceeds that we may receive from the Purchase Agreement or any other sale or disposition of any other assets of USC.

We have indemnification obligations under the ~~Purchase~~USC Agreement, and we may have indemnification obligations under other agreements relating to the sale or disposition of other USC assets, pursuant to which we may be required to indemnify, hold harmless, and pay losses, liabilities, expenses and amounts arising out of certain claims relating to the assets that are the subject of such agreements, including without limitation relating to, among other matters, our breach of the USC Agreement or other applicable agreement, third party claims relating to previous sales of products by USC to customers, or other matters.assets. These indemnification provisions could require us to pay significant amounts to satisfy our indemnification obligations under such agreements, which would reduce the net amounts that we ultimately receive from the sale of the assets subject to such agreements.

In addition, other matters may arise in the future relating to the USC business, USC assets, or USC employees, or arising out of the restructuring, winding down and winding up activities, that could require us to pay amounts in the future. The process of winding down and winding up the remaining business of USC could require us to incur significant additional expenses or pay significant amounts in connection with or relating to the ~~termination of employment of USC’s employees, the~~ disposition of remaining USC assets, the termination of agreements relating to the USC business, or the resolution of outstanding obligations, liabilities, or current or future claims or proceedings. In addition, we could be required to pay significant fines, penalties or other amounts as a result of proceedings by federal or state regulatory authorities relating to the former business and operations of USC.

~~The COVID-19 outbreak adversely affected sales of USC’s compounded pharmacy products and may adversely affect the amount that we receive from sale of USC’s assets.~~

The COVID-19 outbreak adversely affected revenues from sales of products by USC during 2020 and interim periods of 2021. The ongoing impact of the COVID-19 pandemic, or other factors, could adversely affect the amount that we receive in the future pursuant to the Purchase Agreement or other agreements or activities relating to the sale or disposition of USC’s assets.

~~If a compounded drug formulation leads to patient injury or death or results in a product recall, we may be exposed to significant liabilities.~~

The production, labeling and packaging of compounded pharmaceutical preparations is inherently risky. We could be adversely affected if any of USC’s formulations or other products prove to be, or are asserted to be, harmful to patients. There are a number of factors that could result in the injury or death of a patient who receives one of USC’s compounded formulations, including quality issues, manufacturing or labeling flaws, improper packaging or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, safety alert, or other proceedings or actions, relating to one or more of USC’s products. If adverse events or deaths or a product recall, either voluntarily or as required by the FDA or a state board of pharmacy, were associated with one of USC’s formulations or compounds, we could become subject to product and professional liability lawsuits or other proceedings, including enforcement actions by state and federal authorities or other healthcare self-regulatory bodies or product liability claims or lawsuits. In addition, such matters could result in indemnification claims by third parties to which we have sold certain assets of USC, pursuant to our agreements with such third parties relating to such sales. Any of the foregoing matters could result in a material adverse effect on our business, results of operations, financial condition and liquidity. Current or future insurance coverage may prove insufficient to cover any liability claims brought against USC or us.

The compounding pharmaceuticals business formerly conducted by USC is significantly impacted by state and federal statutes and regulations.

The compounding pharmaceuticals business formerly conducted by USC is subject to federal, state and local laws, regulations, and administrative practices, including, among others: federal registration as an outsourcing facility, state and local licensure and registration requirements concerning the operation of outsourcing facilities, and federal and state laws relating to the preparation, purchase, sale, advertisement, promotion, distribution, management, compounding, dispensing, reimbursement, marketing, and labeling of drugs that USC sells and related services as well as state pharmacy, manufacturer, wholesaler and distribution licensure and registration or permit standards; HIPAA and other laws relating to the use, disclosure and transmission of health or other personal information; the ~~Patient Protection and Affordable Care Act, or~~ ACA, and the Health Care and Education Reconciliation Act of 2010; statutes and regulations of the FDA and the U.S. Drug Enforcement Administration, or DEA, and states including relating to controlled substances; and state pharmacy, manufacturer, wholesaler and distribution licensure and registration or permit standards and other state laws and regulations.

~~The federal, state and local laws and regulations applicable to the pharmaceutical and compounding industries are subject to frequent change, whether through change in law or through interpretation.~~ There can be no assurance that we or USC have been or are compliant in material respects with applicable federal and state regulatory requirements. Failure to comply with FDA requirements and other federal or state governmental laws and regulations can result in fines, disgorgement, unanticipated compliance expenditures, ~~recall or seizure of products,~~ exposure to product liability claims, total or partial suspension of production or distribution, enforcement actions, injunctions and civil or criminal prosecution, any of which could have a material adverse effect on our business, financial condition or results of operations.

~~USC and its customers are subject to a variety of federal, state and local laws and regulations relating to the general healthcare industry, which are subject to frequent change.~~

Participants in the healthcare industry, including the company and USC, are subject to a variety of federal, state, and local laws and regulations. Laws and regulations in the healthcare industry are extremely complex and, in many instances, industry participants do not have the benefit of significant regulatory or judicial interpretation. Such laws and regulations are subject to change and often are uncertain in their application. There can be no assurance that USC or we will not be subject to scrutiny or challenge under one or more of these laws or regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could adversely affect our business, financial condition or results of operations.

In addition, we are subject to the federal anti-kickback statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service reimbursable under a federal healthcare program, or purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under a federal healthcare program. We are also subject to state anti-kickback laws and regulations. Violations of the anti-kickback statutes can result in imprisonment, civil or criminal fines, and fines and disciplinary actions relating to our state licensure. Any violation or alleged violation of such federal or state laws could harm USC’s or our reputation, customer relationships or otherwise have a material adverse effect on our business, financial condition and results of operations.

Risks Related to Our Common Stock

Provisions of our charter documents could discourage an acquisition of our company that would benefit our stockholders and may have the effect of entrenching, and making it difficult to remove, management.

Provisions of our restated certificate of incorporation and bylaws may make it more difficult for a third party to acquire control of us, even if a change of control would benefit our stockholders. For example, shares of our preferred stock may be issued in the future without further stockholder approval, and upon such terms and conditions, and having such rights, privileges and preferences, as our board of directors may determine, including, for example, rights to convert into our common stock. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any of our preferred stock that may be issued in the future. The issuance of our preferred stock could have the effect of making it more difficult for a third party to acquire control of us. This could limit the price that certain investors might be willing to pay in the future for shares of our common stock and discourage those investors from acquiring a majority of our common stock. Similarly, our bylaws require that any stockholder proposals or nominations for election to our board of directors must meet specific advance notice requirements and procedures, which make it more difficult for our stockholders to make proposals or director nominations. The existence of these charter provisions could have the effect of entrenching management and making it more difficult to change our management. Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law. These provisions may prohibit or restrict large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us, unless one or more exemptions from such provisions apply. These provisions under Delaware law could discourage potential takeover attempts and could reduce the price that investors might be willing to pay for shares of our common stock in the future.

*The price of our common stock may be volatile.

The market price of our common stock may fluctuate substantially. For example, from January ~~2019~~2020 to ~~June~~September 30, ~~2021,~~2022, the market price of our common stock has fluctuated between ~~$0.27~~approximately $0.18 and ~~$3.29.~~$2.34. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:

	●	relatively low trading volume, which can result in significant volatility in the market price of our common stock based on a relatively smaller number of trades and dollar amount of transactions;
	●	the timing and results of our current and any future preclinical or clinical trials of our product candidates;
	●	the entry into or termination of key agreements, including, among others, key collaboration and license agreements;
	●	the results and timing of regulatory reviews relating to the approval of our product candidates;
	●	the timing of, or delay in the timing of, commercial introduction of any of our products;
	●	the initiation of, material developments in, or conclusion of, litigation to enforce or defend any of our intellectual property rights;
	●	failure of any of our product candidates, if approved, to achieve commercial success;
	●	general and industry-specific economic conditions that may affect our research and development expenditures;
	●	the results of clinical trials conducted by others on products that would compete with our product candidates;
	●	issues in manufacturing our product candidates or any approved products;
	●	the loss of key employees;
	●	the introduction of technological innovations or new commercial products by our competitors;
	●	changes in estimates or recommendations by securities analysts, if any, who cover our common stock;
	●	future sales of our common stock;
	●	publicity or announcements regarding regulatory developments relating to our products;
	●	period-to-period fluctuations in our financial results, including our cash and cash equivalents balance, operating expenses, cash burn rate or revenue levels;
	●	common stock sales in the public market by one or more of our larger stockholders, officers or directors;
	●	our filing for protection under federal bankruptcy laws;
	●	a negative outcome in any litigation or potential legal proceeding;
	●	~~the~~ effects of public health crises, pandemics and epidemics, such as a the COVID-19 outbreak; or
	●	other potentially negative financial announcements, such as a review of any of our filings by the SEC, changes in accounting treatment or restatement of previously reported financial results or delays in our filings with the SEC.

The stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.

Trading of our common stock is limited.

Trading of our common stock is limited, and trading restrictions imposed on us by applicable regulations may further reduce our trading, making it difficult for our stockholders to sell their shares.

The foregoing factors may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and asked prices for our common stock. In addition, without a large public float, our common stock is less liquid than the stock of companies with broader public ownership, and as a result, the trading price of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate his or her investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price of our stock than would be the case if our public float were larger. We cannot predict the price at which our common stock will trade at any given time.

Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock, which could negatively impact the market price and liquidity of our common shares and our ability to access the capital markets.

Our common stock is listed on the Nasdaq Capital Market. If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, or applicable market capitalization or shareholder equity requirements, Nasdaq may take steps to delist our common stock. Such a delisting would have a negative effect on the price of our common stock, impair the ability to sell or purchase our common stock when persons wish to do so, and any delisting materially adversely affect our ability to raise capital or pursue strategic restructuring, refinancing or other transactions on acceptable terms, or at all. Delisting from the Nasdaq Capital Market could also have other negative results, including the potential loss of institutional investor interest and fewer business development opportunities. In the event of a delisting, we would attempt to take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

~~At various times from October 2019 through September 2020, we have received notices from~~On December 31, 2021, the Nasdaq Listing Qualifications Department of The NASDAQ Capital Market (“Nasdaq”) ~~informing~~notified us that because the closing bid price of our common stock had been below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) (the “Rule”) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. ~~The notices had no immediate effect on the listing or the trading of our common stock on The Nasdaq Capital Market.~~ Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), ~~in connection with each notice~~ we were provided an initial compliance period of 180 calendar days, or until June 29, 2022, to regain ~~compliance with the minimum bid price requirement. To regain compliance,~~compliance. The notice stated that if at any time before June 29, 2022, the closing bid price of our common stock ~~must meet~~met or ~~exceed~~exceeded $1.00 per share for a minimum of 10 consecutive business days, ~~during the 180 calendar day grace period. On each such occasion, following such notice~~Nasdaq will provide written notification that we have ~~regained~~achieved compliance with the ~~Rule.~~

~~On May 25, 2021,~~minimum bid price requirement, and the matter would be resolved. We did not regain compliance with the Rule by June 29, 2022. However, we requested additional time to regain compliance and provided notice to Nasdaq of our intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split if necessary. One June 30, 2022, we received a ~~notification~~ letter from Nasdaq notifying us that because the company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Filing” or the “Form 10-Q”), the company was no longer in compliance with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the SEC. The Notice also indicated that the company had 60 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the Filing’s due date to regain compliance. We submitted a plan to regain compliance on July 26, 2021. On August 20, 2021, we received a notification letter (the “Notice”) from Nasdaq notifying us that because we had not filed our Quarterly Report on Form 10-Q for the period ended June 30, 2021, as well as its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Form 10-Qs”), we did not comply with NASDAQ Marketplace Rule 5250(c)(1), which requires timely filing of periodic reports with the SEC. Nasdaq subsequently requested that we submit an updated plan to regain compliance, which we submitted, and Nasdaqbeen granted an ~~exception of up to November 22, 2021, to regain compliance. We have the filed the Form 10-Qs and believe that we have filed the required periodic reports with the SEC~~additional 180-day compliance period or until December 27, 2022, to regain compliance with the Rule. If the Company does not meet the minimum bid requirement for at least 10 consecutive business days at some time during the additional 180-day grace period, Nasdaq will provide written notification to the Company that its shares will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. The Company would remain listed pending the Panel’s decision. There can be no assurance that if the Company does appeal a subsequent delisting determination, that such appeal would be successful. The letter and notification from Nasdaq had no immediate effect on the listing or trading of the Company’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol “ADMP.” There are no assurances that we will be able to regain compliance with the minimum bid price requirements or will otherwise be in compliance with other Nasdaq listing ~~requirements.~~rules.

Our common stock could become subject to additional trading restrictions as a “penny stock,” which could adversely affect the liquidity and price of such stock. If our common stock became subject to the SEC’s penny stock rules, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.

Prior to the listing of our common stock on the NASDAQ Capital Market, our common stock was traded on the OTCQB. The OTCQB, the OTC Bulletin Board and Pink Sheets are viewed by most investors as a less desirable, and less liquid, marketplace. As a result, if our common stock was delisted from the NASDAQ Capital Market and was traded on the OTCQB, the OTC Bulletin Board or the Pink Sheets, an investor could find it more difficult to purchase, dispose of or obtain accurate quotations as to the value of our common stock.

Unless our common stock is listed on a national securities exchange, such as the NASDAQ Capital Market, our common stock may also be subject to the regulations regarding trading in “penny stocks,” which are those securities trading for less than $5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. The following is a list of the general restrictions on the sale of penny stocks:

●

Before the sale of penny stock by a broker-dealer to a new purchaser, the broker-dealer must determine whether the purchaser is suitable to invest in penny stocks. To make that determination, a broker-dealer must obtain, from a prospective investor, information regarding the ~~purchaser's~~purchaser’s financial condition and investment experience and objectives. Subsequently, the broker-dealer must deliver to the purchaser a written statement setting forth the basis of the suitability finding and obtain the ~~purchaser's~~purchaser’s signature on such statement.

	●	A broker-dealer must obtain from the purchaser an agreement to purchase the securities. This agreement must be obtained for every purchase until the purchaser becomes an “established customer.”
	●	The Securities Exchange Act of 1934, or the Exchange Act, requires that before effecting any transaction in any penny stock, a broker-dealer must provide the purchaser with a “risk disclosure document” that contains, among other things, a description of the penny stock market and how it functions and the risks associated with such investment. These disclosure rules are applicable to both purchases and sales by investors.
	●	A dealer that sells penny stock must send to the purchaser, within 10 days after the end of each calendar month, a written account statement including prescribed information relating to the security.

These requirements can severely limit the liquidity of securities in the secondary market because fewer brokers or dealers are likely to be willing to undertake these compliance activities. If our common stock is not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions may limit an investor’s ability to sell to a third party and our ability to raise additional capital. We make no guarantee that market-makers will make a market in our common stock, or that any market for our common stock will continue.

Our stockholders may experience significant dilution as a result of any additional financing using our securities, or as the result of the exercise or conversion of our outstanding securities.

In the future, to the extent that we raise additional funds by issuing equity securities or securities convertible into or exercisable for equity securities, our stockholders may experience significant dilution. In addition, conversion or exercise of other outstanding options, warrants or convertible securities could result in there being a significant number of additional shares outstanding and dilution to our stockholders. If additional funds are raised through the issuance of preferred stock, holders of preferred stock could have rights that are senior to the rights of holders of our common stock, and the agreements relating to any such issuance could contain covenants that would restrict our operations.

We have not paid cash dividends on our common stock in the past and do not expect to pay cash dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.

No cash dividends have been paid on our common stock, and we do not expect to pay cash dividends on our common stock in the foreseeable future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on a stockholder’s investment will only occur if our stock price appreciates.

The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.

Our restated certificate of incorporation gives our board of directors the right to create new series of preferred stock. As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely affect the voting power and equity interest of the holders of common stock. Preferred stock, which could be issued with the right to more than one vote per share, could be utilized as a method of discouraging, delaying or preventing a change of control. The possible impact on takeover attempts could adversely affect the price of our common stock.

*Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.

If in the future we sell additional equity securities to help satisfy funding requirements, those securities may be subject to registration rights or may include warrants with anti-dilutive protective provisions. Future sales in the public market of our common stock, or shares issued upon exercise of our outstanding stock options, warrants or convertible securities, or the perception by the market that these issuances or sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital. Our stockholders may experience substantial dilution and a reduction in the price that they are able to obtain upon the sale of their shares. Also, new equity securities issued may have greater rights, preferences or privileges than our existing common stock.

As ~~of June~~September 30, ~~2021,~~2022, we had ~~148,886,141~~149,983,265 shares of common stock issued and outstanding, substantially all of which we believe may be sold publicly, subject in some cases to volume and other limitations, provisions or limitations in registration rights agreements, or prospectus-delivery or other requirements relating to the effectiveness and use of registration statements registering the resale of such shares.

As of ~~June~~September 30, ~~2021,~~2022, we had reserved for issuance ~~6,113,866~~4,985,415 shares of our common stock issuable upon the exercise of outstanding stock options under our equity incentive plans at a weighted-average exercise price of ~~$4.31~~$4.21 per share, we had outstanding restricted stock units covering ~~2,034,260~~650,000 shares of common stock, and we had outstanding warrants to purchase ~~15,095,238~~14,952,824 shares of common stock at a weighted-average exercise price of ~~$1.28~~$1.13 per share. Subject to applicable vesting requirements, upon exercise of these options or warrants or issuance of shares following vesting of the restricted stock units, the underlying shares may be resold into the public market, subject in some cases to volume and other limitations or prospectus delivery requirements pursuant to registration statements registering the resale of such shares. In the case of outstanding options or warrants that have exercise prices that are below the market price of our common stock from time to time, or upon issuance of shares following vesting of restricted stock units, our stockholders would experience dilution upon the exercise of these options.

*Exercise of our outstanding warrants may result in dilution to our stockholders.

As of ~~June~~September 30, ~~2021,~~2022, we had outstanding warrants, other than the warrants described in the next sentence, to purchase 58,824 shares of common stock, at a weighted average exercise price of $8.50 per share. As of ~~June~~September 30, ~~2021,~~2022, 13,794,000 shares of our common stock were issuable (subject to certain beneficial ownership limitations) upon exercise of warrants, at an exercise price of $1.15 per share, that we issued in connection with our underwritten public offering of common stock and warrants in August 2019; 350,000 shares of our common stock were issuable (subject to certain beneficial ownership limitations) upon exercise of warrants, at an exercise price of $0.70 per share, that we issued in connection with our private placement of warrants in February 2020, and, ~~892,414~~750,000 shares of our common stock were issuable (subject to certain beneficial ownership limitations) upon exercise of warrants, ~~that we issued in the following transactions: warrants to purchase 192,414 shares~~ at an exercise price of ~~$2.90~~$0.47 per share, that we issued in ~~our~~connection with the issuance of Series C Preferred Stock in July 2016 Series A-2 Convertible Preferred transaction; and warrants to purchase 700,000 shares at an exercise price of $2.98 per share in our August 2016 registered direct offering of common stock and warrants.2022.

Our Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for a wide variety of disputes between us and our stockholders, and that the federal district courts of the United States of the America are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Exclusive forum provisions in our Bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our Bylaws, as amended, provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders, including (i) any derivative action or proceeding brought on behalf of the company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to the company or the company’s stockholders; (iii) any action asserting a claim against the company or any director or officer or other employee of the company arising pursuant to any provision of the Delaware General Corporation Law, the certificate of incorporation or the Bylaws of the company, or as to which the Delaware General Corporation Law confers jurisdiction on the Courts of Chancery of the State of Delaware; or (iv) any action asserting a claim against the company or any director or officer or other employee of the company governed by the internal affairs doctrine, in all cases subject to the court’s having personal jurisdiction over the indispensable parties named as defendants (including without limitation as a result of the consent of such indispensable party to the personal jurisdiction of such court). The Bylaws provide that the foregoing provisions do not apply to actions or suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any other claim for which the federal courts have exclusive jurisdiction. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our Bylaws do not relieve us of our duties to comply with federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations. In addition, our Bylaws, as amended, provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and to have consented to these provisions.

Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act. There is uncertainty as to whether a court (other than state courts in the State of Delaware, where the Supreme Court of the State of Delaware decided in March 2020 that exclusive forum provisions for causes of action arising under the Securities Act are facially valid under Delaware law) would enforce forum selection provisions and whether investors can waive compliance with the federal securities laws and the rules and regulations thereunder. We believe the forum selection provisions in Bylaws, as amended, may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against us and/or our directors, officers and employees as it may limit any stockholder’s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers or employees. In addition, stockholders who do bring a claim in the Court of Chancery in the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a future court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.

*We identified material weaknesses in our internal control over financial reporting. If we fail to effectively remediate identified material weaknesses, it could continue to adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner. If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, ~~if we~~identify or discover material weaknesses in our internal control over financial reporting or fail to effectively remediate any identified material weaknesses, ~~or if we discover other material weaknesses or deficiencies in our internal controls over financial reporting,~~ our business and financial condition could be materially and adversely affected and our stock price could decline.

Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. GAAP. Our management is likewise required, on a quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any material changes and weaknesses identified through such evaluation. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and our business and financial condition could be adversely affected. If material weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could decline significantly.

As disclosed in ~~the company's Annual Report~~our Quarterly Reports on Form ~~10-K~~10-Q for the ~~year ended December 31, 2020, management assessed the effectiveness~~first three quarters of our internal control over financial reporting as of December 31, 2020, and as a result of this assessment identified a material weakness in internal control over financial reporting as of that date. As a result of this material weakness, our management concluded that our internal control over financial reporting was not effective as of December 31, 2020, and our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of December 31, 2020. The material weakness resulted in a misstatement of our warrant liabilities and the related gain or loss recognized as a result of the change in the fair value of the warrant liabilities, and related misstatements in, our unaudited condensed consolidated financial statements, for the periods ended March 31, June 30, and September 30, 2020. See Note 4 of the Notes to the consolidated financial statements included in the company's Annual Report on Form 10-K for the year ended December 31, 2020 for additional information. We believe the material weakness has been remediated as of March 31, 2021. In addition,2021, we identified a material ~~weakness~~weaknesses in our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of March 31, 2021, June 30, 2021 and September 30, 2021.

~~Any~~ We believe that the identified weakness was remediated as of December 31, 2021. Nevertheless, any failure to effectively remediate ~~the~~an identified material weakness or otherwise maintain adequate internal controls over financial reporting could adversely impact our ability to report our financial results on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities, and legal proceedings by stockholders or regulatory authorities, which could result in a material adverse effect on our business. We could face monetary judgments, penalties or other sanctions that could have a material adverse effect on our business, financial condition and results of operations and could cause our stock price to decline. Failure to timely file required reports with the SEC, as occurred with respect to our Quarterly Reports on Form 10-Q for the first three quarters of 2021, results in loss of eligibility to utilize short form registration statements on Form S-3 ~~or Form S-4~~ and prospectuses outstanding under previous registration statements not being current or available, which may impair our ability to obtain required capital in a timely ~~fashion to execute our business strategies,~~manner or issue shares ~~to effect an acquisition, or~~for other purposes, and may subject us to legal claims from stockholders or warrant holders. Inadequate internal control could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

We ~~intend to~~ take ~~certain remedial~~responsive actions ~~intended~~ to address ~~the~~ identified material ~~weakness~~weaknesses in our internal control over financial reporting. However, we can give no assurance that such measures will remediate ~~the~~any material weakness that are identified or that any additional material weaknesses or restatements of financial results will not arise in the future. In the future, our management may determine that our disclosure controls and procedures are ineffective or that there are one or more material weaknesses in our internal controls over financial reporting, resulting in a reasonable possibility that a material misstatement to the annual or interim financial statements would not have been prevented or detected. Accordingly, a material weakness increases the risk that the financial information we report contains material errors. Any system of internal controls, however well designed and operated, is based in part on certain assumptions and can provide only reasonable, not absolute, assurances that the objectives of the system are met. Efforts to correct any material weaknesses or deficiencies that may be identified could require significant financial resources to address. Moreover, if remedial measures are insufficient to address the deficiencies that are determined to exist, we may fail to meet our future reporting obligations on a timely basis, our consolidated financial statements could contain material misstatements, we could be required to restate our prior period financial results, our operating results may be harmed, and we could become subject to class action litigation or investigations or proceedings from regulatory authorities. ~~Internal control deficiencies and ineffective disclosure controls and procedures could also cause investors to lose confidence in our reported financial information.~~ Any of these matters could adversely affect our business, reputation, revenues, results of operations, financial condition and stock price.

General Risk Factors

* We depend on our officers. If we are unable to retain our key employees or to attract additional qualified personnel, our product operations and development efforts may be seriously jeopardized.

Our success will be dependent upon the efforts of our management team and ~~staff, including Dennis J. Carlo, Ph.D., our chief executive officer. The employment of Dr. Carlo may be terminated at any time by either us or Dr. Carlo.~~staff. We currently do not have key person life insurance policies covering any of our executive officers or key employees. The employment of Dennis J. Carlo, Ph.D., our former president and chief executive officer, terminated in May 2022 and Dr. Ronald Moss, our former chief medical officer, tendered his resignation effective October 14, 2022. If key individuals leave us, we could be adversely affected if suitable replacement personnel are not quickly recruited. There is competition for qualified personnel in all functional areas, which makes it difficult to attract and retain the qualified personnel necessary for the operation of our business. Our success also depends in part on our ability to attract and retain highly qualified scientific, commercial and administrative personnel. If we are unable to attract new employees and retain existing key employees, the development and commercialization of our product candidates could be delayed or negatively impacted. In addition, any staffing interruptions resulting from geopolitical actions, including war and terrorism, adverse public health developments such as the COVID-19 pandemic, or natural disasters including earthquakes, typhoons, floods and fires, could have an adverse effect on our business.

We may experience difficulties in managing growth.

We are a small company. ~~Future~~Any significant growth ~~will~~that we may experience in the future could impose significant added responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel. ~~We may increase the number of employees in the future depending on the progress of our development of our products and technologies.~~ Our future financial performance and our ability to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to:

	●	manage our clinical studies effectively;
	●	integrate additional management, administrative, manufacturing and regulatory personnel;
	●	maintain sufficient administrative, accounting and management information systems and controls; and
	●	hire and train additional qualified personnel.

We may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial ~~results~~
results.

Our business and operations would suffer in the event of cybersecurity or other system failures. Our business depends on complex information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations.

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers, as well as personally identifiable information of employees. Similarly, our third-party providers possess certain of our sensitive data. The secure maintenance of this information is material to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. Thus, any access, disclosure or other loss of information, including our data being breached at our partners or third-party providers, could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disrupt our operations, and damage our reputation which could adversely affect our business.

A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.

There have been and may continue to be periods when our common stock could be considered “thinly-traded,” meaning that the number of persons interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent. Finance transactions resulting in a large amount of newly issued shares that become readily tradable, conversion of outstanding convertible notes or exercise of outstanding warrants and sale of the shares issuable upon conversion of such notes or exercise of such warrants, issuance of shares following vesting of outstanding restricted stock units, or other events that cause stockholders to sell shares, could place downward pressure on the trading price of our stock. In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock. If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons, substantial amounts of our common stock in the public market, the market price of our common stock could decline. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We may never obtain substantial research coverage by industry or financial analysts. If no or few analysts commence or continue coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Information concerning our sales of unregistered securities during the quarter ended ~~June~~September 30, ~~2021,~~2022, has previously been reported in reports on Form 8-K that we filed during that quarter.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not ~~applicable.~~ Applicable.

ITEM 5. Other Information

~~None.~~

None.

ITEM 6. Exhibits

The following exhibits are attached hereto or incorporated herein by reference.

~~10.1~~3.1		~~Settlement Agreement between the Company, US Compounding Inc., Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., Nephron Sterile Compounding Center, LLC~~Certificate of Designation of Preferences, Rights, and certain other parties. +*Limitations of Series C Convertible Preferred Stock. (1)

~~10.2~~4.1		~~Asset~~Common Stock Purchase ~~Agreement effective as of~~Warrant dated July ~~30, 2021, by and among the Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC.~~5, 2022. (1)*+

~~10.3~~10.1		~~Supply~~Securities Purchase Agreement ~~Addendum by~~dated July 5, 2022, between the Company and ~~among~~ the ~~Registrant, US Compounding, Inc. and Fagron Compounding Services, LLC.~~parties thereto. (1)+

10.2	Registration Rights Agreement dated July 5, 2022, between the Company and the parties thereto. (1)

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

(1)		Incorporated by reference to exhibits filed with the Report on Form 8-K filed by the Company on ~~August 5, 2021.~~

*		Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC.

+		Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the Registrant customarily and actually treats the information contained in such portions as private or confidential and such information is not material.

		July 6, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ADAMIS PHARMACEUTICALS, INC.

Date: November ~~22, 2021~~14, 2022	By:	/s/ ~~Dennis~~David J. ~~Carlo~~Marguglio
		~~Dennis~~David J. ~~Carlo~~Marguglio
		Chief Executive Officer

Date: November ~~22, 2021~~14, 2022	By:	/s/ David C. Benedicto
		David C. Benedicto
		Chief Financial Officer

			Page
PART I FINANCIAL INFORMATION

Item 1.	Financial Statements:

	Condensed Consolidated Balance Sheets at ~~June~~September 30, ~~2021~~2022 (Unaudited) and December 31, ~~2020~~2021		43

	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021	4
		5

	Condensed Consolidated Statements of Mezzanine Equity and Stockholders’ Equity (Unaudited) for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021		65

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~Six~~Nine Months Ended ~~June~~September 30, ~~2021~~2022 and ~~2020~~2021		~~7–8~~6-7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		3126

Item 3.	Quantitative and Qualitative Disclosure of Market Risk		4334

Item 4.	Controls and Procedures		4334

PART II OTHER INFORMATION

Item 1.	Legal Proceedings		4435

Item 1A.	Risk Factors		4636

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		6958

Item 3.	Defaults Upon Senior Securities		6958

Item 4.	Mine Safety Disclosures		6958

Item 5.	Other Information		6958

Item 6.	Exhibits		6959

Signatures			70


	September 30, 2022			December 31, 2021
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	2,419,960		$	23,220,770
Restricted Cash		30,056			30,023
Accounts Receivable, net		1,306,505			815,565
Receivable from Fagron		247,510			5,084,452
Inventories		1,092,445			418,607
Prepaid Expenses and Other Current Assets		803,415			1,313,546
Current Assets of Discontinued Operations (Note 2)		4,188,239			4,320,659
Total Current Assets		10,088,130			35,203,622
LONG TERM ASSETS
Fixed Assets, net		1,594,856			2,334,768
Right-of-Use Assets		402,126			650,460
Other Non-Current Assets		52,174			109,137
Total Assets	$	12,137,286		$	38,297,987
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts Payable	$	5,297,717		$	3,754,010
Accrued Other Expenses		1,341,759			2,800,241
Product Recall Liability		408,130			2,000,000
Accrued Bonuses		—			535,624
Lease Liabilities, current portion		368,809			349,871
Deferred Revenue, current portion		27,779			100,000
Current Liabilities of Discontinued Operations (Note 2)		1,429,925			1,683,246
Total Current Liabilities		8,874,119			11,222,992

LONG TERM LIABILITIES
Deferred Revenue, net of current portion		185,191			750,000
Lease Liabilities, net of current portion		63,209			342,562
Warrant Liabilities, at fair value		12,037			99,655
Total Liabilities		9,134,556			12,415,209

COMMITMENTS AND CONTINGENCIES (Note 12)

Convertible Preferred Stock - Par Value $ .0001 ; 10,000,000 Shares Authorized: Series C Preferred Stock 3,000 Shares Authorized, liquidation preference $110 per share; 3,000 and 0 Issued and Outstanding at September 30, 2022 (Unaudited) and December 31, 2021, respectively. (Note 10)		157,303			—

STOCKHOLDERS’ EQUITY

Common Stock - Par Value $ .0001 ; 200,000,000 Shares Authorized; 150,506,222 and 150,117,219 Issued, 149,983,265 and 149,594,262 Outstanding at September 30, 2022 (Unaudited) and December 31, 2021, respectively.		15,051			15,012
Additional Paid-in Capital		304,072,176			303,958,829
Accumulated Deficit		(301,236,550	)		(278,085,813	)
Treasury Stock, at cost - 522,957 Shares at September 30, 2022 (Unaudited) and December 31, 2021.		(5,250	)		(5,250	)
Total Stockholders’ Equity		2,845,427			25,882,778
Total Liabilities, Mezzanine Equity and Stockholders’ Equity	$	12,137,286		$	38,297,987


	Three Months Ended						Nine Months Ended
	September 30, 2022			September 30, 2021			September 30, 2022			September 30, 2021

REVENUE, net	$	1,505,683		$	759,962		$	2,605,396		$	3,368,115
COST OF GOODS SOLD		1,647,585			1,565,922			3,705,697			5,207,402
Gross Loss		(141,902	)		(805,960	)		(1,100,301	)		(1,839,287	)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		2,508,176			4,794,485			10,096,807			13,247,027
RESEARCH AND DEVELOPMENT		1,977,939			4,620,143			9,520,118			9,066,608
Loss from Operations		(4,628,017	)		(10,220,588	)		(20,717,226	)		(24,152,922	)
OTHER INCOME (EXPENSE)
Interest Expense		—			(1,865	)		—			(6,649	)
Interest/Other Income (Expense)		298,118			1,932			(379,392	)		5,283
Gain on Forgiveness of PPP Loans		—			5,009,590			—			5,009,590
PPP2 Loan Contingent Loss		—			—			(1,787,417	)		—
Change in Fair Value of Warrant Liabilities		58,690			42,525			87,618			(7,642,949	)
Total Other Income (Expense), net		356,808			5,052,182			(2,079,191	)		(2,634,725	)
Net Loss from Continuing Operations before Income Taxes		(4,271,209	)		(5,168,406	)		(22,796,417	)		(26,787,647	)
Income Taxes		—			—			—			—
Net Loss from Continuing Operations		(4,271,209	)		(5,168,406	)		(22,796,417	)		(26,787,647	)
DISCONTINUED OPERATIONS
Net Loss from Discontinued Operations before Income Taxes		(127,692	)		(7,192,642	)		(354,320	)		(10,266,365	)
Income Taxes - Discontinued Operations		—			—			—			—
Net Loss from Discontinued Operations		(127,692	)		(7,192,642	)		(354,320	)		(10,266,365	)
Net Loss Applicable to Common Stock	$	(4,398,901	)	$	(12,361,048	)	$	(23,150,737	)	$	(37,054,012	)

Basic and Diluted Loss Per Share:
Continuing Operations	$	(0.03	)	$	(0.03	)	$	(0.15	)	$	(0.19	)

Discontinued Operations	$	(0.00	)	$	(0.05	)	$	(0.00	)	$	(0.07	)
Basic and Diluted Net Loss Per Share	$	(0.03	)	$	(0.08	)	$	(0.15	)	$	(0.26	)

Basic and Diluted Weighted Average Shares Outstanding		149,983,265			148,886,141			149,806,799			142,483,194

	June 30, 2021			December 31,
	(Unaudited)			2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	$	40,618,554		$	6,855,355
Restricted Cash		30,000			—
Accounts Receivable, net		1,309,949			1,092,857
Inventories		2,170,888			3,115,926
Prepaid Expenses and Other Current Assets		1,999,130			1,459,983
Total Current Assets		46,128,521			12,524,121
LONG TERM ASSETS
Intangible Assets, net		5,812,934			6,289,684
Goodwill		868,412			868,412
Fixed Assets, net		9,541,221			9,586,593
Right -of-Use Assets		1,301,741			1,543,997
Other Non-Current Assets		54,655			54,655
Total Assets	$	63,707,484		$	30,867,462
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts Payable	$	3,010,514		$	3,491,717
Deferred Revenue, current portion		104,100			100,070
Accrued Other Expenses		3,551,863			2,524,412
Accrued Bonuses		874,595			1,047,719
Contingent Loss Liability		—			7,900,000
Lease Liabilities, current portion		509,537			494,342
Bank Loan - Building		2,018,101			2,067,213
Paycheck Protection Plan (PPP) Loans, current portion		3,383,586			2,300,253
Total Current Liabilities		13,452,296			19,925,726
LONG TERM LIABILITIES
Deferred Revenue		800,000			850,000
Deferred Tax Liability, net		112,530			112,530
Lease Liabilities, net of current portion		845,012			1,105,219
PPP Loan, net of current portion		1,573,609			891,447
Warrant Liabilities, at fair value		244,824			4,485,000
Total Liabilities		17,028,271			27,369,922
COMMITMENTS AND CONTINGENCIES (see Note 9)
STOCKHOLDERS’ EQUITY
Preferred Stock – Par Value $0.0001; 10,000,000 Shares Authorized; Series A-2 Convertible, 0 shares Issued and Outstanding at June 30, 2021 (Unaudited) and December 31, 2020, respectively.		—			—
Common Stock - Par Value $0.0001; 200,000,000 Shares Authorized; 149,409,098 and 94,365,015 Issued, 148,886,141 and 93,842,058 Outstanding at June 30, 2021 and December 31, 2020, respectively		14,941			9,437
Additional Paid-in Capital		303,620,101			233,404,968
Accumulated Deficit		(256,950,579	)		(229,911,615	)
Treasury Stock, at cost - 522,957 Shares		(5,250	)		(5,250	)
Total Stockholders’ Equity		46,679,213			3,497,540
Total Liabilities and Stockholders’ Equity	$	63,707,484		$	30,867,462


	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
REVENUE, net	$	4,011,304		$	3,926,342		$	8,119,836		$	8,589,552
COST OF GOODS SOLD		3,870,632			4,683,835			7,512,580			8,370,879
Gross Profit (Loss)		140,672			(757,493	)		607,256			218,673

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		7,131,644			5,653,092			13,051,118			11,707,463
RESEARCH AND DEVELOPMENT		2,232,776			3,085,824			4,494,098			5,122,556
IMPAIRMENT EXPENSE - Goodwill		—			—			—			3,143,200
IMPAIRMENT EXPENSE - Long Lived Assets		9,347			—			9,347			—
IMPAIRMENT EXPENSE - Write-off of Contract Asset		—			1,750,000			—			1,750,000
Loss from Operations		(9,233,095	)		(11,246,409	)		(16,947,307	)		(21,504,546	)

OTHER INCOME (EXPENSE)
Interest Expense		(44,947	)		(32,925	)		(84,272	)		(71,212	)
Other Income		7,886			16,621			24,089			39,676
Change in Fair Value of Warrants		(43,574	)		(1,662,000	)		(7,685,474	)		1,365,000
Total Other Income (Expense), net		(80,635	)		(1,678,304	)		(7,745,657	)		1,333,464
Net Loss	$	(9,313,730	)	$	(12,924,713	)	$	(24,692,964	)	$	(20,171,082	)

Basic and Diluted Loss Per Share	$	(0.06	)	$	(0.18	)	$	(0.18	)	$	(0.29	)

Basic and Diluted Weighted Average Shares Outstanding		148,886,141			73,825,491			139,228,657			70,162,628

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ADMP	NASDAQ Capital Market


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

	●	We borrowed funds pursuant to the Paycheck Protection Program. Even though our loans have been forgiven pursuant to the program, we remain subject to possible review and audit in connection with such loans.

	●	~~Our business is impacted by state and federal statutes and regulations.~~

	●	Our US Compounding Inc. subsidiary, or USC, which is registered as a human drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act, as amended, or FDCA, is subject to many federal, state and local laws, regulations, and administrative practices, including, among others: federal registration as an outsourcing facility, state and local licensure, and registration requirements concerning the operation of outsourcing facilities and the compounding, labeling, marketing, sale and distribution of products from our registered outsourcing facility. . Effective as of July 30, 2021, we entered into an asset purchase agreement pursuant to which we sold and transferred certain assets of USC related to its human compounding pharmaceutical business, and we have approved a restructuring pursuant to which the remaining operations and business of USC will be wound down and wound up and assets relating to USC's business will be sold or otherwise disposed of. Nevertheless, USC and we could become involved in proceedings with the U.S. Food & Drug Administration, or FDA , or other federal or state regulatory authorities alleging non-compliance with applicable federal or state regulatory legal requirements, which could adversely affect our business, financial condition and results of operations.60

	●	~~Changes in healthcare laws could adversely affect the ability or willingness of customers to purchase our products and, as a result, adversely impact our business and financial results.~~

	●	We identified a material weakness in our internal control over financial reporting, concluded that our internal control over financial reporting was not effective and that our disclosure controls and procedures were not effective at the reasonable assurance level, and restated our unaudited condensed consolidated financial statements for the periods ended March 31, 2020, June 30, 2020, and September 30, 2020, which may lead to additional risks and uncertainties, including loss of investor confidence, legal investigations or proceedings, and negative impacts on our business, financial condition and stock price. In addition, we identified a material weakness in our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of March 31, 2021, June 30, 2021 and September 30, 2021. If we fail to effectively remediate material weaknesses in our internal control over financial reporting, it could continue to adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.

	●	Our business depends on complex information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations. Cybersecurity or other system failures could disrupt our business, result in liabilities, and adversely affect our business, financial condition and results of operations.

	●	Provisions of our charter documents could discourage an acquisition of our company that would benefit our stockholders and may have the effect of entrenching, and making it difficult to remove, management.

	●	Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock, which could negatively impact the market price and liquidity of our common shares and our ability to access the capital markets.


	Convertible Preferred Stock (Mezzanine Equity)				Common Stock				Additional Paid-In			Treasury Stock					Accumulated			Total
For the Three Months Ended September 30, 2022	Shares		Amount		Shares		Amount		Capital			Shares		Amount			Deficit			Stockholders' Equity
Balance June 30, 2022		—	$	—		150,506,222	$	15,051	$	303,869,991			522,957	$	(5,250	)	$	(296,837,649	)	$	7,042,143
Issuance of Series C Preferred Stock, net of issuance costs of $ 8,300		3,000		157,303		—		—		—			—		—			—			—
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700		—		—		—		—		127,697			—		—			—			127,697
Stock Based Compensation		—		—		—		—		74,488			—		—			—			74,488
Net Loss		—		—		—		—		—			—		—			(4,398,901	)		(4,398,901	)
Balance September 30, 2022		3,000	$	157,303		150,506,222	$	15,051	$	304,072,176			522,957	$	(5,250	)	$	(301,236,550	)	$	2,845,427
For the Three Months Ended September 30, 2021
Balance June 30, 2021		—	$	—		149,409,098	$	14,941	$	303,620,101			522,957	$	(5,250	)	$	(256,950,579	)	$	46,679,213
Stock Based Compensation		—		—		—		—		152,561			—		—			—			152,561
Net Loss		—		—		—		—		—			—		—			(12,361,048	)		(12,361,048	)
Balance September 30, 2021		—	$	—		149,409,098	$	14,941	$	303,772,662			522,957	$	(5,250	)	$	(269,311,627	)	$	34,470,726
For the Nine Months Ended September 30, 2022
Balance December 31, 2021		—	$	—		150,117,219	$	15,012	$	303,958,829			522,957	$	(5,250	)	$	(278,085,813	)	$	25,882,778
Issuance of Series C Preferred Stock, net of issuance costs of $ 8,300		3,000		157,303		—		—					—		—			—			—
Issuance of 750,000 Warrants, pursuant to the Series C Preferred Stock issuance, net of issuance costs of $6,700		—		—		—		—		127,697			—		—			—			127,697
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)		—		—		389,003		39		(39	)		—		—			—			—
Stock Based Compensation		—		—		—		—		(14,311	)		—		—			—			(14,311)
Net Loss		—		—		—		—		—			—		—			(23,150,737	)		(23,150,737	)
Balance September 30, 2022		3,000	$	157,303		150,506,222	$	15,051	$	304,072,176			522,957	$	(5,250	)	$	(301,236,550	)	$	2,845,427
For the Nine Months Ended September 30, 2021
Balance December 31, 2020		—	$	—		94,365,015	$	9,437	$	238,234,968			522,957	$	(5,250	)	$	(232,257,615	)	$	5,981,540
Common Stock Issued, net of issuance costs of $ 3,330,752		—		—		46,621,621		4,661		48,414,585			—		—			—			48,419,246
Exercise of Warrants		—		—		8,356,000		836		15,292,714			—		—			—			15,293,550
Issuance of Common Stock upon Vesting of Restricted Stock Units (RSUs)		—		—		66,462		7		(7	)		—		—			—			—
Share Based Compensation		—		—		—		—		1,830,402			—		—			—			1,830,402
Net Loss		—		—		—		—		—			—		—			(37,054,012	)		(37,054,012	)
Balance September 30, 2021		—	$	—		149,409,098	$	14,941	$	303,772,662			522,957	$	(5,250	)	$	(269,311,627	)	$	34,470,726


	Nine Months Ended September 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(23,150,737	)	$	(37,054,012	)
Less: Loss from Discontinued Operations		354,320			10,266,365
Adjustments to Reconcile Net Loss to Net		—
Cash Used in Operating Activities:
Stock Based Compensation		(14,311	)		1,830,402
Provision for Excess and Obsolete Inventory		—			587,824
Gain on Repayment of PPP2 Loan Contingent Loss Liability		62,583			—
Change in Fair Value of Warrant Liabilities		(87,618	)		7,642,949
Cash Payments in Excess of Lease Expense		(12,081	)		(3,997	)
Depreciation and Amortization Expense		1,111,495			1,071,830
Gain on Forgiveness of PPP Loans		—			(5,009,589	)
Change in Assets and Liabilities:
Accounts Receivable - Trade		(490,940	)		(492,741	)
Receivable from Fagron		919,413			(6,492,321	)
Inventories		(673,838	)		639,237
Prepaid Expenses and Other Current Assets		567,094			352,833
Accounts Payable		1,319,707			730,759
Contingent Loss Liability		—			(7,900,000	)
PPP2 Loan Contingent Loss Liability Payment		(1,850,000	)		—
PPP2 Loan Contingent Loss Liability		1,787,417			—
Product Recall Liability		(1,591,870)			—
Deferred Revenue		(637,030	)		(75,000	)
Accrued Other Expenses and Bonuses		(1,552,766)			1,203,498
Net Cash Used in Operating Activities of Continuing Operations		(23,939,162	)		(32,701,963	)
Net Cash (Used in) Provided by Operating Activities of Discontinued Operations		(439,301	)		1,590,310
Net Cash Used in Operating Activities		(24,378,463	)		(31,111,653	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Equipment		(588,923	)		(996,268	)
Proceeds from Sale of Non-financial Asset		—			129,811
Proceeds from Receivable from Fagron		3,917,530			—
Net Cash Provided by Investing Activities of Continuing Operations		3,328,607			(866,457	)
Net Cash Used in Investing Activities of Discontinued Operations		—			(15,999	)
Net Cash Provided by (Used in) Investing Activities		3,328,607			(882,456	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Issuance of Common Stock, net of issuance costs of $3,330,752		—			48,419,246
Proceeds from Issuance of Preferred Stock and Warrants, net of issuance costs of $15,000		285,000			—
Proceeds from Exercise of Warrants		—			5,851,900
Proceeds of PPP Loan		—			1,765,495
Net Cash Provided by Financing Activities of Continuing Operations		285,000			56,036,641
Net Cash Used In Financing Activities of Discontinued Operations		—			(2,057,948	)
Net Cash Provided by Financing Activities		285,000			53,978,693
(Decrease) Increase in Cash and Cash Equivalents and Restricted Cash		(20,764,856	)		21,984,584
Cash and Cash Equivalents, and Restricted Cash
Beginning		23,250,793			6,748,945
Change in Cash and Cash Equivalents of Discontinued Operations		(35,921	)		28,376
Ending	$	2,450,016		$	28,761,905


	Convertible Preferred Stock				Common Stock				Additional Paid-In			Treasury Stock					Accumulated
For the Three Months Ended June 30, 2021	Shares		Amount		Shares		Amount		Capital			Shares		Amount			Deficit			Total
Balance March 31, 2021		—	$	—		149,409,098	$	14,941	$	302,822,034			522,957	$	(5,250	)	$	(247,636,849	)	$	55,194,876
Share Based Compensation		—		—		—		—		798,067			—		—			—			798,067
Net Loss		—		—		—		—		—			—		—			(9,313,730	)		(9,313,730	)
Balance June 30, 2021		—	$	—		149,409,098	$	14,941	$	303,620,101			522,957	$	(5,250	)	$	(256,950,579	)	$	46,679,213

For the Three Months Ended June 30, 2020
Balance March 31, 2020		—	$	—		74,255,245	$	7,426	$	219,057,654			522,957	$	(5,250	)	$	(187,766,895	)	$	31,292,935
Series B Convertible Preferred Stock Issued		1,000,000		100		—		—		589,900			—		—			—			590,000
Issuance of Restricted Stock Units (RSUs)		—		—		188,477		18		(18	)		—		—			—			—
Share Based Compensation		—		—		—		—		1,114,758			—		—			—			1,114,758
Net Loss		—		—		—		—		—			—		—			(12,924,713	)		(12,924,713	)
Balance June 30, 2020		1,000,000	$	100		74,443,722	$	7,444	$	220,762,294			522,957	$	(5,250	)	$	(200,691,608	)	$	20,072,980

For the Six Months Ended June 30, 2021
Balance December 31, 2020, as reported		—	$	—		94,365,015	$	9,437	$	233,404,968			522,957	$	(5,250	)	$	(229,911,615	)	$	3,497,540
Adjustment, Conversion of 2019 Warrant Liability upon Adoption of ASU 2020-06		—		—		—		—		4,830,000			—		—			(2,346,000	)		2,484,000
Balance, December 31, 2020, as adjusted		—		—		94,365,015		9,437		238,234,968			522,957		(5,250	)		(232,257,615	)		5,981,540
Common Stock Issued, Net of Issuance Costs of $3,330,752		—		—		46,621,621		4,661		48,414,585			—		—			—			48,419,246
Exercise of Warrants		—		—		8,356,000		836		15,292,714			—		—			—			15,293,550
Issuance of Restricted Stock Units (RSUs)		—		—		66,462		7		(7	)		—		—			—			—
Share Based Compensation		—		—		—		—		1,677,841			—		—			—			1,677,841
Net Loss		—		—		—		—		—			—		—			(24,692,964	)		(24,692,964	)
Balance June 30, 2021		—	$	—		149,409,098	$	14,941	$	303,620,101			522,957	$	(5,250	)	$	(256,950,579	)	$	46,679,213

For the Six months Ended June 30, 2020
Balance December 31, 2019		—	$	—		62,352,465	$	6,235	$	213,520,785			522,957	$	(5,250	)	$	(180,520,526	)	$	33,001,244
Common Stock Issued, Net of Issuance Cost of $494,902		—		—		11,600,000		1,161		6,231,938			—		—			—			6,233,099
Series B convertible Preferred Stock Issued		1,000,000		100		—		—		589,900			—		—			—			590,000
Issuance of February 2020 Warrants		—		—		—		—		(1,914,000	)		—		—			—			(1,914,000	)
Issuance of Restricted Stock Units (RSUs)		—		—		491,257		48		(48	)		—		—			—			—
Share Based Compensation		—		—		—		—		2,333,719			—		—			—			2,333,719
Net Loss		—		—		—		—		—			—		—			(20,171,082	)		(20,171,082	)
Balance June 30, 2020		1,000,000	$	100		74,443,722	$	7,444	$	220,762,294			522,957	$	(5,250	)	$	(200,691,608	)	$	20,072,980

	September 30, 2022			December 31 2021
Carrying amounts of major classes of assets included as part of discontinued operations

Cash and Cash Equivalents	$	1,928		$	37,849
Accounts Receivable, net		—			693
Inventories		—			12,000
Fixed Assets, net		6,779,252			6,799,090
Other Assets		8,501			72,469
Loss recognized on classification as held for sale		(2,601,442	)		(2,601,442	)
Total assets of the disposal group classified as discontinued operations in the statement of financial position	$	4,188,239		$	4,320,659

Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts Payable		621,466			681,646
Accrued Other Expenses		67,183			133,313
Lease Liabilities		285,346			412,357
Contingent Loss Liability		410,000			410,000
Deferred Tax Liability		45,930			45,930
Total liabilities of the disposal group classified as discontinued operations in the statement of financial position	$	1,429,925		$	1,683,246


	Three Months Ended September 30,
	2022			2021
Major line items constituting pretax loss of discontinued operations
REVENUE, net	$	—		$	705,143
COST OF GOODS SOLD		—			(1,882,558	)
Gross Loss		—			(1,177,415	)

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES		(125,722	)		(2,457,162	)
RESEARCH AND DEVELOPMENT		—			(42,076	)
Impairment Expense – Intangible Assets		—			(3,835,158	)
Impairment Expense – Goodwill		—			(868,412	)
Impairment Expense – Inventory		—			(837,414	)
Impairment Expense – Right of Use Asset		—			(448,141	)
Loss from Held for Sale Classification		—			(2,177,844	)
		(125,722	)		(11,843,622	)
OTHER INCOME (EXPENSE)
Interest Income		22			8,619
Gain on Sale of Assets to Fagron		—			4,636,702
Loss on Disposal of Assets		(1,992	)		—
Other Income		—			5,659
Net Loss from discontinued operations before income taxes	$	(127,692	)	$	(7,192,642	)

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied


	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Drug Development & Commercialization:
Outsourced Manufacturing	$	1,275,474	$	721,435	$	2,608,153	$	1,228,719
Compounded Pharmaceuticals:
Sterile	$	1,654,686	$	1,982,506	$	3,279,697	$	5,033,621
Non-Sterile		1,081,144		1,222,401		2,231,986		2,327,212
Total Compounded Pharmaceuticals Revenues	$	2,735,830	$	3,204,907	$	5,511,683	$	7,360,833
Total	$	4,011,304	$	3,926,342	$	8,119,836	$	8,589,552

	June 30, 2021		December 31, 2020		September 30, 2022		December 31, 2021
Finished Goods	$	1,192,893	$	2,059,095
Work-in-Process		—		334,164	$	386,827	$	386,610
Devices & Raw Materials		977,995		722,667
Raw Materials						705,618		31,997
Inventories	$	2,170,888		3,115,926	$	1,092,445	$	418,607

Description	Useful Life (Years)		June 30, 2021			December 31, 2020
Building		30	$	3,040,000		$	3,040,000
Machinery and Equipment		3 - 7		6,109,153			5,633,265
Furniture and Fixtures		7		160,012			160,012
Automobile		5		9,500			9,500
Leasehold Improvements		7 - 15		342,330			342,330
Total Fixed Assets				9,660,995			9,185,107
Less: Accumulated Depreciation				(4,419,013	)		(3,571,870	)
Land				460,000			460,000
Construction In Progress - Equipment, net of impairment of $1,115,560				3,839,239			3,513,356
Fixed Assets, net			$	9,541,221		$	9,586,593

Description	Useful Life (Years)		September 30, 2022			December 31, 2021
Machinery and Equipment		3 - 7	$	5,224,025		$	4,522,583
Less: Accumulated Depreciation				(4,293,062	)		(3,181,567	)
Construction In Progress - Equipment				663,893			993,752
Fixed Assets, net			$	1,594,856		$	2,334,768

June 30, 2021	Gross Carrying Value		Accumulated Amortization			Net Carrying Amount
Definite-lived Intangible assets, estimated lives in years:
FDA 503B Registration & Compliance - USC, 10 years	$	3,963,000	$	(2,068,466	)	$	1,894,534
Customer Relationships - USC, 10 years		5,572,000		(2,908,274	)		2,663,726
Total Definite-lived Assets		9,535,000		(4,976,740	)		4,558,260
Trade Name and Brand - USC, Indefinite		1,245,000		—			1,245,000
SYMJEPI Domain Name		9,674		—			9,674
Balance, June 30, 2021	$	10,789,674	$	(4,976,740	)	$	5,812,934

Year ending December 31,
Remainder of 2021	$	476,750
2022		953,500
2023		953,500
2024		953,500
2025		953,500
Thereafter		267,510
Total	$	4,558,260

Balance, December 31, 2019	$	7,640,622
Less: March 31, 2020 Impairment		(3,143,200)
Less: December 31, 2020 Impairment		(3,629,010)
Balance, December 31, 2020	$	868,412
Balance, June 30, 2021	$	868,412

Right-of Use Assets	June 30, 2021		December 31, 2020
Operating Leases	$	1,301,741	$	1,542,130
Financing Leases		—		1,867
	$	1,301,741	$	1,543,997

Lease Liabilities, Current	June 30, 2021		December 31, 2020
Operating Leases	$	509,537	$	492,804
Financing Leases		—		1,538
	$	509,537	$	494,342
Lease Liabilities, Non-Current
Operating Leases	$	845,012	$	1,105,219
Total Lease Liabilities	$	1,354,549	$	1,599,561

~~June~~September 30, ~~2021~~2022	Operating		~~Financing~~
Weighted Average Remaining Lease Term		~~2.59~~1.17 Years	—
Weighted Average Discount Rate		~~4.34~~3.95%

December 31, 2021	%	Operating
Weighted Average Remaining Lease Term			—1.92 Years

December 31, 2020	Operating			Financing
Weighted Average Remaining Lease Term		3.85 Years			0.42 Years
Weighted Average Discount Rate		4.29	%		3.95	%

Year Ending December 31,	Operating
Remainder of 2022	$	93,431
2023		349,365
Undiscounted Future Minimum Lease Payments		442,796
Less: Difference between undiscounted lease payments and discounted lease liabilities		10,778
Total Lease Liabilities	$	432,018
Short-Term Lease Liabilities	$	368,809
Long-Term Lease Liabilities	$	63,209

Years ending December 31,		Building Loan		First Draw PPP Loan*		Second Draw PPP Loan**		Total
	Remainder of 2021	$	2,018,101	$	2,300,253	$	—	$	4,318,354
	2022		—		891,447		398,245		1,289,692
	2023		—		—		415,914		415,914
	2024		—		—		420,126		420,126
	2025		—		—		424,430		424,430
	Thereafter		—		—		106,780		106,780
		$	2,018,101	$	3,191,700	$	1,765,495	$	6,975,296
	Short-Term Loans	$	2,018,101	$	3,191,700	$	191,886	$	5,401,687
	Long-Term Loans	$	—	$	—	$	1,573,609	$	1,573,609


		• Level 11:		Unadjusted quoted prices in active markets for identical assets or liabilities;

		• Level 22:		Inputs other than quoted prices included within Level 1I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

		• Level 33:		Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.


	Fair Value Measurements at June 30, 2021
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant liability	$	244,824	$	—	$	—	$	244,824

Total common stock warrant liability	$	244,824	$	—	$	—	$	244,824


		Fair Value Measurements at September 30, 2022
	Total		Level 1		Level 2		Level 3
Liabilities
2020 Warrant liability	$	12,037	$	—	$	—	$	12,037


	Fair Value Measurements at December 31, 2020									Fair Value Measurements at December 31, 2021
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Liabilities
2019 Warrant liability	$	2,484,000	$	—	$	—	$	2,484,000
2020 Warrant liability		2,001,000		—		—		2,001,000	$	99,655	$	—	$	—	$	99,655

Total common stock warrant liability	$	4,485,000	$	—	$	—	$	4,485,000


	2019 Warrant						2020 Warrant
	Number of Warrants			Liability			Number of Warrants			Liability
Balance at December 31, 2020		13,800,000		$	2,484,000			8,700,000		$	2,001,000
Adoption of ASC 2020-06		(13,800,000	)		(2,484,000	)		—			—
Change in Fair Value of Warrants at date of exercise		—			—			—			7,521,150
Exercise of Warrants		—			—			(8,350,000	)		(9,441,650	)
Change in Fair Value, March 31, 2021		—			—			—			120,750
Change in Fair Value, June 30, 2021		—			—			—			43,574
Balance at June 30, 2021		—		$	—			350,000		$	244,824